Download Research in Your Backyard

Research in Your Backyard
Developing Cures, Creating Jobs
Pharmaceutical
Clinical Trials in
Texas
Dots show locations of clinical trials in the state.
Executive Summary
Clinical Trials in Texas
•Biopharmaceutical research companies are conducting or have conducted more than 8,200 clinical trials
of new medicines in collaboration with the state’s
clinical research centers, university medical schools
and hospitals (1999 to present).
Freedom fuels innovation, and through our
proud tradition of bold thinking and personal
freedom, Texas is a natural fit for industries
looking to create cutting-edge treatments,
develop cures and improve lives. I’m proud of
Texas’ ranking in clinical studies, and believe
our state has the workforce, talent, universities
and business climate to become a national
leader for biotech research, development and
commercialization.
—Governor Rick Perry
•Of the more than 8,200 clinical trials, more than
4,300 target the nation’s six most debilitating chronic
diseases—asthma, cancer, diabetes, heart disease,
mental illnesses and stroke.
2
Economic Benefits of Clinical
Trials in Texas
•Biopharmaceutical research companies have been an
important source of jobs, tax revenue and research
spending in Texas.
•The 2012 Texas Biotechnology Industry Report from
the Office of Governor Rick Perry found that about
125 biopharmaceutical companies have created a
large pharmaceutical manufacturing workforce,
employing more than 9,500 in Texas, making it one
of the top 10 states in the nation for pharmaceutical
manufacturing jobs.
•In 2010, the total value of Texas pharmaceutical
shipments exceeded $4.7 billion, with manufacturers
making total capital investments of nearly $100 million, according to the U.S. Census Bureau.
•Texas is also a leading pharmaceutical research state.
In 2012, Texas was ranked second nationally for the
number of all clinical trials, with more than 14,000
studies underway, according to the National Institutes of Health database www.clinicaltrials.gov.
•Since 2005, the Texas Emerging Technology Fund
(TETF) has invested over $130 million in pharmaceutical-related startups. Funded companies have
developed a wide range of technologies, including
treatments for cancer, liver disease and obesity.
•Public investment in research and development
(R&D) is supported by the state’s vast network of
public universities and health-related institutions. In
2010, Texas public institutions of higher education
PhRMA • Pharmaceutical Clinical Trials in texas
“The clinical trials of new medicines conducted
by companies in Texas have been an
especially important development for chronic
disease patients in the state and all over the
country—nearly 4,400 of the trials pursued by
biopharmaceutical firms in the Lone Star State
have been aimed at cancer, diabetes, heart
disease, stroke, mental illnesses and asthma,
the nation’s six most debilitating chronic
conditions, which have wreaked havoc in Texas.
Cancer alone will kill nearly 37,000 Texans
this year and about 10 percent of the state’s
adults—1.8 million people—are diabetics.”
—Thomas R. Kowalski, President, Texas Healthcare & Bioscience
Institute
“In a nutshell, clinical trials of new drugs
have been beneficial to patients, the state’s
economy and the advance of science. The
trials account for 45 to 75 percent of the
average $1.2 billion cost of developing one
new drug and biopharmaceutical companies
generally hire local institutions to do this
challenging clinical research work. What’s
more, it is significant, and certainly exciting,
that a respectable number of drugs tested in
Texas over the last 13 years have been newgeneration biotechnology treatments, which
have the strong potential to be more effective
medicines and some of them could improve our
ability to predict and even prevent disease.”
—Bill Hammond, President and Chief Executive Officer, Texas
Association of Business
invested more than $2.5 billion on medical and life
sciences research, accounting for 61 percent of all
higher education R&D expenditures in the state.
• The private sector also has invested in R&D in Texas
with 850 private scientific R&D companies employing more than 21,300 workers.
•In addition to R&D facilities,Texas has more than
2,000 medical and testing laboratories, which include
blood, pathology, imaging, diagnostics and device testing facilities, employing more than 32,200 workers.
• Company employees in Texas include life sciences
researchers, management executives, office and
administrative support workers, production workers,
engineers, architects, computer and math experts and
sales representatives.
About Clinical Trials
• In the development of new medicines, clinical trials
are conducted to prove therapeutic safety and effectiveness and compile the evidence needed for the
Food and Drug Administration (FDA) to approve
treatments.
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
• Clinical tests of new drugs are conducted in three
phases and account for an average of seven of the 10
to 15 years it takes to bring a new drug from development to patients.
• Clinical trials for a given drug or treatment involve
thousands of volunteer patient participants, and the
generation of tens of thousands of pages of technical
and scientific data.
• Clinical trials are responsible for 45 to 75 percent of
the $1.2 billion average cost of developing one new
cutting-edge biotechnology medicine.
Clinical Trials in Texas since 1999—
Completed and Active
All Clinical Trials
Six Major Chronic Diseases
8,254
4,390
Source: www.clinicaltrials.gov
Note: Search criteria = Texas, Phase I, II, III; industry only.
Search performed 10/8/2012.
3
• For patients, the trials offer another potential therapeutic option. Clinical tests may provide a new avenue
of care for some chronic disease sufferers who are still
searching for the medicines that are best for them.
• Some trials are also conducted to compare existing
treatments and some are done to learn if a drug is
appropriate for a different patient population, such
as children. Still others are conducted to find ways
Clinical Trials in Texas Communities
Location
Asthma
Cancer
Diabetes
Heart Disease
Mental Illness
Stroke
Amarillo
—
13
1
6
—
1
Austin
4
31
22
12
47
4
Corpus Christi
—
18
7
3
—
—
Dallas
12
164
58
28
46
8
El Paso
16
13
6
1
—
1
Fort Worth
4
41
10
8
—
4
Houston
6
417
48
35
51
12
Lubbock
—
15
7
1
—
—
New Braunfels
3
4
7
1
—
1
Round Rock
1
10
5
1
—
1
San Antonio
18
152
58
16
25
3
Temple
—
14
—
2
—
1
Waco
13
10
1
3
—
2
Source: www.clinicaltrials.gov
Note: Search criteria = Texas, Phase I, II, II; industry only. Search performed 11/29/2012. See Appendix for detailed information about these clinical trials. Disease columns
will not match totals in the Appendix because some clinical trials are recruiting in more than one city. Please note that database results can change on a daily basis.
4
PhRMA • Pharmaceutical Clinical Trials in texas
“Clinical trials are a critical resource for
the discovery of life saving drugs and the
development of improved diagnostic, prevention
and treatment methods. Texas’ ethnic, racial
and cultural diversity offers pharmaceutical
companies the opportunity to ensure adequate
representation of diverse participants and
generalizability of trial results. We need to find
better ways of communicating with patients,
doctors and advocacy groups about new and
open clinical trials in our Texas communities.
Clinical trials can be an important therapeutic
option for patients suffering from chronic
disease and should be a topic of discussion
between those patients and their doctors.”
—Deborah Vollmer Dahlke, Director, Texas Life Science
Foundation, Chair, Cancer Alliance of Texas
to make existing approved drugs more effective and
easier to use with fewer side effects. cents of every dollar spent on health care.
•Chronic diseases are the leading cause of
death and disability.
•Chronic diseases are a leading driver of rising
health care costs with expenses totaling billions of dollars every year.
•Biopharmaceutical research companies are developing new medicines to help treat those conditions
that are taking an unprecedented toll on American
lives, and many of these medicines are being tested
today in clinical trials throughout Texas.
•Since 1999, biopharmaceutical research companies
are sponsoring or have sponsored 4,390 clinical
trials of potential new medicines in Texas alone for
asthma, cancer, heart disease, stroke, diabetes and
mental illnesses. Of these trials, 914 are either not
yet recruiting or are just now seeking Texas patients.
•Many of the state’s clinical tests involve collaborations with such respected local institutions as the
University of Texas Health Sciences Centers and
Texas A&M University School of Medicine.
•All clinical trials must be reviewed and approved
by an Institutional Review Board (IRB), an independent committee of physicians, statisticians, local
community advocates and others to ensure a trial is
ethically conduced and patient rights are protected.
Clinical Trials for Top Chronic Diseases
•Clinical trial progress reports must be submitted at
least annually to the FDA and IRB.
Chronic Disease
• Many of the medicines being clinically tested here
are new-generation biotechnology treatments.
All Clinical Trials
Clinical Trials
Still Recruiting
Asthma
138
29
Cancer
2,603
633
Diabetes
656
92
Heart Disease
268
49
•Chronic diseases pose the greatest threats to our
nation’s health and our ability to treat and prevent
medical conditions.
Mental Illness
676
96
Stroke
49
15
•According to the Centers for Disease Control and
Prevention, today, in the United States:
Total
4,390
914
•All facilities that conduct or support biomedical
research involving patients must comply with federal
regulations and have an IRB.
Clinical Trials and Chronic Diseases
•Patients with chronic diseases account for 75
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
Source: www.clinicaltrials.gov
Note: Search criteria = Texas, Phase I, II, III; industry only. Search performed
10/8/2012. Some clinical trials appear in more than one disease category.
5
Clinical Trials in Texas
Clinical tests of new medicines are a vitally important part
of the drug development and approval process—they account for 45 to 75 percent of the $1.2 billion average cost
of developing a new drug and are conducted to determine
the safety and effectiveness of that treatment in patients.
Some trials are also conducted to compare existing treatments and some are done to learn if a drug is appropriate for
a different patient population, such as children. Still others
are conducted to find ways to make existing approved drugs
more effective and easier to use with fewer side effects. It’s essential that trials be conducted properly so that clinicians and drug reviewers can develop accurate assessments
of the efficacy and safety of medicines when used by
patients. The FDA is a vigilant regulatory agency and its
pharmaceutical review officers are effective in detecting
flawed information.
Questionable or confusing data can lead to lengthy delays in
product approval or outright FDA rejection of a new drug.
Biopharmaceutical research companies are looking for the
best physicians and research institutions to meticulously
help design and conduct their clinical trials to determine
whether a medicine is safe and effective. Side effects must
be painstakingly documented and a determination made as
to whether they occur too often and are dangerous.
Clinical tests involve three phases and thousands of volunteer patients and are often conducted at multiple sites
around the country. In Texas, biopharmaceutical companies are providing funds to have trials conducted at the
states’ well-respected university medical schools and science centers, local hospitals and clinical research organiza-
6
Clinical Trials for Top Chronic Diseases
All Clinical Trials
Clinical Trials
Still Recruiting
Asthma
138
29
Cancer
2,603
633
Diabetes
656
92
Heart Disease
268
49
Mental Illness
676
96
Stroke
49
15
Total
4,390
914
Chronic Disease
Source: www.clinicaltrials.gov
Note: Search criteria = Texas, Phase I, II, III; industry only. Search performed
10/8/2012. Some clinical trials appear in more than one disease category.
tions. According to U.S. News and World Report, the University of Texas Southwestern Medical Center in Dallas ranked 20th, Baylor College of Medicine in Houston
ranked 21st, the University of Texas Health Science
Center in Houston ranked 55th, the University of Texas
Health Science Center in San Antonio ranked 67th, and
the Texas A&M Health Science Center in Bryan ranked
83rd among this year’s top 100 research-oriented medical
schools in the United States. Other listed medical schools
included Texas Tech University Health Sciences Center
in Lubbock, the University of North Texas Health Science Center in Fort Worth, and the University of Texas
Medical Branch in Galveston.
PhRMA • Pharmaceutical Clinical Trials in texas
Asthma is a debilitating condition for more than 23 mil-
Heart disease and stroke are the first and third leading
lion Americans, including 7 million children under the age
of 18. The toll is also severe in Texas where, in 2008, more
than 1.2 million adults and nearly 600,000 children in
Texas suffered from asthma, according to the U.S. Centers
for Disease Control and Prevention (CDC).
disease causes of death in the United States and the first
and fourth in Texas. According to the American Heart Association, more than 82 million Americans are affected by
these diseases. In Texas, in 2010, more than 38,000 residents died from some form of heart disease and 9,154 died
from a stroke, according to the Texas Department of State
Health Services.
Currently, 29 clinical trials of new asthma medicines are
recruiting patients in Texas. Trials are being conducted at
the Western Sky Medical Research in El Paso, North
Texas Institute for Clinical Trials in Fort Worth and
Alamo Clinical Research in Austin.
Cancer, the second leading cause of death in the United
States, now afflicts nearly 12 million Americans, according to the National Cancer Institute. In Texas, more than
110,000 new cancer cases will be diagnosed this year
and 36,820 victims in the state will die, according to the
American Cancer Society.
Currently, 633 clinical trials of new cancer medicines are
recruiting patients in Texas. Biopharmaceutical companies
are collaborating on the tests with such prominent institutions as the Cancer Therapy and Research Center
at University of Texas in San Antonio, the Charles A.
Sammons Cancer Center at Baylor University in Dallas, M.D. Anderson Cancer Center at the University of
Texas in Houston, and the Texas Tech University Health
Science Center in El Paso.
Diabetes affects more than 20 million Americans—about
8 percent of the U.S. population—and nearly one-third are
unaware they have the disease. In Texas, about 10 percent of adults—1.8 million people—have been afflicted
with diabetes, according to the Texas Department of State
Health Services. In 2010, diabetes was the cause of death
of 4,738 residents.
Currently, 92 diabetes clinical tests are seeking patients in
Texas. The trials are being conducted in Dallas at the Baylor Research Institute, Dallas South Hampton Community Hospital, and the University of Texas Southwestern Medical Center, and the Texas Center for
Drug Development and Methodist Hospital in Houston.
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
Currently, 49 heart disease and 15 stroke clinical tests are
seeking patients in Texas. The trials are underway at the
Jack and Jane Hamilton Heart and Vascular Hospital at
Baylor in Dallas, the DeBakey Heart and Vascular Center at Methodist Hospital in Houston, the San Antonio
Endovascular and Heart Institute in San Antonio, the
Cardiology Center of Amarillo, and the Heart Hospital
of Austin in Austin.
Mental illness affects nearly 60 million Americans suffering from some form of the disease—from anxiety to
depression to schizophrenia to eating disorders. In Texas,
about 833,000 adults live with serious mental illness and
about 288,000 children live with serious mental health
conditions, according to the National Alliance on Mental Illness.
Currently, 96 clinical trials for mental illness are recruiting
patients in Texas. The trials are taking place at the Baylor
College of Medicine in Houston, Red Oak Psychiatry
Associates in Houston, San Antonio Psychiatric Research Center in San Antonio, Senior Adults Specialty
Research in Austin, and the University of Texas in Houston, San Antonio and Dallas.
Physicians and patients can find out about clinical trials being
conducted all over the state in collaboration with local institutions
by accessing www.clinicaltrials.gov, a database sponsored by
the National Institutes of Health. Information on medicines in
development is also available on www.phrma.org, the website
of the Pharmaceutical Research and Manufacturers of America
(PhRMA), under “Clinical Research and Trials.”
7
New Generation
Medicines in Development
Many of the medicines being tested in Texas are cuttingedge biotechnology drugs. America’s biopharmaceutical research companies are using biotechnology to develop hundreds of medicines and
vaccines today. And Texas is one of the states where newgeneration research and development work is being done.
Many of the medicines in clinical testing at Texas medical
schools and research centers feature these technologies. For
example:
•A genetically-modified virus-based vaccine to treat
melanoma.
•A monoclonal antibody for the treatment of cancer.
Through biotechnology, new ways are being developed to
not only more effectively treat disease, but also to predict it
and eventually prevent it. •An antisense medicine for the treatment of cancer.
Biotechnology medicines are developed through biological processes using living cells or organisms, rather than
traditional chemical synthesis, the mainstay of pharmaceutical development for decades.
•A monoclonal antibody in the pipeline targets lupus
and various types of cancer.
Such novel treatments use a variety of new approaches to
treat disease. For example, a monoclonal antibody is a laboratory-made version of the naturally occurring immune
system protein that binds to and neutralizes foreign invaders. Interferons are proteins that interfere with the ability
of a cell to reproduce.
Antisense drugs, meanwhile, are medicines that interfere
with the communication process that tells a cell to produce an unwanted protein. In addition, nanotechnology
is being used in biotechnology research to provide drugdelivery systems, new treatments and diagnostics.
8
•A recombinant fusion protein to treat diabetic
macular edema.
•A therapeutic vaccine, designed to jump-start the
immune system to fight disease, is in development
for lung cancer and melanoma.
These are only a portion of the examples of new ways the
nation’s biopharmaceutical companies and Texas research
institutions are working together to attack disease. The
biotechnology medicines and vaccines in development are
helping to expand the frontiers of science and potentially
bring more and better treatments to patients.
PhRMA • Pharmaceutical Clinical Trials in texas
Conclusion
Biopharmaceutical companies’ close collaboration with
clinicians and research institutions in Texas benefits
patients, the state’s economy and the advancement
of science and patient care. Clinical trials provide
stimulating biopharmaceutical research work and a
reliable source of revenue for the state’s university
medical schools and science centers, hospitals and
clinical organizations and the medicines being tested
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
are often cutting-edge cell and protein treatments with
the potential to be safer and more effective than older
chemical compound drugs. What’s more, Texans considering participation in
clinical trials of new drugs have a wide range of choices,
including 914 tests of new medicines for the six most
debilitating chronic diseases in America.
9
The Drug Discovery, Development and Approval Process
It takes 10-15 years on average for an experimental drug to travel from the lab to U.S. patients. Only five in 5,000
compounds that enter preclinical testing make it to human testing. One of these five tested in people is approved.
Clinical Trials
Phase II
Phase III
FDA
Years
6.5
1.5
2
3.5
1.5
Test
Population
Laboratory and
animal studies
20 to 80
healthy
volunteers
100 to 300
patient
volunteers
1,000 to 3,000
patient
volunteers
Determine
safety
and dosage
Evaluate
effectiveness, look for
side effects
Confirm
effectiveness,
monitor adverse
­reactions from
long-term use
Purpose
Success
Rate
Assess safety,
biological activity
and formulations
5,000
compounds
evaluated
5
enter trials
File NDA/BLA at FDA
Phase I
File IND at FDA
Discovery/
Preclinical Testing
Review
process/
approval
Phase IV
Additional
postmarketing
testing
required
by FDA
1
approved
The Drug Development and Approval Process
The U.S. system of new drug approvals is
perhaps the most rigorous in the world.
It takes 10-15 years, on average, for an
experimental drug to travel from lab to U.S.
patients, according to the Tufts Center for the
Study of Drug Development. Only five in 5,000
compounds that enter preclinical testing make
it to human testing. And only one of those five
is approved for sale.
On average, it costs a company $1.2 billion,
including the cost of failures, to get one new
medicine from the laboratory to U.S. patients,
according to a 2007 study by the Tufts Center
for the Study of Drug Development.
Once a new compound has been identified in
the laboratory, medicines are usually developed as follows:
Preclinical Testing. A pharmaceutical company conducts laboratory and animal studies
to show biological activity of the compound
against the targeted disease, and the compound is evaluated for safety.
Investigational New Drug Application (IND).
After completing preclinical testing, a company
files an IND with the U.S. Food and Drug
Administration (FDA) to begin to test the drug
10
in people. The IND shows results of previous
experiments; how, where and by whom the
new studies will be conducted; the chemical
structure of the compound; how it is thought
to work in the body; any toxic effects found in
the animal studies; and how the compound
is manufactured. All clinical trials must be
reviewed and approved by the Institutional
Review Board (IRB) where the trials will be
conducted. Progress reports on clinical trials
must be submitted at least annually to FDA and
the IRB.
Clinical Trials, Phase I—Researchers test
the drug in a small group of people, usually
between 20 and 80 healthy adult volunteers, to
evaluate its initial safety and tolerability profile,
determine a safe dosage range, and identify
potential side effects.
Clinical Trials, Phase II—The drug is given
to volunteer patients, usually between 100 and
300, to see if it is effective, identify an optimal
dose, and further evaluate its short-term safety.
Clinical Trials, Phase III—The drug is given to
a larger, more diverse patient population, often
involving between 1,000 and 3,000 patients (but
sometime many more thousands), to generate
statistically significant evidence to confirm its
safety and effectiveness. They are the longest
studies, and usually take place in multiple sites
around the world.
New Drug Application (NDA)/Biologic
License Application (BLA). Following the
completion of all three phases of clinical trials,
a company analyzes all of the data and files an
NDA or BLA with FDA if the data successfully
demonstrate both safety and effectiveness.
The applications contain all of the scientific
information that the company has gathered.
Applications typically run 100,000 pages or
more.
Approval. Once FDA approves an NDA or
BLA, the new medicine becomes available
for physicians to prescribe. A company must
continue to submit periodic reports to FDA,
including any cases of adverse reactions and
appropriate quality-control records. For some
medicines, FDA requires additional trials
(Phase IV) to evaluate long-term effects.
Discovering and developing safe and effective
new medicines is a long, difficult, and expensive
process. PhRMA member companies invested
an estimated $49.5 billion in research and
development in 2011.
PhRMA • Pharmaceutical Clinical Trials in texas
The Good News—Many
Clinical Trials are Still Recruiting
There are 914 clinical trials of new chronic disease drugs recruiting patients in Texas. These trials target the
six most debilitating chronic conditions—cancer, heart disease, stroke, asthma, diabetes and mental illnesses.
Clinical Trials in Texas Communities
Location
Asthma
Cancer
Diabetes
Heart Disease
Mental Illness
Stroke
Amarillo
—
13
1
6
—
1
Austin
4
31
22
12
47
4
Corpus Christi
—
18
7
3
—
—
Dallas
12
164
58
28
46
8
El Paso
16
13
6
1
—
1
Fort Worth
4
41
10
8
—
4
Houston
6
417
48
35
51
12
Lubbock
—
15
7
1
—
—
New Braunfels
3
4
7
1
—
1
Round Rock
1
10
5
1
—
1
San Antonio
18
152
58
16
25
3
Temple
—
14
—
2
—
1
Waco
13
10
1
3
—
2
Source: www.clinicaltrials.gov
Note: Search criteria = Texas, Phase I, II, II; industry only. Search performed 11/29/2012. See Appendix for detailed information about these clinical trials. Disease columns
will not match totals in the Appendix because some clinical trials are recruiting in more than one city. Please note that database results can change on a daily basis.
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
11
The Good News – Many Clinical Trials are Still Recruiting
(continued)
Asthma—Leading Institutions
Conducting Clinical Trials
Cancer Center of the High Plains, Amarillo
Alamo Clinical Research Associates, San Antonio
Cancer Therapy and Research Center
at University of Texas, San Antonio
Allergy & Asthma Care of Waco, Waco
Central Austin Cancer Center, Austin
Allergy & Asthma Center of Boerne, Boerne
Central Texas Veterans Healthcare System, Temple
Allergy / Immunology Research Center of
North Texas, Dallas
Charles A. Sammons Cancer Center at
Baylor University, Dallas
Allergy Asthma Research Institute, Waco
Dallas Presbyterian Hospital, Dallas
Breath of Life Research Institute, Katy
Don & Sybil Harrington Cancer Center, Amarillo
Central Texas Health Research, New Braunfels
East Texas Hematology Clinic, Lufkin
Dallas Allergy Immunology Research, Dallas
El Paso Cancer Treatment Center-East, El Paso
Gastroenterology Consultants, Houston
Excel Diagnostics Imaging Clinic, Houston
Isis Clinical Research, Austin
Harry Hines Medical Center, Dallas
Live Oak Allergy and Asthma Clinic, Live Oak
Joe Arrington Cancer Research and Treatment Center, Lubbock
North Texas Institute for Clinical Trials, Fort Worth
Pharmaceutical Research & Consulting, Dallas
Pioneer Research Solutions, Houston
Quality Assurance Research Center, San Antonio
SAM Clinical Research Center, San Antonio
Sirius Clinical Research, Austin
Southwest Allergy and Asthma Research Center,
San Antonio
Sylvana Research Associates, San Antonio
Tekton Research, Austin
M.D. Anderson Cancer Center at the University
of Texas, Houston
Marnie McFaddin Ward Cancer Center, Beaumont
Mary Crowley Cancer Research Center, Dallas
Midland Allison Cancer Center, Midland
Oncology Consultants, Houston
Scott and White Memorial Hospital, Temple
South Texas Accelerated Research Therapeutics,
San Antonio
TTS Research, Boerne
South Texas Comprehensive Cancer Centers,
Corpus Christi
Western Sky Medical Research, El Paso
South Texas Oncology and Hematology, San Antonio
Cancer—Leading Institutions
Conducting Clinical Trials
Southwest Cancer Treatment and Research Center, Lubbock
Advanced Research Network, Houston, Lubbock
Baylor College of Medicine, Houston
Baylor Research Institute, Dallas
Ben Taub Hospital, Houston
Brooke Army Medical Center, Fort Sam Houston
Cancer Care Centers of South Texas, San Antonio
12
St. Luke’s Episcopal Hospital, Houston
Texas Cancer Center at Medical City, Dallas
Texas Oncology Cancer Care and Research Center, Waco
Texas Oncology, Abilene
Texas Oncology, Amarillo
PhRMA • Pharmaceutical Clinical Trials in texas
Texas Oncology, Austin
Arlington Family Research Center, Arlington
Texas Oncology, Bedford
Austin Retina Associates, Austin
Texas Oncology, Dallas
Baylor Endocrine Center, Dallas
Texas Oncology, Denton
Baylor Eye Physicians and Surgeons, Houston
Texas Oncology, El Paso
Baylor Research Institute, Dallas
Texas Oncology, Fort Worth
Breco Research, Sugarland
Texas Oncology, Garland
Centex Research, Houston
Texas Oncology, Grapevine
Cetero Research, San Antonio
Texas Oncology, Lewisville
Complete Family Foot Care, McAllen
Texas Oncology, McAllen
Covenant Clinical Research, San Antonio
Texas Oncology, Paris
Dallas Diabetes and Endocrine Research Center, Dallas
Texas Oncology, Plano
Dependable Clinical Research, Houston
Texas Oncology, Round Rock
Diabetech, Dallas
Texas Oncology, Sherman
DiscoveResearch, Beaumont
Texas Oncology, Tyler
Endeavor Clinical Trials, San Antonio
Texas Oncology, Waco
Excel Clinical Research, Houston
Texas Oncology-Medical City, Dallas
Heart Care Center of Northwest Houston, Houston
Texas Oncology-Memorial City, Houston
Hill Country Medical Associates, New Braunfels
Texas Tech University Health Science Center, El Paso
Hillcrest Family Health Center, Waco
Texas Urology Specialists, Tomball
Houston Neurocare, Houston
The Methodist Hospital, Houston
Humble Cardiology Associates, Humble
Tyler Cancer Center, Tyler
Innovative Clinical Trials, San Antonio
University of Texas Health Science Center Institute
for Drug Development, San Antonio
Internal Medicine Clinical Research, Dallas
University of Texas Health Sciences, San Antonio
University of Texas Medical Branch, Galveston
University of Texas Southwestern Medical Center,
Dallas
Urology Associates of North Texas, Arlington
Urology Associates of South Texas, McAllen
Urology Clinics of North Texas, Dallas
Diabetes—Leading Institutions
Conducting Clinical Trials
3rd Coast Research Associates, Corpus Christi
Abbott Clinical Research Group, San Antonio
Advances in Health, Houston
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
Juno Research, Houston
Junoi Sun Research Institute, San Antonio
KRK Medical Research, Dallas
Lone Star Clinical Research, Houston
Lone Star Heart Center, Amarillo
Med-Olam Clinical Research, Pasadena
Mercury Clinical Research, Houston
Methodist Neurological Institute, Houston
Millennium Research, Houston
Mountain Diabetes & Endocrine Center, Dallas
North Hills Medical Research, North Richland Hills
Northeast Clinical Research of San Antonio,
San Antonio
13
Padre Coast Medical Associates, Corpus Christi
Heart Disease—Leading Institutions
Conducting Clinical Trials
Paragon Research Center, San Antonio
3rd Coast Research Associates, Corpus Christi
Podiatry Associates, San Antonio
Advances in Health, Houston
Protenium Clinical Research, Hurst
Baylor Heart and Vascular Hospital, Dallas
R/D Clinical Research, Lake Jackson
Baylor Research Institute, Plano
Radiant Research, Dallas
Baylor University Medical Center, Dallas
Renaissance Clinical Research and Hypertension,
Dallas
Cardiology Associates of Corpus Christi, Corpus Christi
Renal Associates, San Antonio
Cardiology Center of Amarillo, Amarillo
Research Across America, Houston
Clinical Trial Network, Houston
Research Institute of Dallas, Dallas
Dallas VA Medical Center, Dallas
Retina and Vitreous of Texas, Houston
DiscoveResearch, Beaumont
Retina Research Center, Austin
East Texas Cardiology, Houston
Retinal Consultants of Houston, Houston
Gamma Medical Research, Mission
Retinal Consultants of San Antonio, San Antonio
Heart Hospital of Austin, Austin
San Antonio Kidney Disease Center Physicians Group, San Antonio
Hillcrest Family Health Center, Waco
Northwest Houston Heart Center, Houston
Seton Heart Institute, Austin
Cardiovascular Associates of East Texas, Tyler
Humble Cardiology Associates, Humble
Sonterra Clinical Research, San Antonio
Jack and Jane Hamilton Heart and Vascular Hospital
at Baylor, Dallas
South Hampton Community Hospital, Dallas
Katy Cardiology Associates, Katy
Southwest Clinical Trials, Houston
Leachman Cardiology, Houston
Southwest Houston Research, Houston
Lone Star Heart Center, Amarillo
T&R Clinic, Fort Worth
Medical City Dallas, Dallas
Tarrant Nephrology Associates, Fort Worth
Memorial Hermann, Houston
Texas Center for Drug Development, Houston
Texas Diabetes and Endocrinology, Austin
Methodist DeBakey Heart and Vascular Center at Methodist Hospital, Houston
Texas Diabetes and Endocrinology, Round Rock
Methodist Health Systems, San Antonio
Texas Diabetes, Austin, El Paso
NECRSA, Schertz
Texas Retina Associates, Dallas
North Dallas Research Associates, McKinney
Texas Retina Associates, Lubbock
North Texas Healthcare System, Department of
Veteran’s Affairs, Dallas
The Methodist Hospital, Houston
University of Texas Health Science Center, Houston
University of Texas Southwestern Medical Center,
Dallas
Northwest Houston Heart Center, Tomball
Padre Coast Medical Associates, Corpus Christi
Protenium Clinical Research, Hurst
Valley Retina Associates, McAllen
R/D Clinical Research, Lake Jackson
Village Family Practice, Houston
Radiant Research, Dallas
West Houston Clinical Research, Houston
Radiant Research, San Antonio
14
PhRMA • Pharmaceutical Clinical Trials in texas
Research Institute of Dallas, Dallas
Houston Clinical Trials, Houston
San Antonio Endovascular and Heart Institute,
San Antonio
Houston Sleep Center, Houston
Scott & White Memorial Hospital, Temple
Sonterra Clinical Research, San Antonio
South Texas Cardiovascular Consultants, San Antonio
Texas Cardiac Arrhythmia Research Foundation, Austin
Texas Heart Institute at St. Luke’s Episcopal Hospital, Houston
The Cardiology Center of Amarillo, Amarillo
The Heart Center of Northwest Houston, Houston
The Heart Hospital Baylor, Plano
The Medical Center of Plano, Plano
Tyler Cardiovascular Consultants, Tyler
University Medical Center at Brackenridge, Austin
University of Texas Health Science Center, Houston
University of Texas Health Science Center, San Antonio
University of Texas Medical Branch, Galveston
University of Texas Southwestern Medical Center,
Dallas
Veterans Affairs North Texas Health Care Systems,
Dallas
Victoria Heart and Vascular Center, Victoria
West Houston Area Clinical Trial Consultants, Houston
Mental Illness—Leading Institutions
Conducting Clinical Trials
Bay Area Clinical Services, Friendswood
Baylor College of Medicine, Houston
Bayou City Research, Houston
Ben Taub General Hospital, Houston
CEDRA Clinical Research, San Antonio
Claghorn-Lesem Research Clinic, Houston
Clinical Trials of Texas, San Antonio
Community Clinical Research, Austin
Family Psychiatry of the Woodlands, The Woodlands
Future Search Trials of Dallas, Dallas
FutureSearch Clinical Trials, Austin
Grayline Clinical Drug Trials, Wichita Falls
InSite Clinical Research, DeSoto
Integra Clinical Research, San Antonio
KRK Medical Research, Dallas
Michael E. DeBakey VA Medical Center, Houston
Paragon Research Center, San Antonio
Pillar Clinical Research, Dallas
R/D Clinical Research, Lake Jackson
Red Oak Psychiatry Associates, Houston
Research Across America, Dallas
San Antonio Psychiatric Research Center, San Antonio
Senior Adults Specialty Research, Austin
Sleep Medicine Associates of Texas, Dallas
South Texas Veterans Health Care System, San Antonio
Texas Neurology, Dallas
University Hills Clinical Research, Irving
University of Texas Health Sciences Center, Houston
University of Texas Health Sciences Center,
San Antonio
University of Texas Southwestern Medical Center,
Dallas
Westex Clinical Investigations, Lubbock
Wharton Research Center, Wharton
Stroke—Leading Institutions
Conducting Clinical Trials
Baylor Research Institute, Dallas
Dallas Veterans Administration Medical Center, Dallas
Heart Hospital of Austin, Austin
Methodist Neurological Institute, Houston
Presbyterian Hospital of Dallas, Dallas
St. Luke’s Episcopal Hospital, Houston
The Methodist Hospital, Houston
University Medical Center at Brackenridge, Austin
University of Texas Medical Branch, Galveston
University of Texas Medical School, Houston
University of Texas Southwestern Medical Center,
Dallas
Harry Croft and Associates, San Antonio
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
15
Appendix
The clinical trials listed here involve tests that have not yet started recruiting patients or are just now
seeking volunteers to participate. This information is potentially valuable to patients still seeking effective
treatments for their chronic diseases. It provides a new therapeutic option to discuss with physicians.
Those interested in obtaining more information about certain trials can use the URL code listed for each
test to log onto www.clinicaltrials.gov, the clinical tests database of the National Institutes of Health.
Asthma
(29 clinical trials recruiting)
Study 1:
A Study of the Effectiveness and Safety of Different
Doses of Fluticasone Propionate Taken From a Dry
Powder Inhaler in Adolescents and Adults Who Have
Asthma That is Not Controlled by Asthma Medications
Not Containing Steroids
http://ClinicalTrials.gov/show/NCT01479621
Study 2:
A 12-week Study to Compare the Efficacy and Safety
of Albuterol in Dry Powder Inhaler Versus a Placebo in
People 12 Years and Older With Persistent Asthma
http://ClinicalTrials.gov/show/NCT01424813
Study 3:
A Study of the Effectiveness and Safety of Different
Doses of Fluticasone Propionate Taken From a Dry
Powder Inhaler (Puffer) in Adolescents and Adults Who
Have Asthma That is Not Controlled by High Dose
Inhaled Corticosteroid Asthma Medications
http://ClinicalTrials.gov/show/NCT01576718
16
Study 4:
Efficacy and Safety Study to Compare Formoterol
Fumerate in the Pressair DPI to the Foradil Aerolizer
in Patient With Mild to Moderate Asthma
http://ClinicalTrials.gov/show/NCT01641081
Study 5:
A Study to Evaluate the Efficacy and Safety of
Reslizumab (3.0 mg/kg) in the Reduction of Clinical
Asthma Exacerbations in Patients (12-75 Years of Age)
With Eosinophilic Asthma
http://ClinicalTrials.gov/show/NCT01285323
Study 6:
A Safety, Efficacy and Tolerability Study in Pediatric
Subjects With Asthma
http://ClinicalTrials.gov/show/NCT00809757
Study 7:
A Study to Evaluate the Efficacy and Safety of
Reslizumab (3.0 mg/kg) in the Reduction of Clinical
Asthma Exacerbations and Change in Lung Function in
Patients (12-75 Years of Age) With Eosinophilic Asthma
http://ClinicalTrials.gov/show/NCT01287039
PhRMA • Pharmaceutical Clinical Trials in texas
Study 8:
Dose Finding Study for QAW039 in Asthma
http://ClinicalTrials.gov/show/NCT01437735
Study 9:
A Study of Mometasone Furoate Metered Dose Inhaler
in Children With Persistent Asthma (P04223 AM2)
http://ClinicalTrials.gov/show/NCT01502371
Study 10:
A 6-week Study in Asthmatic Children Aged 6 to <12
Yrs Comparing Budesonide pMDI 160ug Twice Daily
With Placebo
http://ClinicalTrials.gov/show/NCT01136382
Study 11:
A Safety and Efficacy Study of Inhaled R940343 in
Patients With Mild to Moderate Asthma
http://ClinicalTrials.gov/show/NCT01591044
Study 12:
Clinical Study Evaluating Safety and Efficacy of
Fluticasone Furoate and Fluticasone Propionate in
People With Asthma
http://ClinicalTrials.gov/show/NCT01436110
Study 13:
A Dose-Ranging Study of MK-1029 in Adults With
Persistent Asthma (MK-1029-012 AM1)
http://ClinicalTrials.gov/show/NCT01656395
Study 14:
A Study of Lebrikizumab in Patients Whose Asthma
is Uncontrolled With Inhaled Corticosteroids and A
Second Controller Medication (LUTE)
http://ClinicalTrials.gov/show/NCT01545440
Study 15:
A Study of Lebrikizumab in Patients With
Uncontrolled Asthma Who Are on Inhaled
Corticosteroids and A Second Controller Medication
(VERSE)
http://ClinicalTrials.gov/show/NCT01545453
Study 16:
A Study of MEMP1972A in Patients With Allergic
Asthma Inadequately Controlled on Inhaled Steroids
And A Second Controller (COSTA)
http://ClinicalTrials.gov/show/NCT01582503
Study 17:
Study to Evaluate the Efficacy and Safety of
Reslizumab Treatment in Patients With Moderate to
Severe Asthma
http://ClinicalTrials.gov/show/NCT01508936
Study 18:
A Study to Evaluate the Efficacy and Safety of
Reslizumab (0.3 or 3.0 mg/kg) as Treatment for
Patients (12-75 Years of Age) With Eosinophilic Asthma
http://ClinicalTrials.gov/show/NCT01270464
Study 19:
Albuterol DPI (A006) Clinical Study-B2: Efficacy,
Dose-Ranging and Initial Safety Evaluation
http://ClinicalTrials.gov/show/NCT01581177
Study 20:
Efficacy and Safety of 2 Doses of Tiotropium
Respimat® Compared to Placebo in Children With
Moderate Persistent Asthma
http://ClinicalTrials.gov/show/NCT01634139
Study 21:
Efficacy and Safety of 2 Doses of Tiotropium Via
Respimat Compared to Placebo in Adolescents With
Moderate Persistent Asthma
http://ClinicalTrials.gov/show/NCT01257230
Study 22:
A 3-period Crossover Study With GSK573719 as
Monotherapy in Adult Subjects With Asthma
http://ClinicalTrials.gov/show/NCT01641692
Study 23:
A Study of ARRY-502 in Patients With Persistent
Asthma
http://ClinicalTrials.gov/show/NCT01561690
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
17
Study 24:
Dose-ranging Study of Vilanterol (VI) Inhalation
Powder in Children
http://ClinicalTrials.gov/show/NCT01573767
Study 25:
Evaluate Safety of Technosphere® Insulin Inhalation
Powder (TI Inhalation Powder) on Diabetic Subjects
With Mild Obstructive Pulmonary Disease
http://ClinicalTrials.gov/show/NCT00642616
Study 26:
Study 3:
Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients
With HER2 Negative, Locally Advanced or Metastatic
Breast Cancer
http://ClinicalTrials.gov/show/NCT01495247
Study 4:
A Trial of Preoperative MM-121 With Paclitaxel in
HER2-negative Breast Cancer
http://ClinicalTrials.gov/show/NCT01421472
Study 5:
A Dose-ranging Study of Fluticasone Furoate (FF)
Study of Anti-HB-EGF Antibody KHK2866 in Subjects
With Advanced Solid Tumors and Ovarian Cancer
http://ClinicalTrials.gov/show/NCT01563029
http://ClinicalTrials.gov/show/NCT01279291
Study 27:
Efficacy and Safety of Budesonide Foam for Patients
With Active Mild to Moderate Ulcerative Proctitis or
Proctosigmoiditis
http://ClinicalTrials.gov/show/NCT01008410
Study 28:
Study 6:
TRINOVA-1: A Study of AMG 386 or Placebo, in
Combination With Weekly Paclitaxel Chemotherapy,
as Treatment for Ovarian Cancer, Primary Peritoneal
Cancer and Fallopian Tube Cancer
http://ClinicalTrials.gov/show/NCT01204749
Study 7:
Efficacy and Safety of Budesonide Foam for Patients
With Active Mild to Moderate Ulcerative Proctitis or
Proctosigmoiditis
TRINOVA-3: A Study of AMG 386 or AMG 386
Placebo in Combination With Paclitaxel and
Carboplatin to Treat Ovarian Cancer
http://ClinicalTrials.gov/show/NCT01008423
http://ClinicalTrials.gov/show/NCT01493505
Study 29:
The Safety and Tolerability of Budesonide Foam
in Subjects With Active Ulcerative Proctitis or
Proctosigmoiditis
http://ClinicalTrials.gov/show/NCT01349673
Cancer
(633 clinical trials recruiting)
Study 8:
Anemia Treatment for Advanced Non-Small Cell Lung
Cancer (NSCLC) Patients Receiving Chemotherapy
http://ClinicalTrials.gov/show/NCT00858364
Study 9:
Study of Cabozantinib (XL184) Versus Prednisone
in Men With Metastatic Castration-resistant Prostate
Cancer Previously Treated With Docetaxel and
Abiraterone or MDV3100
http://ClinicalTrials.gov/show/NCT01605227
Study 1:
A Study of LY2228820 for Recurrent Ovarian Cancer
http://ClinicalTrials.gov/show/NCT01663857
Study 2:
A Study of MGCD265 Given With Erlotinib or
Docetaxel in Subjects With Advanced Malignancies or
Non-Small Cell Lung Cancer
Study 10:
A Study Comparing the Combination of the Best
Supportive Care Plus E7080 Versus Best Supportive
Care Alone, in Patients With Advanced Lung Cancer
or Lung Cancer That Has Spread, Who Have Been
Previously Treated, Unsuccessfully, With at Least 2
Different Treatments
http://ClinicalTrials.gov/show/NCT01529112
http://ClinicalTrials.gov/show/NCT00975767
18
PhRMA • Pharmaceutical Clinical Trials in texas
Study 11:
Phase Ib, Dose Escalation Study of Oral LDE225 in
Combination With BKM120 in Patients With Advanced
Solid Tumors
http://ClinicalTrials.gov/show/NCT01576666
Study 12:
Study 18:
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
http://ClinicalTrials.gov/show/NCT00911170
Study 19:
Study of Abiraterone Acetate in Patients With
Advanced Prostate Cancer
A Phase II Study to Evaluate the Efficacy of TKI258
for the Treatment of Patients With FGFR2 Mutated or
Wild-type Advanced and/or Metastatic Endometrial
Cancer
http://ClinicalTrials.gov/show/NCT01217697
http://ClinicalTrials.gov/show/NCT01379534
A Study to Evaluate New or Worsening Lens
Opacifications in Subjects With Non-metastatic
Prostate Cancer Receiving Denosumab for Bone Loss
Due to Androgen-Deprivation Therapy
Study 13:
Study to Assess Safety and Tolerability of Oral CC115 for Patients With Advanced Solid Tumors, NonHodgkin’s Lymphoma or Multiple Myeloma
http://ClinicalTrials.gov/show/NCT01353625
Study 14:
Study of Cabozantinib (XL184) Versus Mitoxantrone
Plus Prednisone in Men With Previously Treated
Symptomatic Castration-resistant Prostate Cancer
http://ClinicalTrials.gov/show/NCT01522443
Study 15:
Study 20:
http://ClinicalTrials.gov/show/NCT00925600
Study 21:
Study of Denosumab as Adjuvant Treatment for
Women With High Risk Early Breast Cancer Receiving
Neoadjuvant or Adjuvant Therapy (D-CARE)
http://ClinicalTrials.gov/show/NCT01077154
Study 22:
Study of PX-866 and Docetaxel in Solid Tumors
http://ClinicalTrials.gov/show/NCT01204099
A Study Comparing Treatment With 177Lu-DOTA0Tyr3-Octreotate to Octreotide LAR in Patients With
Inoperable, Progressive, Somatostatin Receptor Positive
Midgut Carcinoid Tumours
Safety and Efficacy Study of Enzalutamide Versus
Bicalutamide in Men With Prostate Cancer
http://ClinicalTrials.gov/show/NCT01578239
http://ClinicalTrials.gov/show/NCT01664923
Study 16:
Comparison of Docetaxel/Prednisone to Docetaxel/
Prednisone in Combination With OGX-011 in Men
With Prostate Cancer
http://ClinicalTrials.gov/show/NCT01188187
Study 17:
A Study of Chemotherapy and Ramucirumab vs.
Chemotherapy Alone in Second Line Non-small Cell
Lung Cancer Participants Who Received Prior First
Line Platinum Based Chemotherapy
http://ClinicalTrials.gov/show/NCT01168973
Study 23:
Study 24:
The BEACON Study (Breast Cancer Outcomes With
NKTR-102)
http://ClinicalTrials.gov/show/NCT01492101
Study 25:
Study of XL147 (SAR245408) or XL765 (SAR245409)
in Combination With Letrozole in Subjects With Breast
Cancer
http://ClinicalTrials.gov/show/NCT01082068
Study 26:
Continued HER2 Suppression With Lapatinib Plus
Trastuzumab Versus Trastuzumab Alone
http://ClinicalTrials.gov/show/NCT00968968
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
19
Study 27:
Study 34:
Efficacy and Safety Evaluation of EN3348
(Mycobacterial Cell Wall-DNA Complex [MCC])
as Compared With Mitomycin C in the Intravesical
Treatment of Subjects With BCG Recurrent/Refractory
Non-muscle Invasive Bladder Cancer
Randomized Phase II Trial of Letrozole With or
Without Dasatinib as First and Second-line Treatment
for Hormone Receptor-positive, HER2-negative Postmenopausal Breast Cancer That is Unresectable, Locally
Recurrent or Metastatic
http://ClinicalTrials.gov/show/NCT01200992
http://ClinicalTrials.gov/show/NCT00696072
Study 28:
A Study of Onartuzumab (MetMAb) in Combination
With Tarceva (Erlotinib) in Patients With Met
Diagnostic-Positive Non-Small Cell Lung Cancer
Who Have Received Chemotherapy For Advanced or
Metastatic Disease (MetLung)
Study 35:
MLN8237 in Patients With Ovarian, Fallopian Tube
or Peritoneal Cancer Preceded by Phase 1 Study of
MLN8237 Plus Paclitaxel Treatment of Ovary or Breast
Cancer
http://ClinicalTrials.gov/show/NCT01091428
http://ClinicalTrials.gov/show/NCT01456325
Study 29:
A Study of Onartuzumab (MetMAb) in Combination
With mFOLFOX6 in Patients With Metastatic HER2Negative Gastroesophageal Cancer
Study 36:
MLN8237 in Adults With Nonhematological
Malignancies, Followed by MLN8237 in Lung, Breast,
Head and Neck or Gastroesophageal Malignancies
http://ClinicalTrials.gov/show/NCT01045421
http://ClinicalTrials.gov/show/NCT01590719
Study 30:
A Study of Pertuzumab in Addition to Chemotherapy
and Herceptin (Trastuzumab) as Adjuvant Therapy in
Patients With HER2-Positive Primary Breast Cancer
http://ClinicalTrials.gov/show/NCT01358877
Study 31:
Efficacy and Safety of Zoledronic Acid (Every 4 Weeks
vs. Every 12 Weeks) in Patients With Documented Bone
Metastases From Bone Cancer
http://ClinicalTrials.gov/show/NCT00320710
Study 32:
A Phase 3 Efficacy Study of a Recombinant Vaccinia
Virus Vaccine to Treat Metastatic Prostate Cancer
Study 37:
Phase 1b/2 Study of Carfilzomib in Relapsed Solid
Tumors, Multiple Myeloma, or Lymphoma
http://ClinicalTrials.gov/show/NCT00531284
Study 38:
EMD525797 in Subjects With Asymptomatic or Mildly
Symptomatic Metastatic Castrate-resistant Prostate
Cancer
http://ClinicalTrials.gov/show/NCT01360840
Study 39:
Study of an Investigational Drug, ASP3026, in Patients
With Advanced Malignancies (Solid Tumors and B-Cell
Lymphoma)
http://ClinicalTrials.gov/show/NCT01284192
http://ClinicalTrials.gov/show/NCT01322490
Study 33:
Phase 1-2 Study of a Cancer Vaccine to Treat Patients
With Advanced Stage Ovarian, Fallopian or Peritoneal
Cancer
http://ClinicalTrials.gov/show/NCT01416038
Study 40:
Safety, PK of AKT and MEK Combination
http://ClinicalTrials.gov/show/NCT01138085
Study 41:
A Study That Provides Long-term Safety Follow-up
and Examines Long-term Exposure to Abiraterone
Acetate
http://ClinicalTrials.gov/show/NCT01517802
20
PhRMA • Pharmaceutical Clinical Trials in texas
Study 42:
Immunotherapy Study for Surgically Resected
Pancreatic Cancer
http://ClinicalTrials.gov/show/NCT01072981
Study 43:
Study of Imprime PGG® in Combination With
Cetuximab in Subjects With Recurrent or Progressive
KRAS Wild Type Colorectal Cancer
http://ClinicalTrials.gov/show/NCT01309126
Study 44:
Phase 3 Study of ProstAtak™ With Standard Radiation
Therapy for Localized Prostate Cancer
http://ClinicalTrials.gov/show/NCT01436968
Study 45:
Neo-adjuvant Abiraterone + Luteinizing HormoneReleasing Hormone (LHRH) Versus LHRH in Prostate
Cancer
http://ClinicalTrials.gov/show/NCT01088529
Study 46:
A Study in Second Line Metastatic Colorectal Cancer
http://ClinicalTrials.gov/show/NCT01183780
Study 47:
Study for Women With Platinum Resistant Ovarian
Cancer Evaluating EC145 in Combination With Doxil®
(PROCEED)
http://ClinicalTrials.gov/show/NCT01170650
Study 48:
A Phase 1 Dose Escalation Trial of ASG-5ME in
Pancreatic or Gastric Adenocarcinoma
Study 50:
Study to Assess Safety, Pharmacokinetics, and Efficacy
of Oral CC-223 for Patients With Advanced Solid
Tumors, Non-Hodgkin Lymphoma or Multiple
Myeloma
http://ClinicalTrials.gov/show/NCT01177397
Study 51:
A Study of Carboplatin and Paclitaxel With or Without
MEDI-575 in Adults With Previously Untreated,
Advanced Non-Small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT01268059
Study 52:
Randomized Study to Compare CyberKnife to
Surgical Resection In Stage I Non-small Cell Lung
Cancer
http://ClinicalTrials.gov/show/NCT00840749
Study 53:
Combination Study of BMS-754807 and Erbitux® in
Subjects With Advanced or Metastatic Solid Tumors
http://ClinicalTrials.gov/show/NCT00908024
Study 54:
A Double-blind Study Evaluating IPI-504 and
Docetaxel in Patients With Non-Small Cell Lung
Cancer
http://ClinicalTrials.gov/show/NCT01362400
Study 55:
Long Term Safety of Sativex® Oromucosal Spray
(Sativex®; Nabiximols) as Adjunctive Therapy in
Patients With Uncontrolled Persistent Chronic Cancer
Related Pain
http://ClinicalTrials.gov/show/NCT01337089
http://ClinicalTrials.gov/show/NCT01166490
Study 49:
A Randomized, Phase 2, Neoadjuvant Study of Weekly
Paclitaxel With LCL161 in Patients With Triple Negative
Breast Cancer
Study 56:
Eribulin With Trastuzumab as First-line Therapy for
Locally Recurrent or Metastatic HER2 Positive Breast
Cancer
http://ClinicalTrials.gov/show/NCT01269346
http://ClinicalTrials.gov/show/NCT01617668
Study 57:
Efficacy and Safety Study of NeuVax™ Vaccine to
Prevent Breast Cancer Recurrence
http://ClinicalTrials.gov/show/NCT01479244
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
21
Study 58:
LDK378 in Crizotinib naïve Adult Patients With ALKactivated Non-small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT01685138
Study 65:
Study of MEDI-573 Plus Standard Endocrine Therapy
for Women With Hormone-sensitive Metastatic Breast
Cancer
http://ClinicalTrials.gov/show/NCT01446159
Study 59:
Efficacy & Safety of ODSH (2-0, 3-0 Desulfated
Heparin) in Patients With Metastatic Pancreatic Cancer
Treated With Gemcitabine & Abraxane
http://ClinicalTrials.gov/show/NCT01461915
Study 66:
Study of IMC-18F1 or Ramucirumab DP in
Combination With Capecitabine or Capecitabine on
Previously Treated Breast Cancer Patients
http://ClinicalTrials.gov/show/NCT01234402
Study 60:
Trial Evaluating Dovitinib Combined With Fulvestrant,
in Postmenopausal Patients With HER2- and HR+
Breast Cancer
http://ClinicalTrials.gov/show/NCT01528345
Study 61:
A Study of Ramucirumab (IMC-1121B) in
Combination With Eribulin Versus Eribulin Alone in
Patients With Breast Cancer
http://ClinicalTrials.gov/show/NCT01427933
Study 62:
Study 67:
A Study of Abiraterone Acetate Plus Prednisone With
or Without Exemestane in Postmenopausal Women
With Estrogen Receptor-Positive (ER+) Metastatic
Breast Cancer Progressing After Letrozole or
Anastrozole Therapy
http://ClinicalTrials.gov/show/NCT01381874
Study 68:
Diffuse Gastric and Esophagogastric Junction Cancer
S-1 Trial
http://ClinicalTrials.gov/show/NCT01285557
A Study of the Experimental Drug BKM120 With
Paclitaxel in Patients With HER2 Negative, Locally
Advanced or Metastatic Breast Cancer, With or Without
PI3K Activation
A Phase 2 Study of LY2495655 in Participants With
Pancreatic Cancer
http://ClinicalTrials.gov/show/NCT01572727
http://ClinicalTrials.gov/show/NCT01505530
Study 63:
Study 69:
Study 70:
Phase III Study of BKM120/Placebo With Fulvestrant
in Postmenopausal Patients With Hormone Receptor
Positive HER2-negative Locally Advanced or Metastatic
Breast Cancer Refractory to Aromatase Inhibitor
A Phase III Study of BKM120 With Fulvestrant in
Patients With HR+, HER2-, AI Treated, Locally
Advanced or Metastatic Breast Cancer Who Progressed
on or After mTORi
http://ClinicalTrials.gov/show/NCT01610284
http://ClinicalTrials.gov/show/NCT01633060
Study 64:
Study 71:
A Phase 2 Study Comparing Chemotherapy in
Combination With OGX-427 or Placebo in Patients
With Bladder Cancer
Study Comparing Orteronel Plus Prednisone in
Patients With Metastatic Castration-Resistant Prostate
Cancer
http://ClinicalTrials.gov/show/NCT01454089
http://ClinicalTrials.gov/show/NCT01193257
Study 72:
A Study of Tasquinimod in Men With Metastatic
Castrate Resistant Prostate Cancer
http://ClinicalTrials.gov/show/NCT01234311
22
PhRMA • Pharmaceutical Clinical Trials in texas
Study 73:
Study 80:
Study of Bevacizumab/mFOLFOX6 Versus
Bevacizumab/Folfiri With Biomarker Stratification
in Patients With Previously Untreated Metastatic
Colorectal Cancer
A Study to Evaluate Corrected QT Interval and DrugDrug Interaction of Trastuzumab on Carboplatin in the
Presence of Docetaxel in Patients With HER2-Positive
Metastatic or Locally Advanced Inoperable Cancer
http://ClinicalTrials.gov/show/NCT01374425
http://ClinicalTrials.gov/show/NCT00927589
Study 74:
FOLFOX/Bevacizumab With Onartuzumab (MetMAb)
Versus Placebo as First-Line Treatment in Patients With
Metastatic Colorectal Cancer
http://ClinicalTrials.gov/show/NCT01418222
Study 81:
Study of GDC-0941 or GDC-0980 With Fulvestrant
Versus Fulvestrant in Advanced or Metastatic Breast
Cancer in Patients Resistant to Aromatase Inhibitor
Therapy
http://ClinicalTrials.gov/show/NCT01437566
Study 75:
Safety and Efficacy of BKM120 in Patients With
Metastatic Non-small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT01297491
Study 76:
Study of Palifosfamide-tris in Combination With
Carboplatin and Etoposide in Chemotherapy Naïve
Patients With Extensive-Stage Small Cell Lung Cancer
(The MATISSE Study)
http://ClinicalTrials.gov/show/NCT01555710
Study 77:
Efficacy/Safety of Imprime PGG® Injection With
Bevacizumab and Paclitaxel/Carboplatin in Patients
With Untreated Advanced Non-Small Cell Lung
Cancer (NSCLC)
http://ClinicalTrials.gov/show/NCT00874107
Study 78:
Study To Evaluate the Efficacy and Safety Of
Bevacizumab, and Associated Biomarkers, In
Combination With Paclitaxel Compared With Paclitaxel
Plus Placebo as First-line Treatment Of Patients With
Her2-Negative Metastatic Breast Cancer
http://ClinicalTrials.gov/show/NCT01663727
Study 79:
Study 82:
Study of BMS-936558 Compared to Docetaxel in
Previously Treated Advanced or Metastatic Squamous
Cell Non-small Cell Lung Cancer (NSCLC)
http://ClinicalTrials.gov/show/NCT01642004
Study 83:
Study of MK-3475 in Participants With Progressive
Locally Advanced or Metastatic Carcinoma, Melanoma,
or Non-small Cell Lung Carcinoma (P07990/MK-3475001 AM5)
http://ClinicalTrials.gov/show/NCT01295827
Study 84:
A Study of Trastuzumab Emtansine in Comparison
With Treatment of Physician’s Choice in Patients With
HER2-Positive Breast Cancer Who Have Received at
Least Two Prior Regimens of HER2-Directed Therapy
(TH3RESA)
http://ClinicalTrials.gov/show/NCT01419197
Study 85:
A Study of Pertuzumab in Combination With
Trastuzumab Plus an Aromatase Inhibitor in Patients
With Hormone Receptor-Positive, Metastatic HER2positive Breast Cancer
http://ClinicalTrials.gov/show/NCT01491737
A Study to Test Safety and Efficacy of IMGN901 in
Combination With Carboplatin/Etoposide in Patients
With Advanced Solid Tumors and Extensive Stage
Small Cell Lung Cancer
Phase I/II Study of APS001F With Flucytosine and
Maltose in Solid Tumors
http://ClinicalTrials.gov/show/NCT01237678
http://ClinicalTrials.gov/show/NCT01562626
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
Study 86:
23
Study 87:
Study 95:
Safety and Efficacy Trial of Ipilimumab Versus
Pemetrexed in Non-Squamous Non-Small Cell Lung
Cancer
A Phase 1b/2 Study of OMP-59R5 in Combination
With Gemcitabine in Subjects With Previously
Untreated Stage IV Pancreatic Cancer
http://ClinicalTrials.gov/show/NCT01471197
http://ClinicalTrials.gov/show/NCT01647828
Study 88:
A Study of CDX-1127 in Patients With Select Solid
Tumor Types or Hematologic Cancers
http://ClinicalTrials.gov/show/NCT01460134
Study 89:
A Study of IMC-TR1 in Patients With Advanced Solid
Tumors
http://ClinicalTrials.gov/show/NCT01646203
Study 90:
Study of Denosumab in the Treatment of
Hypercalcemia of Malignancy in Subjects With
Elevated Serum Calcium
http://ClinicalTrials.gov/show/NCT00896454
Study 91:
A Phase I Study of LJM716 in Squamous Cell
Carcinoma of Head and Neck, or HER2+ Breast
Cancer or Gastric Cancer
http://ClinicalTrials.gov/show/NCT01598077
Study 96:
A Clinical Trial Testing The Efficacy Of Crizotinib
Versus Standard Chemotherapy Pemetrexed Plus
Cisplatin Or Carboplatin In Patients With ALK Positive
Non Squamous Cancer Of The Lung
http://ClinicalTrials.gov/show/NCT01154140
Study 97:
Evaluation of an Anti-cancer Immunotherapy Combined
With Standard Neoadjuvant Treatment in Patients With
WT1-positive Primary Invasive Breast Cancer
http://ClinicalTrials.gov/show/NCT01220128
Study 98:
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine
in Pancreatic Cancer Patients Receiving at Least 2
Prior Therapies
http://ClinicalTrials.gov/show/NCT01510561
Study 99:
Dose-escalation Study of Oral CX-4945
http://ClinicalTrials.gov/show/NCT00891280
Study 92:
A Study in Ovarian, Non-Small Cell Lung, Prostate,
Colorectal, Gastroesophageal Cancers, and Squamous
Cell Carcinoma of the Head and Neck
http://ClinicalTrials.gov/show/NCT01059643
Study 93:
Safety Study of PLX108-01 in Patients With Solid
Tumors
http://ClinicalTrials.gov/show/NCT01004861
Study 94:
Phase I Intratumoral Pbi-shRNA STMN1 LP in
Advanced and/or Metastatic Cancer
http://ClinicalTrials.gov/show/NCT01505153
Study 100:
A Study to Determine Safety and Tolerability of
Enzalutamide (MDV3100) in Combination With
Abiraterone Acetate in Bone Metastatic CastrationResistant Prostate Cancer Patients
http://ClinicalTrials.gov/show/NCT01650194
Study 101:
Phase III Trial Comparing Capecitabine in
Combination With Sorafenib or Placebo in the
Treatment of Locally Advanced or Metastatic HER2Negative Breast Cancer
http://ClinicalTrials.gov/show/NCT01234337
Study 102:
A Phase 1 Study of AMG 208 in Subjects With
Advanced Solid Tumors
http://ClinicalTrials.gov/show/NCT00813384
24
PhRMA • Pharmaceutical Clinical Trials in texas
Study 103:
A Study of BYL719 in Adult Patients With Advanced
Solid Malignancies, Whose Tumors Have an Alteration
of the PIK3CA Gene
Study 111:
LDK378 in Adult Patients With ALK-activated NSCLC
Previously Treated With Chemotherapy and Crizotinib
http://ClinicalTrials.gov/show/NCT01685060
http://ClinicalTrials.gov/show/NCT01219699
Study 104:
A Phase Ib/II Study of BEZ235 and Trastuzumab in
Patients With HER2-positive Breast Cancer Who Failed
Prior to Trastuzumab
Study 112:
Safety and Pharmacokinetics of Escalating Doses of
DNIB0600A in Patients With Non-Small Cell Lung
Cancer and Platinum Resistant Ovarian Cancer
http://ClinicalTrials.gov/show/NCT01363947
http://ClinicalTrials.gov/show/NCT01471847
Study 105:
Study of a Drug [DCVax®-L] to Treat Newly
Diagnosed GBM Brain Cancer
Study 113:
A Study of Oral CFG920 in Patients With Castration
Resistant Prostate Cancer
http://ClinicalTrials.gov/show/NCT01647789
http://ClinicalTrials.gov/show/NCT00045968
Study 106:
A Study of AMG 337 in Subjects With Advanced Solid
Tumors
http://ClinicalTrials.gov/show/NCT01253707
Study 114:
M402 and Gemcitabine in Pancreatic Cancer-Part A
http://ClinicalTrials.gov/show/NCT01621243
Study 115:
A Study of AMG 820 in Subjects With Advanced Solid
Tumors
A Clinical Study in Cancer Patients to Investigate the
Potential Impact of Custirsen, on the Blood Levels of
the Chemotherapeutic Drug, Paclitaxel, When Given
Together as Part of a Treatment Regimen
http://ClinicalTrials.gov/show/NCT01444404
http://ClinicalTrials.gov/show/NCT01497470
Study 107:
Study 108:
Efficacy and Safety of BEZ235 Compared to
Everolimus in Patients With Advanced Pancreatic
Neuroendocrine Tumors
Study 116:
A Study of MDV3100 Versus Bicalutamide in Castrate
Men With Metastatic Prostate Cancer
http://ClinicalTrials.gov/show/NCT01288911
http://ClinicalTrials.gov/show/NCT01628913
Study 109:
A Study of Oral LGK974 in Patients With Malignancies
Dependent on Wnt Ligands
Study 117:
GRN1005 Alone or in Combination With Trastuzumab
in Breast Cancer Patients With Brain Metastases
http://ClinicalTrials.gov/show/NCT01480583
http://ClinicalTrials.gov/show/NCT01351103
Study 110:
An A/B Dose Escalation Study of AbGn-7 Alone and
With FOLFOX7 Treatment in Patients With Advanced
Solid Tumors
http://ClinicalTrials.gov/show/NCT01466569
Study 118:
A Study in Head and Neck Cancer
http://ClinicalTrials.gov/show/NCT01081041
Study 119:
Study is Designed to Assess the Safety and Tolerability
of AZD4547 at Increasing Doses in Patients With
Advanced Tumours
http://ClinicalTrials.gov/show/NCT00979134
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
25
Study 120:
Trial of Adjuvant FANG™ Vaccine for High Risk Stage
IIIc Ovarian Cancer
http://ClinicalTrials.gov/show/NCT01309230
Study 127:
Study Assessing Safety, Pharmacokinetics and Efficacy
of CC-223 With Either Erlotinib or Oral Azacitidine in
Advanced Non-Small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT01545947
Study 121:
Study 128:
Study Evaluating the Safety and Efficacy of
Onartuzumab (Metmab) And/Or Bevacizumab
in Combination With Paclitaxel in Patients With
Metastatic, Triple Negative Breast Cancer
Study of VGX-100 Administered Alone and Coadministered With Bevacizumab in Adult Subjects With
Advanced Solid Tumors
http://ClinicalTrials.gov/show/NCT01186991
http://ClinicalTrials.gov/show/NCT01514123
Study 122:
A Multi-arm Phase I Safety Study of BMS-936558
in Combination With Gemcitabine/Cisplatin,
Pemetrexed/Cisplatin, Carboplatin/Paclitaxel,
Bevacizumab Maintenance, Erlotinib or Monotherapy
Alone in Subjects With Stage IIIB/IV Non-small Cell
Lung Cancer (NSCLC)
http://ClinicalTrials.gov/show/NCT01454102
Study 123:
Study of HF10 in Patients With Refractory Head and
Neck Cancer or Solid Tumors With Cutaneous and/or
Superficial Lesions
http://ClinicalTrials.gov/show/NCT01017185
Study 124:
ASPECCT: A Study of Panitumumab Efficacy and
Safety Compared to Cetuximab in Subjects With
KRAS Wild-Type Metastatic Colorectal Cancer
http://ClinicalTrials.gov/show/NCT01001377
Study 129:
Pharmacokinetic Drug-drug Interaction Study of
Dovitinib (TKI258) in Patients With Advanced Solid
Tumors
http://ClinicalTrials.gov/show/NCT01700270
Study 130:
Dasatinib Added to Gemcitabine for Subjects With
Locally-advanced Pancreatic Cancer
http://ClinicalTrials.gov/show/NCT01395017
Study 131:
Intravesical Administration of INSTILADRIN (rAdIFN With Syn3) in Patients With Bladder Cancer
http://ClinicalTrials.gov/show/NCT01687244
Study 132:
Efficacy and Safety of Leuprolide Acetate 22.5 mg
Depot in Treatment of Prostate Cancer
http://ClinicalTrials.gov/show/NCT01415960
Study 125:
Study 133:
Two-Dose Level Evaluation of NX-1207 for the
Treatment of Low Risk, Localized (T1c) Prostate
Cancer
Sativex® for Relieving Persistent Pain in Patients With
Advanced Cancer
http://ClinicalTrials.gov/show/NCT01620515
http://ClinicalTrials.gov/show/NCT01361607
Study 126:
Brentuximab Vedotin in Patients With CD30-positive
Nonlymphomatous Malignancies
Study 134:
A Phase 1 Study in Patients With Advanced Cancer
http://ClinicalTrials.gov/show/NCT01115790
http://ClinicalTrials.gov/show/NCT01461538
26
PhRMA • Pharmaceutical Clinical Trials in texas
Study 135:
The Study Evaluating Efficacy And Tolerability Of
Veliparib in Combination With Temozolomide or
In Combination With Carboplatin and Paclitaxel
Versus Placebo in Subjects With BRCA1 and BRCA2
Mutation and Metastatic Breast Cancer
http://ClinicalTrials.gov/show/NCT01506609
Study 136:
Phase II of AUY922 in Second-line Gastric Cancer
in Combination With Trastuzumab in HER2 Positive
Patients
Study 142:
Study of BMS-936558 Compared to Docetaxel in
Previously Treated Advanced or Metastatic Nonsquamous NSCLC
http://ClinicalTrials.gov/show/NCT01673867
Study 143:
A Phase 1 Study of MLN8237 in Patients With
Advanced Solid Tumors Including Castration-Resistant
Prostate Cancer Receiving a Standard Docetaxel
Regimen
http://ClinicalTrials.gov/show/NCT01094288
http://ClinicalTrials.gov/show/NCT01402401
Study 137:
A Phase 2 Diagnostic Imaging Study With 99mTcMIP-1404 in Men With High-Risk Prostate Cancer
Scheduled for Radical Prostatectomy (RP) and
Extended Pelvic Lymph Node Dissection (EPLND)
Compared to Histopathology
http://ClinicalTrials.gov/show/NCT01667536
Study 138:
Open-label, Phase II, Study of Everolimus Plus
Letrozole in Postmenopausal Women With ER+
Metastatic Breast Cancer
http://ClinicalTrials.gov/show/NCT01698918
Study 139:
Phase I, Open-label, Dose-escalation Study of ISISSTAT3Rx, Administered to Patients With Advanced
Cancers
http://ClinicalTrials.gov/show/NCT01563302
Study 140:
Clinical Study of WT2725 in Patients With Advanced
Solid Malignancies
http://ClinicalTrials.gov/show/NCT01621542
Study 141:
Safety and Tolerability Study of ISIS EIF4E Rx in
Combination With Carboplatin and Paclitaxel
Study 144:
Phase 3 Study of Immunotherapy to Treat Advanced
Prostate Cancer
http://ClinicalTrials.gov/show/NCT01057810
Study 145:
A Study of Trastuzumab Emtansine Versus Taxane in
Patients With Advanced Gastric Cancer
http://ClinicalTrials.gov/show/NCT01641939
Study 146:
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With
Prednisone for the Treatment of Metastatic Castration
Resistant Prostate Cancer
http://ClinicalTrials.gov/show/NCT01308580
Study 147:
Erlotinib Plus ARQ 197 Versus Single Agent
Chemotherapy in Locally Advanced or Metastatic NonSmall Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT01395758
Study 148:
Study Evaluating the Safety and Efficacy Of
Carboplatin/Paclitaxel And Carboplatin/Paclitaxel/
Bevacizumab With and Without GDC-0941 in Patients
With Previously Untreated Advanced Or Recurrent
Non-small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT01493843
Paclitaxel|Drug: Carboplatin
http://ClinicalTrials.gov/show/NCT01234038
Study 149:
A Clinical Trial Assessing Safety and Efficacy of
BZL101 for Metastatic Breast Cancer
http://ClinicalTrials.gov/show/NCT00907959
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
27
Study 150:
The Study of Biodistribution and Dosimetry of
99mTc-Glycopeptide(99mTc-GP) in Patients With
Breast Cancer
http://ClinicalTrials.gov/show/NCT01159405
Study 158:
Study of BMS-754807 Combined With Letrozole
or BMS-754807 Alone in Patients With Hormone
Receptor-Positive Breast Cancer and Resistance to
Non-Steroidal Aromatase Inhibitors
http://ClinicalTrials.gov/show/NCT01225172
Study 151:
Phase III Study of the Effect of GTx-024 on Muscle
Wasting in Patients With Non-Small Cell Lung Cancer
(NSCLC)
http://ClinicalTrials.gov/show/NCT01355484
Study 159:
Safety, Pharmacokinetics and Pharmacodynamics of
BEZ235 Plus MEK162 in Selected Advanced Solid
Tumor Patients
http://ClinicalTrials.gov/show/NCT01337765
Study 152:
Effect of GTx-024 on Muscle Wasting in Patients With
Non-Small Cell Lung Cancer (NSCLC) on First Line
Platinum
http://ClinicalTrials.gov/show/NCT01355497
Study 153:
Study of Eniluracil + 5-Fluorouracil (5-FU) +
Leucovorin Versus Capecitabine in Metastatic Breast
Cancer
http://ClinicalTrials.gov/show/NCT01231802
Study 154:
A Study of Trastuzumab Emtansine (T-DM1) in
Combination With Docetaxel, and Potentially
Pertuzumab, in Patients With Advanced Breast Cancer
http://ClinicalTrials.gov/show/NCT00934856
Study 155:
Trial of Active Immunotherapy With Globo H-KLH
(OPT-822) in Metastatic Breast Cancer Subjects
http://ClinicalTrials.gov/show/NCT01516307
Study 156:
Study 160:
LUX-Head&Neck 1: A Phase III Trial of Afatinib
(BIBW2992) Versus Methotrexate for the Treatment
of Recurrent and/or Metastatic (R/M) Head and
Neck Squamous Cell Cancer After Platinum Based
Chemotherapy
http://ClinicalTrials.gov/show/NCT01345682
Study 161:
Randomized Phase II Adjuvant Chemotherapy ±
FANG™ in Colorectal Carcinoma With Liver Metastases
http://ClinicalTrials.gov/show/NCT01505166
Study 162:
Trial in Squamous Non Small Cell Lung Cancer
Subjects Comparing Ipilimumab Plus Paclitaxel
and Carboplatin Versus Placebo Plus Paclitaxel and
Carboplatin
http://ClinicalTrials.gov/show/NCT01285609
Study 163:
ARCHER 1009: A Study Of PF-00299804
(Dacomitinib) Vs. Erlotinib In The Treatment Of
Advanced Non-Small Cell Lung Cancer
A Study of Pertuzumab in Combination With
Herceptin (Trastuzumab) And Vinorelbine in First Line
in Patients With Metastatic or Locally Advanced HER2Positive Breast Cancer
http://ClinicalTrials.gov/show/NCT01360554
http://ClinicalTrials.gov/show/NCT01565083
A Study in Advanced Cancer
A Study of MK-1775 in Combination With Paclitaxel
and Carboplatin Versus Paclitaxel and Carboplatin
Alone for Participants With Platinum-Sensitive Ovarian
Tumors With the P53 Gene Mutation (MK-1775-004
AM3)
http://ClinicalTrials.gov/show/NCT01226485
http://ClinicalTrials.gov/show/NCT01357161
Study 157:
28
Study 164:
PhRMA • Pharmaceutical Clinical Trials in texas
Study 165:
Safety and Tolerability of Different Dose Combinations
of Ridaforolimus With MK-2206 or MK-0752 for
Participants With Advanced Cancer (MK-8669-049
AM1)
http://ClinicalTrials.gov/show/NCT01295632
Study 166:
Tesetaxel as First-line Therapy for Metastatic Breast
Cancer
Study 174:
A Phase I Study to Assess the Safety and Distribution
of VB-111 in Patients With Advanced Metastatic Cancer
http://ClinicalTrials.gov/show/NCT00559117
Study 175:
A Study of RO5185426 (Vemurafenib) in Patients With
Metastatic or Unresectable Papillary Thyroid Cancer
Positive for the BRAF V600 Mutation
http://ClinicalTrials.gov/show/NCT01286753
http://ClinicalTrials.gov/show/NCT01221870
Study 167:
A Phase 2b Study of Modified Vaccinia Virus to Treat
Patients Advanced Liver Cancer Who Failed Sorafenib
Study 176:
A Study of DS-2248, in Subjects With Advanced Solid
Tumors
http://ClinicalTrials.gov/show/NCT01288430
http://ClinicalTrials.gov/show/NCT01387555
Study 168:
A Study of LY3007113 in Patients With Advanced Cancer
http://ClinicalTrials.gov/show/NCT01463631
Study 169:
Salvage Ovarian FANG Vaccine + Bevacizumab
Study 177:
A Study to Evaluate the Safety and Efficacy of
Inactivated Varicella-zoster Vaccine (VZV) as a
Preventative Treatment for Herpes Zoster (HZ) and
HZ-related Complications in Adult Participants With
Solid Tumor or Hematologic Malignancy (V212-011
AM2)
http://ClinicalTrials.gov/show/NCT01254630
http://ClinicalTrials.gov/show/NCT01551745
Study 170:
Efficacy and Safety of GS-6624 With FOLFIRI as
Second Line Treatment in Colorectal Adenocarcinoma
Study 178:
An Assessment of an Attenuated Live Listeria Vaccine
in CIN 2+
http://ClinicalTrials.gov/show/NCT01116245
http://ClinicalTrials.gov/show/NCT01479465
Study 171:
A Study to Evaluate the Efficacy and Safety of GS-6624
Combined With Gemcitabine for Metastatic Pancreatic
Adenocarcinoma
http://ClinicalTrials.gov/show/NCT01472198
Study 172:
Safety Study of Recombinant Vaccinia Virus to Treat
Refractory Solid Tumors in Pediatric Patients
http://ClinicalTrials.gov/show/NCT01169584
Study 173:
Study Evaluating Orally Administered AMG 900 in
Adult Subjects With Acute Leukemias and Related
Disorders
Study 179:
Study of KB004 in Subjects With Hematologic
Malignancies
http://ClinicalTrials.gov/show/NCT01211691
Study 180:
Afatinib (BIBW2992) in HER2-overexpressing
Inflammatory Breast Cancer
http://ClinicalTrials.gov/show/NCT01325428
Study 181:
Everolimus Plus Best Supportive Care vs. Placebo Plus
Best Supportive Care in the Treatment of Patients
With Advanced Neuroendocrine Tumors (GI or Lung
Origin)
http://ClinicalTrials.gov/show/NCT01524783
http://ClinicalTrials.gov/show/NCT01380756
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
29
Study 182:
Study 190:
A Study of LY2228820 in Patients With Advanced
Cancer
BAY80-6946 Open Label, Phase I Study in Patients
With Advanced Cancer
http://ClinicalTrials.gov/show/NCT01393990
http://ClinicalTrials.gov/show/NCT00962611
Study 183:
A Phase 1 Study of LY2835219 In Subjects With
Advanced Cancer
http://ClinicalTrials.gov/show/NCT01394016
Study 191:
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive
Metastatic Breast Cancer Patients After One Prior
Herceptin Treatment
http://ClinicalTrials.gov/show/NCT01125566
Study 184:
Study 192:
Study of CC-122 to Evaluate the Safety, Tolerability,
and Effectiveness for Patients With Advanced Solid
Tumors, Non-Hodgkin’s Lymphoma, or Multiple
Myeloma
A Study to Look at the Electrical Activity of the Heart
in Subjects With Solid Tumor Cancers, Before and
After Receiving the Study Treatment, GSK1120212
http://ClinicalTrials.gov/show/NCT01421524
http://ClinicalTrials.gov/show/NCT01658553
Study 185:
Study Of Dacomitinib In Advanced NSCLC Patients
(Post Chemo Or Select First Line) To Evaluate
Prophylactic Intervention On Derm And GI AEs And
PRO
http://ClinicalTrials.gov/show/NCT01465802
Study 186:
A Study of MM-121 Combination Therapy in Patients
With Advanced Non-Small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT00994123
Study 187:
A Study of PNT2258 in Patients With Advanced Solid
Tumors
http://ClinicalTrials.gov/show/NCT01191775
Study 188:
Dose Escalation Study of Pasireotide (SOM230) in
Patients With Advanced Neuroendocrine Tumors
(NETs)
Study 193:
Trial of Mitogen-activated Protein/Extracellular Signalregulated Kinase Kinase (MEK) Inhibitor
http://ClinicalTrials.gov/show/NCT00957580
Study 194:
A Study of Vemurafenib in Patients With BRAF V600
Mutation-Positive Cancers
http://ClinicalTrials.gov/show/NCT01524978
Study 195:
Study in Head and Neck Cancer
http://ClinicalTrials.gov/show/NCT01099358
Study 196:
A Study of Pemetrexed & Carboplatin/Cisplatin or
Gemcitabine & Carboplatin/Cisplatin With or Without
IMC-1121B in Patients Previously Untreated With
Recurrent or Advanced Non-small Cell Lung Cancer
(NSCLC)
http://ClinicalTrials.gov/show/NCT01160744
http://ClinicalTrials.gov/show/NCT01364415
Study 189:
Phase 1 Study of CEP-37250/KHK2804 in Subjects
With Advanced Solid Tumors
Study 197:
A Study in Head and Neck Cancer
http://ClinicalTrials.gov/show/NCT01063075
http://ClinicalTrials.gov/show/NCT01447732
30
PhRMA • Pharmaceutical Clinical Trials in texas
Study 198:
Clinical Study of BYM338 for the Treatment of
Unintentional Weight Loss in Patients With Cancer of
the Lung or the Pancreas
Study 206:
A Study Of PF-04449913 In Select Hematologic
Malignancies
http://ClinicalTrials.gov/show/NCT00953758
http://ClinicalTrials.gov/show/NCT01433263
Study 199:
A Study of Dalotuzumab + MK-2206, Dalotuzumab +
MK-0752, and Dalotuzumab + MK-8669 Combination
Therapies in Participants With Advanced Cancer (MK0646-027 AM2)
http://ClinicalTrials.gov/show/NCT01243762
Study 200:
Sorafenib Tosylate Following a Liver Transplant in
Treating Patients With Liver Cancer
Study 207:
A Open-Label, Multiple Ascending Dose Study of DS3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects
With Advanced Solid Tumors or Lymphomas
http://ClinicalTrials.gov/show/NCT01588678
Study 208:
Phase I Study to Assess the Safety, Tolerability, and
Pharmacokinetics of Orally Administered CUDC-101
in Cancer Patients
http://ClinicalTrials.gov/show/NCT01702285
http://ClinicalTrials.gov/show/NCT01624285
Study 201:
Study 209:
A Dose Escalation Trial of PR610 Treating Patients
With Solid Tumors
Study of MLN2480 in Patients With Relapsed
or Refractory Solid Tumors Followed by a Dose
Expansion in Patients With Metastatic Melanoma
http://ClinicalTrials.gov/show/NCT01631279
http://ClinicalTrials.gov/show/NCT01425008
Study 202:
Study 210:
Study of GO-203-2C Given Intravenously in Patients
With Advanced Solid Tumors Including Lymphomas
A Study of LY2784544 in Participants With
Myeloproliferative Neoplasms
http://ClinicalTrials.gov/show/NCT01279603
http://ClinicalTrials.gov/show/NCT01594723
Study 203:
Study 211:
Phase 1 Study of ONT-10 in Patients With Solid
Tumors
An Extension Study of RO5045337 in Patients
Participating in Previous Cancer Studies
http://ClinicalTrials.gov/show/NCT01556789
http://ClinicalTrials.gov/show/NCT01677780
Study 204:
Trial of Bi-shRNA-furin and Granulocyte Macrophage
Colony Stimulating Factor (GMCSF) Augmented
Autologous Tumor Cell Vaccine for Advanced Cancer
http://ClinicalTrials.gov/show/NCT01061840
Study 212:
LUX-Head&Neck 2: A Phase III Trial of Afatinib
(BIBW 2992) Versus Placebo for the Treatment of Head
and Neck Squamous Cell Cancer After Treatment With
Chemo-radiotherapy
http://ClinicalTrials.gov/show/NCT01345669
Study 205:
Study 213:
A Rollover Study to Provide Continued Treatment
With GSK2118436 to Subjects With BRAF MutationPositive Tumors
Vaccine Therapy in Treating Patients With Breast
Cancer
http://ClinicalTrials.gov/show/NCT01231594
http://ClinicalTrials.gov/show/NCT00524277
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
31
Study 214:
Arimidex With or Without Faslodex In Postmenopausal
Women With HR Positive Breast Cancer
http://ClinicalTrials.gov/show/NCT00570323
Study 222:
A Phase Ib/II Study of LGX818 in Combination With
MEK162 in Adult Patients With BRAF Dependent
Advanced Solid Tumors
http://ClinicalTrials.gov/show/NCT01543698
Study 215:
Study 223:
A Phase I Study of Systemic Gene Therapy With SGT94 in Patients With Solid Tumors
A Study of Nilotinib Versus Imatinib in GIST Patients
http://ClinicalTrials.gov/show/NCT01517464
http://ClinicalTrials.gov/show/NCT00785785
Study 216:
Evaluation of Safety, Tolerability, PK & PD of
Intravenous VX15/2503 in Patients With Advanced
Solid Tumors
http://ClinicalTrials.gov/show/NCT01313065
Study 224:
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase
Inhibitor BAY80-6946 With MEK (Mitogen-activated
Protein Kinase) Inhibitor BAY86-9766 in Patients With
Advanced Cancer
http://ClinicalTrials.gov/show/NCT01392521
Study 217:
An Investigational Drug, PF-02341066, Is Being Studied
In Patients With Advanced Non-Small Cell Lung
Cancer With A Specific Gene Profile Involving The
Anaplastic Lymphoma Kinase (ALK) Gene
Study 225:
Safety and Efficacy Study of In-111 Pentetreotide to
Treat Neuroendocrine Tumors
http://ClinicalTrials.gov/show/NCT00442533
http://ClinicalTrials.gov/show/NCT00932451
Study 218:
Incontinent Urinary Diversion Using an Autologous
Neo-Urinary Conduit
http://ClinicalTrials.gov/show/NCT01087697
Study 226:
A Study to Investigate Safety, Pharmacokinetics
(PK) and Pharmacodynamics (PD) of BKM120 Plus
GSK1120212 in Selected Advanced Solid Tumor
Patients
http://ClinicalTrials.gov/show/NCT01155453
Study 219:
Efficacy of Everolimus Alone or in Combination With
Pasireotide LAR in Advanced PNET
http://ClinicalTrials.gov/show/NCT01374451
Study 220:
Safety and Efficacy of ALD518 for Reducing Oral
Mucositis in Head and Neck Cancer Subjects
http://ClinicalTrials.gov/show/NCT01403064
Study 221:
Safety Study of the Drug MM-151 in Patients With
Advanced Solid Tumors Resisting Ordinary Treatment
http://ClinicalTrials.gov/show/NCT01520389
Study 227:
A Phase 1 Study to Evaluate the Safety, Tolerability,
and Pharmacokinetics of MEDI0639 in Advanced Solid
Tumors
http://ClinicalTrials.gov/show/NCT01577745
Study 228:
Dasatinib in Combination With Zoledronic Acid for
the Treatment of Breast Cancer With Bone Metastasis
http://ClinicalTrials.gov/show/NCT00566618
Study 229:
Safety Study of Infusion of SGT-53 to Treat Solid
Tumors
http://ClinicalTrials.gov/show/NCT00470613
32
PhRMA • Pharmaceutical Clinical Trials in texas
Study 230:
Study 238:
Phase 1 Pharmacokinetics Study of Oral MLN9708 in
Patients With Advanced Nonhematologic Malignancies
or Lymphoma
A Phase 1 Dose Escalation Study of AV-203, an ERBB3
Inhibitory Antibody, in Subjects With Advanced Solid
Tumors
http://ClinicalTrials.gov/show/NCT01454076
http://ClinicalTrials.gov/show/NCT01603979
Study 231:
Study 239:
A Study of the Safety and Pharmacokinetics of
SAR245409 Tablets in Patients With Solid Tumors or
Lymphoma
Cabazitaxel With or Without Carboplatin in Patients
With Metastatic Castration-Resistant Prostate Cancer
Previously Treated With Docetaxel-Based Therapy
http://ClinicalTrials.gov/show/NCT01596270
http://ClinicalTrials.gov/show/NCT01505868
Study 232:
Study 240:
A Study of QBI-139 in Subjects With Advanced Solid
Tumors
First in Human Trial of TAS266 in Patients With
Advanced Solid Tumors
http://ClinicalTrials.gov/show/NCT00818831
http://ClinicalTrials.gov/show/NCT01529307
Study 233:
A Study to Evaluate the Effects of Combining
Cabazitaxel With Cisplatin Given Every 3 Weeks in
Patients With Advanced Solid Cancer
Study 241:
Azacitidine and CAPOX in Metastatic Colorectal
Cancer
http://ClinicalTrials.gov/show/NCT01193517
http://ClinicalTrials.gov/show/NCT00925743
Study 234:
Study 242:
A Dose Escalation Study of OMP-18R5 in Subjects
With Solid Tumors
Bortezomib With Gemcitabine/Doxorubicin in
Patients With Urothelial Cancer and Other Solid
Tumors
http://ClinicalTrials.gov/show/NCT01345201
http://ClinicalTrials.gov/show/NCT00479128
Study 235:
Study 243:
A Dose Escalation Study of OMP-59R5 in Subjects
With Solid Tumors
First-line Treatment of Weekly Paclitaxel With
Carboplatin and Bevacizumab in Ovarian Cancer
http://ClinicalTrials.gov/show/NCT01277146
http://ClinicalTrials.gov/show/NCT01097746
Study 236:
Dose-Escalation Phase 1 Study of G-202 in Patients
With Advanced Solid Tumors
http://ClinicalTrials.gov/show/NCT01056029
Study 244:
Oral Azacitidine as a Single Agent and in Combination
With Carboplatin or ABI-007 in Subjects With
Relapsed or Refractory Solid Tumors
http://ClinicalTrials.gov/show/NCT01478685
Study 237:
Phase 1 Study of ONX 0912 Administered Orally in
Patients With Advanced Refractory or Recurrent Solid
Tumors
http://ClinicalTrials.gov/show/NCT01129349
Study 245:
A Study to Compare the Safety and Efficacy of an
Aromatase Inhibitor in Combination With Lapatinib,
Trastuzumab or Both for the Treatment of Hormone
Receptor Positive, HER2+ Metastatic Breast Cancer
http://ClinicalTrials.gov/show/NCT01160211
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
33
Study 246:
Phase I Study of PI3 (Phosphoinositol 3)-Kinase
Inhibitor BAY80-6946 With Paclitaxel in Patients With
Advanced Cancer
http://ClinicalTrials.gov/show/NCT01411410
Study 247:
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line
Metastatic Breast Cancer
http://ClinicalTrials.gov/show/NCT00924352
Study 248:
Drug-drug Interaction Study of Tivantinib (ARQ 197)
With Omeprazole, S-warfarin, Caffeine, Midazolam,
and Digoxin in Cancer Subjects
http://ClinicalTrials.gov/show/NCT01517399
Study 249:
Study Determining the Safety and Tolerability
of Combination Therapy With Pazopanib and
GSK1120212 in Advanced Solid Tumors Enriched With
Patients With Advanced Differentiated Thyroid Cancer
http://ClinicalTrials.gov/show/NCT01438554
Study 250:
Evaluation of a New Anti-cancer Immunotherapy in
Patients With Non-operable and Progressing Metastatic
Cutaneous Melanoma
http://ClinicalTrials.gov/show/NCT01213472
Study 251:
A Study to Investigate the Safety and Efficacy of
AT13387, Alone or in Combination With Imatinib, in
Patients With GIST
http://ClinicalTrials.gov/show/NCT01294202
Study 252:
Sunitinib Plus Temsirolimus in Patients With Renal Cell
Cancer (RCC)
http://ClinicalTrials.gov/show/NCT01122615
Study 253:
Panitumumab, Nab-paclitaxel and Carboplatin for
HER2 Negative Inflammatory Breast Cancer
Study 254:
Study of Ruxolitinib in Pancreatic Cancer Patients
http://ClinicalTrials.gov/show/NCT01423604
Study 255:
BATTLE-FL: Front-Line Biomarker-Integrated
Treatment Study in Non Small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT01263782
Study 256:
A Study of RO5137382 (GC33) in Patients With
Advanced or Metastatic Hepatocellular Carcinoma
http://ClinicalTrials.gov/show/NCT01507168
Study 257:
5-Azacytidine and Oxaliplatin With Advanced Cancers
Relapsed or Refractory to Any Platinum Therapy
http://ClinicalTrials.gov/show/NCT01039155
Study 258:
First-in-Man, Dose-escalation Trial of C-met Kinase
Inhibitor EMD 1214063 in Subjects With Advanced
Solid Tumors
http://ClinicalTrials.gov/show/NCT01014936
Study 259:
A Combination Therapy Study of MK2206 and
AZD6244 in Participants With Advanced Solid Tumors
(MK-2206-010 AM5)
http://ClinicalTrials.gov/show/NCT01021748
Study 260:
Trial in Extensive-Disease Small Cell Lung Cancer
(ED-SCLC) Subjects Comparing Ipilimumab Plus
Etoposide and Platinum Therapy to Etoposide and
Platinum Therapy Alone
http://ClinicalTrials.gov/show/NCT01450761
Study 261:
A Study to Evaluate Pazopanib as an Adjuvant
Treatment for Localized Renal Cell Carcinoma (RCC)
http://ClinicalTrials.gov/show/NCT01235962
http://ClinicalTrials.gov/show/NCT01036087
34
PhRMA • Pharmaceutical Clinical Trials in texas
Study 262:
Study 271:
Preoperative Chemotherapy in Triple Negative Invasive
Breast Cancer That Can be Removed by Surgery
Bevacizumab, Erlotinib and Capecitabine for Advanced
Pancreatic Cancer
http://ClinicalTrials.gov/show/NCT00777673
http://ClinicalTrials.gov/show/NCT00614653
Study 263:
Nilotinib in Patients With Relapsed or Metastatic
Pigmented Villonodular Synovitis/Tenosynovial Giant
Cell Tumor/Diffuse-Type Giant Cell Tumor
http://ClinicalTrials.gov/show/NCT01207492
Study 264:
Pharmacokinetics (PK) of TKI258 in Cancer Patients
With Normal and Impaired Hepatic Function
http://ClinicalTrials.gov/show/NCT01443481
Study 265:
Phase I/II Bevacizumab Versus Bevacizumab Plus TPI
287 for Recurrent Glioblastoma
http://ClinicalTrials.gov/show/NCT01582152
Study 266:
FOLFOXIRI Plus Panitumumab Patients With
Metastatic KRAS Wild-Type Colorectal Cancer With
Liver Metastases Only
http://ClinicalTrials.gov/show/NCT01226719
Study 267:
Cabozantinib and Androgen Ablation in Patients With
Androgen-Dependent Metastatic Prostate Cancer
http://ClinicalTrials.gov/show/NCT01630590
Study 268:
TKI258 in Castrate Resistant Prostate Cancer
Study 272:
Neoadjuvant Axitinib in Prostate Cancer
http://ClinicalTrials.gov/show/NCT01409200
Study 273:
FOLFOX Chemotherapy Regimen (5-FU, Leucovorin,
Oxaliplatin) in Metastatic Colorectal Cancer
http://ClinicalTrials.gov/show/NCT00501410
Study 274:
ExAblate Conformal Bone System Treatment of
Metastatic Bone Tumors for the Palliation of Pain
http://ClinicalTrials.gov/show/NCT00981578
Study 275:
A Study of RO5429083 in Patients With Metastatic
and/or Locally Advanced, CD44-Expressing, Malignant
Solid Tumors
http://ClinicalTrials.gov/show/NCT01358903
Study 276:
Phase I-II Everolimus and Sorafenib in Recurrent
High-Grade Gliomas
http://ClinicalTrials.gov/show/NCT01434602
Study 277:
Lapatinib in Combination With Trastuzumab in
Patients With HER2-Positive, Metastatic Breast Cancer
http://ClinicalTrials.gov/show/NCT00470704
http://ClinicalTrials.gov/show/NCT00831792
Study 269:
TKI258 for Metastatic Inflammatory Breast Cancer
Patients
http://ClinicalTrials.gov/show/NCT01262027
Study 278:
Neoadjuvant Study of Sequential Eribulin Followed by
FAC Compared to Sequential Paclitaxel Followed by
FEC in Early Stage Breast Cancer Not Overexpressing
HER-2
http://ClinicalTrials.gov/show/NCT01593020
Study 270:
RAD001 for Patients With Radioiodine Refractory
Thyroid Cancer
http://ClinicalTrials.gov/show/NCT00936858
Study 279:
Phase 1 Dose Escalation Study of ARQ 092 in Adult
Subjects With Advanced Solid Tumors
http://ClinicalTrials.gov/show/NCT01473095
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
35
Study 280:
Phase II Randomized Trial Evaluating Neoadjuvant
Therapy With Neratinib and/or Trastuzumab Followed
by Postoperative Trastuzumab in Women With Locally
Advanced HER2-positive Breast Cancer
http://ClinicalTrials.gov/show/NCT01008150
Study 281:
TPI 287 in Breast Cancer Metastatic to the Brain
Study 288:
Effect of Tivantinib on the QTC Interval in Cancer
Subjects
http://ClinicalTrials.gov/show/NCT01699061
Study 289:
A Dose Escalation Study of Iniparib as a Single Agent
and in Combination in Solid Tumors
http://ClinicalTrials.gov/show/NCT01455532
http://ClinicalTrials.gov/show/NCT01332630
Study 282:
Study 290:
Study of PM060184 in Patients With Advanced Solid
Tumors
Study of Safety and Pharmacokinetics of MK-8242
in Participants With Advanced Solid Tumors (P07650
AM1)
http://ClinicalTrials.gov/show/NCT01299636
http://ClinicalTrials.gov/show/NCT01463696
Study 283:
An Investigational Drug, PF-02341066 Is Being Studied
Versus Standard Of Care In Patients With Advanced
Non-Small Cell Lung Cancer With A Specific Gene
Profile Involving The Anaplastic Lymphoma Kinase
(ALK) Gene
http://ClinicalTrials.gov/show/NCT00932893
Study 284:
Study of Orally Administered TAK-960 in Patients With
Advanced Nonhematologic Malignancies
Study 291:
An Open-Label Study to Assess the Pharmacokinetics
and Safety of HALAVEN™ in Subjects With Cancer
Who Also Have Impaired Renal Function
http://ClinicalTrials.gov/show/NCT01418677
Study 292:
First in Man Study of SAR566658 Administered Every
3 Weeks in Patients With DS6-positive and Refractory
Solid Tumors
http://ClinicalTrials.gov/show/NCT01156870
http://ClinicalTrials.gov/show/NCT01179399
Study 285:
ABT-348 as Monotherapy or Combination With
Carboplatin or Docetaxel to Treat Advanced Solid
Tumors
http://ClinicalTrials.gov/show/NCT01110486
Study 286:
A Study of LOR-253 HCl in Patients With Advanced or
Metastatic Solid Tumours
http://ClinicalTrials.gov/show/NCT01281592
Study 287:
Study of TAK-733 in Combination With Alisertib
in Adult Patients With Advanced Nonhematologic
Malignancies
Study 293:
BATTLE-2 Program: A Biomarker-Integrated Targeted
Therapy Study
http://ClinicalTrials.gov/show/NCT01248247
Study 294:
Neoadjuvant Ipilimumab in Prostate Cancer
http://ClinicalTrials.gov/show/NCT01194271
Study 295:
A Dose Finding Study With Oral LDK378 in Patients
With Tumors Characterized by Genetic Abnormalities
in Anaplastic Lymphoma Kinase (ALK)
http://ClinicalTrials.gov/show/NCT01283516
http://ClinicalTrials.gov/show/NCT01613261
36
PhRMA • Pharmaceutical Clinical Trials in texas
Study 296:
Study 304:
Safety and Pharmacokinetic Study of Cabazitaxel
in Patients With Advanced Solid Tumors and Liver
Impairment
Open-label Study to Evaluate the Safety, PK, and PD of
MEK Inhibitor GSK1120212 in Subjects With Relapsed
or Refractory Leukemias
http://ClinicalTrials.gov/show/NCT01140607
http://ClinicalTrials.gov/show/NCT00920140
Study 297:
Androgen Deprivation Therapy +/- Bevacizumab for
PSA Recurrence of Prostate Cancer After Definitive
Local Therapy
Study 305:
Ipilimumab + Androgen Deprivation Therapy in
Prostate Cancer
http://ClinicalTrials.gov/show/NCT01377389
http://ClinicalTrials.gov/show/NCT00776594
Study 298:
Levonorgestrel Intrauterine Device (IUD) to Treat
Complex Atypical Hyperplasia (CAH) and Grade 1
Endometrioid Endometrial Carcinoma (G1EEC)
http://ClinicalTrials.gov/show/NCT00788671
Study 299:
Neo-Adjuvant Study in Triple Negative Breast Cancer
Patients
http://ClinicalTrials.gov/show/NCT01097642
Study 300:
Combination Immunotherapy With Herceptin and the
HER2 Vaccine NeuVax
http://ClinicalTrials.gov/show/NCT01570036
Study 301:
Trial of Eribulin/Cyclophosphamide or Docetaxel/
Cyclophosphamide as Neoadjuvant Therapy in Locally
Advanced HER2-Negative Breast Cancer
http://ClinicalTrials.gov/show/NCT01527487
Study 302:
Safety and Efficacy of Cryoablation for the Palliation of
Painful Bone Metastases
http://ClinicalTrials.gov/show/NCT01461265
Study 303:
Safety and Tolerability Study of GSK1120212, a MEK
Inhibitor, in Combination With Docetaxel, Erlotinib,
Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed +
Cisplatin, or Nab-Paclitaxel
http://ClinicalTrials.gov/show/NCT01192165
Study 306:
Capecitabine/Tesetaxel Versus Capecitabine/Placebo as
Second-line Therapy for Gastric Cancer
http://ClinicalTrials.gov/show/NCT01573468
Study 307:
Study of Everolimus With Bevacizumab to Treat
Refractory Malignant Peripheral Nerve Sheath Tumors
http://ClinicalTrials.gov/show/NCT01661283
Study 308:
Trial of Poor Performance Status Patients (ToPPS)
http://ClinicalTrials.gov/show/NCT00892710
Study 309:
Pazopanib and Everolimus in PI3KCA Mutation
Positive/PTEN Loss Patients
http://ClinicalTrials.gov/show/NCT01430572
Study 310:
Extension Study of Lapatinib Plus Herceptin With or
Without Endocrine Therapy
http://ClinicalTrials.gov/show/NCT00999804
Study 311:
Trial of Eribulin in Patients Who Do Not Achieve
Pathologic Complete Response (pCR) Following
Neoadjuvant Chemotherapy
http://ClinicalTrials.gov/show/NCT01401959
Study 312:
Clinical Study of Vorinostat in Combination With
Etoposide in Pediatric Patients < 21 Years at Diagnosis
With Refractory Solid Tumors
http://ClinicalTrials.gov/show/NCT01294670
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
37
Study 313:
Bendamustine and Bevacizumab for Advanced Cancers
http://ClinicalTrials.gov/show/NCT01152203
Study 314:
Panitumumab Pediatric Study
http://ClinicalTrials.gov/show/NCT00658658
Study 315:
Multiple Ascending Dose (MDX1105-01)
http://ClinicalTrials.gov/show/NCT00729664
Study 316:
Combination Trial MSC1936369B With Temsirolimus
http://ClinicalTrials.gov/show/NCT01378377
Study 317:
A Phase I Dose-Escalation and PK Study of TG02
Citrate in Patients With Advanced Hematological
Malignancies
http://ClinicalTrials.gov/show/NCT01204164
Study 318:
Erlotinib Plus Bevacizumab in Hepatocellular
Carcinoma (HCC) as Second-line Therapy
http://ClinicalTrials.gov/show/NCT01180959
Study 319:
Neoadjuvant Axitinib in Locally Advanced Renal Cell
Carcinoma (RCC)
http://ClinicalTrials.gov/show/NCT01263769
Study 322:
REGN910 (SAR307746) and Aflibercept (“Zivaflibercept” in the U.S.) in Patients With Advanced
Solid Malignancies
http://ClinicalTrials.gov/show/NCT01688960
Study 323:
GSK1120212 Rollover Study
http://ClinicalTrials.gov/show/NCT01376310
Study 324:
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell
Renal Cell Carcinoma (RCC)
http://ClinicalTrials.gov/show/NCT01392183
Study 325:
Everolimus Versus Sunitinib in Non-Clear Cell Renal
Cell Carcinoma
http://ClinicalTrials.gov/show/NCT01185366
Study 326:
Preventing Sexual Dysfunction With Aromatase
Inhibitors
http://ClinicalTrials.gov/show/NCT01603303
Study 327:
The Role of Ghrelin in Cancer Cachexia
http://ClinicalTrials.gov/show/NCT01505764
Study 328:
Multiple Ascending Dose of BMS-911543
http://ClinicalTrials.gov/show/NCT01236352
Study 320:
Maximum Androgen Depletion
http://ClinicalTrials.gov/show/NCT01254864
Study 321:
Study 329:
Bevacizumab Versus Bevacizumab Plus Vorinostat in
Adults With Recurrent Glioblastoma
http://ClinicalTrials.gov/show/NCT01266031
Pooled Unrelated Donor Umbilical Cord Blood
Transplant For Hematologic Malignancy Needing
Allogeneic Stem Cell Transplant Without Related HLAMatch
Phase I / II Vorinostat, Erlotinib and Temozolomide
for Recurrent Glioblastoma Multiforme (GBM)
http://ClinicalTrials.gov/show/NCT01500161
http://ClinicalTrials.gov/show/NCT01110876
38
Study 330:
PhRMA • Pharmaceutical Clinical Trials in texas
Study 331:
Pilot Clinical Trial of Repeated Doses of Macimorelin
to Assess Safety and Efficacy in Patients With Cancer
Cachexia
http://ClinicalTrials.gov/show/NCT01614990
Study 332:
Phase II, Open Label, Single Arm Study of SAR302503
In Myelofibrosis Patients Previously Treated With
Ruxolitinib
http://ClinicalTrials.gov/show/NCT01523171
Study 333:
Study With SAR302503 in Patients With Polycythemia
Vera or Essential Thrombocythemia
Study 339:
Sorafenib Long Term Extension Program (STEP)
http://ClinicalTrials.gov/show/NCT00625378
Study 340:
CAPOX in KRAS Wild-Type Advanced
Adenocarcinoma of the Small Bowel or Ampulla of
Vater
http://ClinicalTrials.gov/show/NCT01202409
Study 341:
Study of Erlotinib in the Treatment of Recurrent
or Metastatic Cutaneous Squamous Cell Carcinoma
(CSCC) of the Skin
http://ClinicalTrials.gov/show/NCT01198028
http://ClinicalTrials.gov/show/NCT01420783
Study 334:
Phase 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients
With Argininousccinate Synthetase Deficient Advanced
Tumors
Study 342:
Phase II Study of Cetuximab With or Without OSI906 in Head and Neck Squamous Cell Carcinoma
(HNSCC)
http://ClinicalTrials.gov/show/NCT01427205
http://ClinicalTrials.gov/show/NCT01665183
Study 335:
Lenalidomide in Combination With Bevacizumab,
Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin,
Oxaliplatin (FOLFOX)
http://ClinicalTrials.gov/show/NCT01183663
Study 336:
Trial of RAD001 and Erlotinib With Recurrent Head
and Neck Squamous Cell Carcinoma
http://ClinicalTrials.gov/show/NCT00942734
Study 337:
ABT-348 as Monotherapy and in Combination
With Azacitidine to Treat Advanced Hematologic
Malignancies
http://ClinicalTrials.gov/show/NCT01110473
Study 338:
Bevacizumab With Capecitabine and Oxaliplatin in
Advanced Adenocarcinoma of the Small Bowel or
Ampulla of Vater
Study 343:
Clinical Trial of ARQ 761 in Advanced Solid Tumors
http://ClinicalTrials.gov/show/NCT01502800
Study 344:
Safety and Exploratory Efficacy of Kanglaite Injection
in Non Small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT01640730
Study 345:
A Study of Sativex® for Relieving Persistent Pain in
Patients With Advanced Cancer
http://ClinicalTrials.gov/show/NCT01262651
Study 346:
An Efficacy Study in Gastric and Gastroesophageal
Junction Cancer Comparing Ipilimumab Versus
Standard of Care Immediately Following First Line
Chemotherapy
http://ClinicalTrials.gov/show/NCT01585987
http://ClinicalTrials.gov/show/NCT01208103
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
39
Study 347:
Study 356:
Safety and Efficacy Study of PRI-724 in Subjects With
Advanced Myeloid Malignancies
Investigate Safety, Pharmacokinetics and
Pharmacodynamics of GSK2118436 & GSK1120212
http://ClinicalTrials.gov/show/NCT01606579
http://ClinicalTrials.gov/show/NCT01072175
Study 348:
Study 357:
Phase II Study of Ofatumumab in Elderly Patients
With Chronic Lymphocytic Leukemia (CLL)
An Extension Protocol for Subjects Who Were
Previously Enrolled in Other ARQ 197 Protocols
http://ClinicalTrials.gov/show/NCT01444716
http://ClinicalTrials.gov/show/NCT01178411
Study 349:
A Study of the Safety and Effectiveness of JNJ42160443 as add-on Treatment in Patients With Cancerrelated Pain
Study 358:
Fludarabine, Bendamustine and Rituximab
Conditioning for Patients With Lymphoid Malignancies
http://ClinicalTrials.gov/show/NCT00880815
http://ClinicalTrials.gov/show/NCT00929188
Study 350:
A Study Evaluating the Safety, Tolerability and
Pharmacokinetics of GDC-0917 Administered to
Patients With Refractory Solid Tumors or Lymphoma
Study 359:
Open Label Treatment Extension Study With
SAR245408 or SAR245409 as a Monotherapy or as a
Combination Regimen
http://ClinicalTrials.gov/show/NCT01587040
http://ClinicalTrials.gov/show/NCT01226277
Study 351:
Phase 1 and 2 Study of PX-866 and Cetuximab
http://ClinicalTrials.gov/show/NCT01252628
Study 360:
Pharmacokinetic (PK) and Pharmacodynamic (PD)
Study of Nelarabine in Patients With Relapsed/
Refractory Lymphoid Malignancies
http://ClinicalTrials.gov/show/NCT01094860
Study 352:
Treatment Extension Study for Patients Who Have
Previously Participated and Have Benefited From
Iniparib in a Clinical Trial
Study 361:
Study of REGN910 (SAR307746)
http://ClinicalTrials.gov/show/NCT01271972
http://ClinicalTrials.gov/show/NCT01593228
Study 353:
A Phase 1 Study of LY2787106 in Cancer and Anemia
http://ClinicalTrials.gov/show/NCT01340976
Study 354:
Trial of Dasatinib in Subjects With Advanced Cancers
Harboring DDR2 Mutation or Inactivating B-RAF
Mutation
http://ClinicalTrials.gov/show/NCT01514864
Study 362:
First in Human Study to Determine the Safety,
Tolerability and Preliminary Efficacy of an AntiCXCR4 Antibody in Subjects With Acute Myelogenous
Leukemia and Selected B-cell Cancers
http://ClinicalTrials.gov/show/NCT01120457
Study 363:
A Study of MM-111 in Combination With Multiple
Treatments in Patients With HER2 Positive Cancer
http://ClinicalTrials.gov/show/NCT01304784
Study 355:
CMC-544 and Allogeneic Transplantation for CD22
Positive-Lymphoid Malignancies
http://ClinicalTrials.gov/show/NCT01664910
40
PhRMA • Pharmaceutical Clinical Trials in texas
Study 364:
Study 372:
An Extension Study for Patients Who Are Deriving
Benefit With CAL-101 to Continue on Treatment at the
End of the Current Study
A Study of KW-2478 in Combination With Bortezomib
in Subjects With Relapsed and/or Refractory Multiple
Myeloma
http://ClinicalTrials.gov/show/NCT01090414
http://ClinicalTrials.gov/show/NCT01063907
Study 365:
Rasburicase in Patients at High Risk for Tumor Lysis
Syndrome (TLS) During Cycle-2
http://ClinicalTrials.gov/show/NCT01200485
Study 373:
Phase I Study to Determine the Maximum Tolerable
Dose of BAY94-9343 in Patients With Advanced Solid
Tumors.
http://ClinicalTrials.gov/show/NCT01439152
Study 366:
HepaSphere/Quadrasphere Microspheres for Delivery
of Doxorubicin for the Treatment of Hepatocellular
Cancer
http://ClinicalTrials.gov/show/NCT01387932
Study 374:
Study to Learn if Two Doses of a Test Drug
(Fostamatinib) Helps People With Large B-Cell
Lymphoma,a Type of Blood Cancer
http://ClinicalTrials.gov/show/NCT01499303
Study 367:
A Study of LY2510924 in Patients With Extensive-Stage
Small Cell Lung Carcinoma
http://ClinicalTrials.gov/show/NCT01439568
Study 375:
Preoperative Treatment With Cetuximab and/or
IMC-A12
http://ClinicalTrials.gov/show/NCT00957853
Study 368:
Dabrafenib Plus Trametinib vs Vemurafenib Alone in
Unresectable or Metastatic BRAF V600E/K Cutaneous
Melanoma
Study 376:
Treatment of Blood Clots in Children With Cancer
http://ClinicalTrials.gov/show/NCT00952380
http://ClinicalTrials.gov/show/NCT01597908
Study 369:
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992)
Versus Erlotinib for the Treatment of Squamous Cell
Lung Cancer After at Least One Prior Platinum Based
Chemotherapy
http://ClinicalTrials.gov/show/NCT01523587
Study 370:
Safety and Efficacy Study for Solid Tumor Patients
Treated With Eltrombopag
http://ClinicalTrials.gov/show/NCT01147809
Study 377:
F18PET/CT Versus TC-MDP Scanning to Detect Bone
Mets
http://ClinicalTrials.gov/show/NCT00882609
Study 378:
A Study of REOLYSIN® in Combination With
Paclitaxel and Carboplatin in Patients With Squamous
Cell Carcinoma of the Lung
http://ClinicalTrials.gov/show/NCT00998192
Study 379:
Bortezomib and Reduced Intensity Allogenic Stem
Cell Transplantation for Lymphoid Malignancies
Study of Ramucirumab or IMC-18F1 With Docetaxel
or Docetaxel Alone as Second-Line Therapy in
Participants With Bladder, Urethra, Ureter, or Renal
Pelvis Carcinoma
http://ClinicalTrials.gov/show/NCT00439556
http://ClinicalTrials.gov/show/NCT01282463
Study 371:
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
41
Study 380:
Study 389:
A Phase I Dose Finding and Safety Study of Oral
LDE225 in Children and a Phase II Portion to Assess
Preliminary Efficacy in Recurrent or Refractory MB
Phase III Study of Lenalidomide and Dexamethasone
With or Without Elotuzumab to Treat Relapsed or
Refractory Multiple Myeloma
http://ClinicalTrials.gov/show/NCT01125800
http://ClinicalTrials.gov/show/NCT01239797
Study 381:
Phase II FANG in Advanced Melanoma
http://ClinicalTrials.gov/show/NCT01453361
Study 382:
Continuing Access To AG- 013736 (A406) For Patients
Previously Receiving AG 013736 In Clinical Trials
http://ClinicalTrials.gov/show/NCT00828919
Study 383:
Safety and Efficacy of Marqibo in Metastatic Malignant
Uveal Melanoma
http://ClinicalTrials.gov/show/NCT00506142
Study 384:
A Study of Vemurafenib in Metastatic Melanoma
Patients With Brain Metastases
http://ClinicalTrials.gov/show/NCT01378975
Study 385:
Evaluation of Sentinel Lymph Nodes in Head and Neck
Squamous Cell Carcinoma
http://ClinicalTrials.gov/show/NCT00911326
Study 386:
Study of ACE-041 in Patients With Squamous Cell
Carcinoma of the Head and Neck
http://ClinicalTrials.gov/show/NCT01458392
Study 387:
Zevalin-Containing Nonmyeloablative Conditioning for
Stem Cell Transplantation (SCT)
http://ClinicalTrials.gov/show/NCT01490723
Study 388:
Study of Bortezomib and Dexamethasone With or
Without Elotuzumab to Treat Relapsed or Refractory
Multiple Myeloma
Study 390:
Phase III Study of Lenalidomide and Dexamethasone
With or Without Elotuzumab to Treat Newly
Diagnosed, Previously Untreated Multiple Myeloma
http://ClinicalTrials.gov/show/NCT01335399
Study 391:
Effect of NovoTTF-100A Together With Temozolomide
in Newly Diagnosed Glioblastoma Multiforme (GBM)
http://ClinicalTrials.gov/show/NCT00916409
Study 392:
Assessment of Efficacy and Safety of Perifosine,
Bortezomib and Dexamethasone in Multiple Myeloma
Patients
http://ClinicalTrials.gov/show/NCT01002248
Study 393:
Study in Patients With Untreated Multiple Myeloma
and Renal Insufficiency
http://ClinicalTrials.gov/show/NCT01337752
Study 394:
A Study of Siltuximab (Anti- IL 6 Monoclonal
Antibody) in Patients With High-risk Smoldering
Multiple Myeloma
http://ClinicalTrials.gov/show/NCT01484275
Study 395:
A Study of LY2510924 and Sunitinib in Patients With
Metastatic Renal Cell Carcinoma
http://ClinicalTrials.gov/show/NCT01391130
Study 396:
BT062 in Combination With Lenalidomide/
Dexamethasone in Patients With Multiple Myeloma
http://ClinicalTrials.gov/show/NCT01638936
http://ClinicalTrials.gov/show/NCT01478048
42
PhRMA • Pharmaceutical Clinical Trials in texas
Study 397:
Safety and Efficacy of 72-hour and 120-hour Infusion
of Rigosertib in Acute Myeloid Leukemia (AML) and
Acute Lymphoid Leukemia (ALL)
http://ClinicalTrials.gov/show/NCT01167166
Study 405:
A Study of Imatinib Versus Nilotinib in Adult Patients
With Newly Diagnosed Philadelphia Chromosome
Positive (Ph+) Chronic Myelogenous Leukemia in
Chronic Phase (CML-CP)
http://ClinicalTrials.gov/show/NCT00471497
Study 398:
Study of Dovitinib Versus Sorafenib in Patients With
Metastatic Renal Cell Carcinoma
http://ClinicalTrials.gov/show/NCT01223027
Study 399:
PF-04856884 (CVX-060) In Combination With Axitinib
In Patients With Previously Treated Metastatic Renal
Cell Carcinoma
http://ClinicalTrials.gov/show/NCT01441414
Study 400:
Study of Oral MLN9708 in Combination With
Lenalidomide and Dexamethasone in Patients With
Newly Diagnosed Multiple Myeloma
http://ClinicalTrials.gov/show/NCT01383928
Study 401:
A Study of ARRY-520 in Patients With Relapsed or
Refractory Multiple Myeloma
http://ClinicalTrials.gov/show/NCT00821249
Study 402:
Study of ACY-1215 Alone and in Combination With
Bortezomib and Dexamethasone in Multiple Myeloma
http://ClinicalTrials.gov/show/NCT01323751
Study 403:
A Study of hLL1-DOX (Milatuzumab-Doxorubicin
Antibody-Drug Conjugate) in Patients With Multiple
Myeloma
http://ClinicalTrials.gov/show/NCT01101594
Study 404:
Study 406:
Study of Vosaroxin or Placebo in Combination
With Cytarabine in Patients With First Relapsed or
Refractory Acute Myeloid Leukemia (AML)
http://ClinicalTrials.gov/show/NCT01191801
Study 407:
A Study of ARRY-520 and Bortezomib Plus
Dexamethasone in Patients With Relapsed/Refractory
Multiple Myeloma
http://ClinicalTrials.gov/show/NCT01248923
Study 408:
Study of Pomalidomide to Evaluate the
Pharmacokinetics and Safety for Patients With Multiple
Myeloma and Impaired Renal Function
http://ClinicalTrials.gov/show/NCT01575925
Study 409:
IMGN901 in Combination With Lenalidomide and
Dexamethasone
http://ClinicalTrials.gov/show/NCT00991562
Study 410:
Phase 3 Study With Carfilzomib and Dexamethasone
Versus Velcade and Dexamethasone for Relapsed
Multiple Myeloma Patients
http://ClinicalTrials.gov/show/NCT01568866
Study 411:
Study of BHQ880 in Patients With High Risk
Smoldering Multiple Myeloma
http://ClinicalTrials.gov/show/NCT01302886
Study of Elotuzumab in Combination With
Lenalidomide and Dexamethasone in Subjects With
Multiple Myeloma and Various Levels of Renal
Function
A Study of Oral LGH447 in Patients With Relapsed
and/or Refractory Multiple Myeloma
http://ClinicalTrials.gov/show/NCT01393964
http://ClinicalTrials.gov/show/NCT01456689
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
Study 412:
43
Study 413:
Study of Oral MLN9708 in Adult Patients With
Relapsed and/or Refractory Multiple Myeloma
http://ClinicalTrials.gov/show/NCT00932698
Study 422:
Induction Therapy-Docetaxel, Cisplatin and
Fluorouracil in Untreated Advanced Squamous Cell or
Undifferentiated Carcinoma of the Paranasal Sinuses
http://ClinicalTrials.gov/show/NCT00707473
Study 414:
Study 423:
Clinical Study With Blinatumomab in Pediatric
and Adolescent Patients With Relapsed/Refractory
B-precursor Acute Lymphoblastic Leukemia
Study of Denileukin Diftitox in Patients With Stage
IIIC and Stage IV Melanoma
http://ClinicalTrials.gov/show/NCT01471782
http://ClinicalTrials.gov/show/NCT01127451
Study 415:
Ipilimumab for Uveal Melanoma
http://ClinicalTrials.gov/show/NCT01585194
Study 416:
Phase 3 Trial of Autologous Dendritic Cell
Immunotherapy (AGS-003) Plus Standard Treatment of
Advanced Renal Cell Carcinoma (RCC)
http://ClinicalTrials.gov/show/NCT01582672
Study 417:
A Phase 2 Study of PLX3397 in Patients With
Recurrent Glioblastoma
http://ClinicalTrials.gov/show/NCT01349036
Study 418:
A Phase II Study of Crenolanib (CP-868,596), a
Selective and Potent Inhibitor of PDGFR, for the
Treatment of Adult Gliomas
http://ClinicalTrials.gov/show/NCT01229644
Study 419:
Phase III Study of Rindopepimut/GM-CSF in Patients
With Newly Diagnosed Glioblastoma
Study 424:
Safety and Efficacy Study of Trans Sodium Crocetinate
(TSC) With Concomitant Radiation Therapy and
Temozolomide in Newly Diagnosed Glioblastoma
(GBM)
http://ClinicalTrials.gov/show/NCT01465347
Study 425:
Escalating Dose Study in Subjects With Relapsed
or Refractory B Cell Non-Hodgkin Lymphoma,
Chronic Lymphocytic Leukemia, and Waldenstrom’s
Macroglobulinemia
http://ClinicalTrials.gov/show/NCT01351935
Study 426:
Open-Label Study of TPI 287 for Patients With
Metastatic Melanoma
http://ClinicalTrials.gov/show/NCT01340729
Study 427:
A Phase 1 Study Evaluating the Safety and
Pharmacokinetics of ABT-199 in Subjects With
Relapsed or Refractory Chronic Lymphocytic
Leukemia and Non-Hodgkin Lymphoma
http://ClinicalTrials.gov/show/NCT01328626
http://ClinicalTrials.gov/show/NCT01480479
Study 420:
A Study of Rindopepimut/GM-CSF in Patients With
Relapsed EGFRvIII-Positive Glioblastoma
Study 428:
Azacitidine (AZA) in Minimal Residual Disease (MRD)
Chronic Myeloid Leukemia (CML)
http://ClinicalTrials.gov/show/NCT01460498
http://ClinicalTrials.gov/show/NCT01498328
Study 421:
Study 429:
Genasense, Carboplatin, Paclitaxel (GCP) Combination
in Uveal Melanoma
Combination Therapy of Lenalidomide/Bortezomib/
Dexamethasone and Panobinostat in Transplant Eligible
New Diagnosed Multiple Myeloma (MM) Patients
http://ClinicalTrials.gov/show/NCT01200342
http://ClinicalTrials.gov/show/NCT01440582
44
PhRMA • Pharmaceutical Clinical Trials in texas
Study 430:
Lenalidomide/Bortezomib/Dexamethasone & CNTO
328 in Transplant Eligible Newly Diagnosed Multiple
Myeloma (MM)
http://ClinicalTrials.gov/show/NCT01531998
Study 439:
Ofatumumab Versus Rituximab Salvage
Chemoimmunotherapy Followed by Autologous Stem
Cell Transplant in Relapsed or Refractory Diffuse Large
B Cell Lymphoma
http://ClinicalTrials.gov/show/NCT01014208
Study 431:
Carfilzomib Plus Panobinostat in Relapsed/Refractory
Multiple Myeloma (MM)
http://ClinicalTrials.gov/show/NCT01301807
Study 432:
A Safety Study of Carfilzomib and Pomalidomide
With Dexamethasone in Patients With Relapsed or
Refractory Multiple Myeloma
http://ClinicalTrials.gov/show/NCT01464034
Study 433:
Arry-520 + Carfilzomib for Multiple Myeloma (MM)
http://ClinicalTrials.gov/show/NCT01372540
Study 434:
Randomized Trial of Lenalidomide, Bortezomib,
Dexamethasone vs High-Dose Treatment With SCT in
MM Patients up to Age 65
http://ClinicalTrials.gov/show/NCT01208662
Study 435:
Ofatumumab for Minimal Residual Disease (MRD)
and Maintenance Therapy
http://ClinicalTrials.gov/show/NCT01258933
Study 436:
Study to Evaluate Two Lenalidomide Dose Regimens
With Low Dose Dexamethasone for the Treatment
Relapsed Multiple Myeloma
http://ClinicalTrials.gov/show/NCT01380106
Study 437:
Acupuncture for Chemo-Induced Peripheral
Neuropathy
http://ClinicalTrials.gov/show/NCT00891618
Study 438:
Busulfan Plus Melphalan Versus Melphalan
Study 440:
A Study to Evaluate the Safety and Efficacy of
Ustekinumab in Patients With Moderately to Severely
Active Crohn’s Disease Who Have Failed or Are
Intolerant to Tumor Necrosis Factor (TNF) Antagonist
Therapy (UNITI-1)
http://ClinicalTrials.gov/show/NCT01369329
Study 441:
Phase II Study of BKM120 for Subjects With Recurrent
Glioblastoma
http://ClinicalTrials.gov/show/NCT01339052
Study 442:
Treatment With Dasatinib in Patients With Acral
Lentiginous, Mucosal, or Chronic Sun-damaged
Melanoma
http://ClinicalTrials.gov/show/NCT01092728
Study 443:
Lymphodepletion Plus Adoptive Cell Transfer With or
Without Dendritic Cell Immunization
http://ClinicalTrials.gov/show/NCT00338377
Study 444:
A Phase 2, Multicenter, Open-label Study of MEDI-551
in Adults With Relapsed or Refractory
http://ClinicalTrials.gov/show/NCT01466153
Study 445:
SGN-35 in CD30-positive Lymphoproliferative
Disorders (ALCL), Mycosis Fungoides (MF), and
Extensive Lymphomatoid Papulosis (LyP)
http://ClinicalTrials.gov/show/NCT01352520
Study 446:
Study of BMS-936558 vs. Everolimus in Pre-Treated
Advanced Or Metastatic Clear-cell RCC
http://ClinicalTrials.gov/show/NCT01668784
http://ClinicalTrials.gov/show/NCT01413178
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
45
Study 447:
A Study in Recurrent Glioblastoma (GB)
http://ClinicalTrials.gov/show/NCT01582269
Study 448:
An Open-Label, 2-Cohort, Multicenter, Study of E7080
in Previously Treated Subjects With Unresectable Stage
III or Stage IV Melanoma
http://ClinicalTrials.gov/show/NCT01136967
Study 449:
Phase III Trans-Arterial Chemo-Embolization (TACE)
Adjuvant HCC
http://ClinicalTrials.gov/show/NCT00908752
Study 450:
A Study of AMNN107 in the Treatment of Metastatic
and/or Inoperable Melanoma Harboring a c-Kit
Mutation
http://ClinicalTrials.gov/show/NCT01028222
Study 451:
Study of a Melanoma Vaccine in Stage IIb, IIc, and III
Melanoma Patients
http://ClinicalTrials.gov/show/NCT01546571
Study 452:
A Study of Trabectedin or Dacarbazine for the
Treatment of Patients With Advanced Liposarcoma or
Leiomyosarcoma
http://ClinicalTrials.gov/show/NCT01343277
Study 453:
ch14.18 Pharmacokinetic Study in High-risk
Neuroblastoma
http://ClinicalTrials.gov/show/NCT01592045
Study 454:
A Phase II Study of Efficacy and Safety in Patients
With Locally Advanced or Metastatic Basal Cell
Carcinoma
http://ClinicalTrials.gov/show/NCT01327053
Study 455:
A Study of E7080 Alone, and in Combination With
Everolimus in Subjects With Unresectable Advanced or
Metastatic Renal Cell Carcinoma Following One Prior
Vascular Endothelial Growth Factor (VEGF)-Targeted
Treatment
http://ClinicalTrials.gov/show/NCT01136733
Study 456:
Single-Arm Open-Label Multicenter Study of VB-111
in Patients With Recurrent Glioblastoma Multiforme
http://ClinicalTrials.gov/show/NCT01260506
Study 457:
An Efficacy and Safety Study of Oral Netupitant
and Palonosetron for the Prevention of Nausea and
Vomiting
http://ClinicalTrials.gov/show/NCT01339260
Study 458:
A Subject Treatment Preference Study of Tivozanib
Hydrochloride Versus Sunitinib in Subjects With
Metastatic Renal Cell Carcinoma
http://ClinicalTrials.gov/show/NCT01673386
Study 459:
Philips Pivotal Clinical Trial for MRI-HIFU of Uterine
Fibroids
http://ClinicalTrials.gov/show/NCT01504308
Study 460:
Trial In Pediatric Patients With Familial Adenomatous
Polyposis (FAP)
http://ClinicalTrials.gov/show/NCT00585312
Study 461:
A Phase I Dose Escalation Study of BKM120 With
Radiation Therapy and Temozolomide in Patients With
Newly Diagnosed Glioblastoma
http://ClinicalTrials.gov/show/NCT01473901
Study 462:
Safety and Efficacy Study of TH-302 CNS Penetration
in Recurrent High Grade Astrocytoma Following
Bevacizumab
http://ClinicalTrials.gov/show/NCT01403610
46
PhRMA • Pharmaceutical Clinical Trials in texas
Study 463:
A Study of Onartuzumab (MetMAb) in Combination
With Bevacizumab Compared to Bevacizumab Alone
or Onartuzumab Monotherapy in Patients With
Recurrent Glioblastoma
Study 470:
Safety Study of Adenovirus Vector Engineered to
Express hIL-12 in Combination With Activator Ligand
to Treat Melanoma
http://ClinicalTrials.gov/show/NCT01397708
http://ClinicalTrials.gov/show/NCT01632228
Study 464:
Macitentan in Combo With Dose-dense Temozolomide
in Patients With Recurrent Glioblastoma
Study 471:
A Study of Vemurafenib Adjuvant Therapy in Patients
With Resected Cutaneous BRAF Mutant Melanoma
http://ClinicalTrials.gov/show/NCT01667419
http://ClinicalTrials.gov/show/NCT01499251
Study 465:
Study 472:
Erlotinib Versus Oral Etoposide in Patients With
Recurrent or Refractory Pediatric Ependymoma
A Study of Vemurafenib in Pediatric Patients
With Stage IIIC or Stage IV Melanoma Harboring
BRAFV600 Mutations
http://ClinicalTrials.gov/show/NCT01032070
http://ClinicalTrials.gov/show/NCT01519323
Study 466:
An Open-Label Study to Explore the Clinical Efficacy
of GS 7977 With Ribavirin Administered PreTransplant in Preventing Hepatitis C Virus (HCV)
Recurrence Post-Transplant
http://ClinicalTrials.gov/show/NCT01559844
Study 473:
A Study of The Safety and Pharmacology of
MPDL3280A Administered in Combination With
Vemurafenib (Zelboraf®) in Patients With Previously
Untreated BRAFV600-Mutation Positive Metastatic
Melanoma
http://ClinicalTrials.gov/show/NCT01656642
Study 467:
A Study of Ramucirumab (IMC-1121B) Drug Product
(DP) and Best Supportive Care (BSC) Versus Placebo
and BSC as 2nd-Line Treatment in Patients With
Hepatocellular Carcinoma After 1st-Line Therapy With
Sorafenib
Study 474:
A Study Comparing Trametinib and Dabrafenib
Combination Therapy to Dabrafenib Monotherapy in
Subjects With BRAF-mutant Melanoma
http://ClinicalTrials.gov/show/NCT01584648
http://ClinicalTrials.gov/show/NCT01140347
Study 468:
Study of Sorafenib With or Without VT-122 in Patients
With Hepatocellular Carcinoma (HCC)
Study 475:
A Study of Intratumoral CAVATAK in Patients With
Stage IIIc and Stage IV Malignant Melanoma
http://ClinicalTrials.gov/show/NCT01227551
http://ClinicalTrials.gov/show/NCT01265576
Study 469:
ADI-PEG 20 Versus Placebo in Subjects With Advanced
Hepatocellular Carcinoma Who Have Failed Prior
Systemic Therapy
http://ClinicalTrials.gov/show/NCT01287585
Study 476:
Safety Study of IL-21/Ipilimumab Combination in the
Treatment of Melanoma
http://ClinicalTrials.gov/show/NCT01489059
Study 477:
Study to Assess the Tolerability of a Bispecific Targeted
Biologic IMCgp100 in Malignant Melanoma
http://ClinicalTrials.gov/show/NCT01211262
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
47
Study 478:
Study of REOLYSIN® in Combination With Paclitaxel
and Carboplatin in Patients With Metastatic Melanoma
http://ClinicalTrials.gov/show/NCT00984464
Study 486:
A Study Evaluating the Efficacy and Safety of
Vismodegib (GDC-0449) in Operable Basal Cell
Carcinoma (BCC)
http://ClinicalTrials.gov/show/NCT01201915
Study 479:
Study 487:
A Study of the Effect of Food on the Pharmacokinetics
of Single Dose RO5185426 And the Safety And Efficacy
of Continuous Administration in Patients With BRAF
V600E Mutation-Positive Metastatic Melanoma
Efficacy and Safety of Midostaurin in Patients With
Aggressive Systemic Mastocytosis or Mast Cell
Leukemia
http://ClinicalTrials.gov/show/NCT01264380
http://ClinicalTrials.gov/show/NCT00782067
Study 480:
Tesetaxel as Second-line Therapy for Patients With
Advanced Melanoma and Normal Serum LDH
http://ClinicalTrials.gov/show/NCT01092585
Study 481:
Phase 1 Biomarker Study of Anti-PD-1 in Advanced
Melanoma
http://ClinicalTrials.gov/show/NCT01621490
Study 488:
A Phase 3 Study to Compare Efficacy and Safety of
Masitinib to Placebo in the Treatment of Patients
With Smouldering Systemic, Indolent Systemic or
Cutaneous Mastocytosis With Handicap
http://ClinicalTrials.gov/show/NCT00814073
Study 489:
A Study of IMC-3G3 in Soft Tissue Sarcoma
http://ClinicalTrials.gov/show/NCT01185964
Study 482:
Extension of Study ZPV-200
http://ClinicalTrials.gov/show/NCT01631903
Study 483:
Evaluation of Safety, Pharmacokinetics, and Efficacy
of Proellex Administered Vaginally in Women With
Uterine Fibroids
http://ClinicalTrials.gov/show/NCT01451424
Study 484:
Study of Fc-Optimized Anti-CD19 Antibody
(MOR00208) to Treat B-cell Acute Lymphoblastic
Leukemia(B-All)
http://ClinicalTrials.gov/show/NCT01685021
Study 485:
NGR015: Study in Second Line for Patient With
Advanced Malignant Pleural Mesothelioma Pretreated
With Pemetrexed
http://ClinicalTrials.gov/show/NCT01098266
Study 490:
Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton
Myasthenic Syndrome
http://ClinicalTrials.gov/show/NCT01511978
Study 491:
A Study of REOLYSIN® in Combination With
Gemcitabine in Patients With Advanced Pancreatic
Adenocarcinoma
http://ClinicalTrials.gov/show/NCT00998322
Study 492:
A Study to Provide Access to Trabectedin in Patients
With Non L-type Soft Tissue Sarcoma Who Have
Persistent or Recurrent Disease and Who Are Not
Expected to Benefit From Currently Available Standard
of Care Treatment
http://ClinicalTrials.gov/show/NCT00210665
Study 493:
Preliminary Efficacy and Safety of INNO-206
Compared to Doxorubicin in Advanced Soft Tissue
Sarcoma
http://ClinicalTrials.gov/show/NCT01514188
48
PhRMA • Pharmaceutical Clinical Trials in texas
Study 494:
BNC105P in Combination With Everolimus/Following
Everolimus For Progressive Metastatic Clear Cell Renal
Cell Carcinoma
Study 502:
High-dose Interleukin-2 (HDIL-2), Combined With
recMAGE-A3 + AS15 ASCI
http://ClinicalTrials.gov/show/NCT01266603
http://ClinicalTrials.gov/show/NCT01034631
Study 495:
Irinotecan Plus Lenalidomide in Adult Patients With
Recurrent Glioblastoma Multiforme
Study 503:
Study of Weekly LOC-paclitaxel Injection for
Melanoma
http://ClinicalTrials.gov/show/NCT01039844
http://ClinicalTrials.gov/show/NCT00671801
Study 496:
Vorinostat, Isotretinoin and Temozolomide in Adults
With Recurrent Glioblastoma Multiforme (GBM)
http://ClinicalTrials.gov/show/NCT00555399
Study 497:
A Phase I/II Study of TPI 287-Temozolomide
Combination in Melanoma
http://ClinicalTrials.gov/show/NCT01067066
Study 498:
A-dmDT390-bisFv (UCHT1) Immunotoxin Therapy
for Patients With T-cell Diseases
Study 504:
GSK2118436 and GSK1120212
http://ClinicalTrials.gov/show/NCT01619774
Study 505:
Phase II Study Incorporating Pegylated Interferon In
the Treatment For Children With High-Risk Melanoma
http://ClinicalTrials.gov/show/NCT00539591
Study 506:
Evaluate Safety/Tolerability Intra-Arterial
Temozolomide in Patients w/Extremity Melanoma by
Isolated Limb Infusion
http://ClinicalTrials.gov/show/NCT01127594
http://ClinicalTrials.gov/show/NCT00611208
Study 499:
Study 507:
Safety and Efficacy of Telavancin
A Study Of Inotuzumab Ozogamicin Plus Rituximab
For Relapsed/Refractory Aggressive Non-Hodgkin
Lymphoma Patients Who Are Not Candidates For
Intensive High-Dose Chemotherapy
http://ClinicalTrials.gov/show/NCT01321879
http://ClinicalTrials.gov/show/NCT01232556
Study to Assess the Effectiveness of RCHOP With or
Without VELCADE in Previously Untreated NonGerminal Center B-Cell-like Diffuse Large B-Cell
Lymphoma Patients
Study 500:
Study of US-ATG-F to Prevent Chronic Graft Versus
Host Disease (GVHD)
http://ClinicalTrials.gov/show/NCT01295710
Study 501:
A Study to Investigate the Efficacy and Safety of
Bendamustine Compared With Bendamustine+
RO5072759 (GA101) in Patients With RituximabRefractory, Indolent Non-Hodgkin’s Lymphoma
(GADOLIN)
Study 508:
http://ClinicalTrials.gov/show/NCT00931918
Study 509:
Phase III Study of RAD001 Adjuvant Therapy in Poor
Risk Patients With Diffuse Large B-Cell Lymphoma
(DLBCL) of RAD001 Versus Matching Placebo After
Patients Have Achieved Complete Response With Firstline Rituximab-chemotherapy
http://ClinicalTrials.gov/show/NCT00790036
http://ClinicalTrials.gov/show/NCT01059630
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
49
Study 510:
Comparison of Pixantrone + Rituximab With
Gemcitabine + Rituximab in Patients With Aggressive
B-cell Non-Hodgkin Lymphoma or Follicular Grade 3
Lymphoma Who Have Relapsed After Therapy and Are
Not Eligible for Stem Cell Transplant
Study 518:
A Randomized, Double-Blind and Placebo-Controlled
Study of GS-1101 in Combination With Bendamustine
and Rituximab for Previously Treated Chronic
Lymphocytic Leukemia (CLL)
http://ClinicalTrials.gov/show/NCT01569295
http://ClinicalTrials.gov/show/NCT01321541
Study 511:
Pediatric Philadelphia Positive Acute Lymphoblastic
Leukemia
Study 519:
A Study of Oral Sapacitabine in Elderly Patients With
Newly Diagnosed Acute Myeloid Leukemia
http://ClinicalTrials.gov/show/NCT01303796
http://ClinicalTrials.gov/show/NCT01460160
Study 512:
A Study of RO5072759 (GA101) in Combination With
CHOP Chemotherapy in Patients With Previously
Untreated Advanced Diffuse Large B-Cell Lymphoma
(GATHER)
http://ClinicalTrials.gov/show/NCT01414855
Study 513:
A Study Comparing RO5072759 (GA101) 1000 mg
Versus 2000 mg in Patients With Previously Untreated
Chronic Lymphocytic Leukemia (GAGE)
http://ClinicalTrials.gov/show/NCT01414205
Study 520:
Most Closely HLA Matched Allogeneic Virus Specific
Cytotoxic T-Lymphocytes (CTL)
http://ClinicalTrials.gov/show/NCT00711035
Study 521:
A Randomized, Double-Blind and Placebo-Controlled
Study of GS-1101 in Combination With Rituximab for
Previously Treated Chronic Lymphocytic Leukemia
(CLL)
http://ClinicalTrials.gov/show/NCT01539512
Study 522:
A Study of Brentuximab Vedotin in Patients With
CD30-positive Non-Hodgkin Lymphoma
A Phase II Study of Dasatinib in Children and
Adolescents With Newly Diagnosed Chronic Phase
CML or With Ph+ Leukemias Resistant or Intolerant to
Imatinib
http://ClinicalTrials.gov/show/NCT01421667
http://ClinicalTrials.gov/show/NCT00777036
Study 514:
Study 515:
Ofatumumab and Bendamustine Followed by
Maintenance Ofatumumab for Rituximab Relapsed
Indolent B-cell Non-Hodgkin’s Lymphoma (B-NHL)
Study 523:
Combined Rituximab and Lenalidomide Treatment for
Untreated Patients With Follicular Lymphoma
http://ClinicalTrials.gov/show/NCT01476787
http://ClinicalTrials.gov/show/NCT01294579
Study 516:
Study 524:
Randomized Study of ON 01910.Na in Refractory
Myelodysplastic Syndrome Patients With Excess Blasts
A Extension Study of GS-1101 for Patients With
Chronic Lymphocytic Leukemia Who Participated in
GS-US-312-0116
http://ClinicalTrials.gov/show/NCT01241500
http://ClinicalTrials.gov/show/NCT01539291
Study 517:
Study 525:
Efficacy and Safety of Nilotinib Patients With Newly
Diagnosed CML-CP (Chronic Myelogenous LeukemiaChronic Phase)
Study Using Chemotherapy +/- Pleurectomy/
Decortication Followed By Intensity Modulated
Radiation Therapy
http://ClinicalTrials.gov/show/NCT00718263
http://ClinicalTrials.gov/show/NCT00715611
50
PhRMA • Pharmaceutical Clinical Trials in texas
Study 526:
Paclitaxel + Bevacizumab (Avastin®) for the Treatment
of Metastatic or Unresectable Angiosarcoma
http://ClinicalTrials.gov/show/NCT01055028
Study 534:
Safety, Pharmacodynamics (PD), Pharmacokinetics
(PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous
T-Cell Lymphoma (CTCL)
http://ClinicalTrials.gov/show/NCT01433731
Study 527:
Phase II Study Evaluating the Role of Pazopanib in
Angiosarcoma
http://ClinicalTrials.gov/show/NCT01462630
Study 528:
Study of Pazopanib in the Treatment of Surgically
Unresectable or Metastatic Chondrosarcoma
http://ClinicalTrials.gov/show/NCT01330966
Study 529:
A Study of Two Subcutaneous Regimens of SGI110, a DNA Hypomethylating Agent, in Subjects
With Myelodysplastic Syndromes (MDS) or Acute
Myelogenous Leukemia (AML)
http://ClinicalTrials.gov/show/NCT01261312
Study 535:
A Phase 3 Study of Ibrutinib (PCI-32765) Versus
Ofatumumab in Patients With Relapsed or Refractory
Chronic Lymphocytic Leukemia
http://ClinicalTrials.gov/show/NCT01578707
Study 536:
TXA127 in Enhancement of Engraftment in Adult
Double Cord Blood Transplantation
http://ClinicalTrials.gov/show/NCT01300611
Study 537:
A Study to Assess AC220 Given in Combination
With Induction and Consolidation Therapy in Newly
Diagnosed Acute Myeloid Leukemia (AML)
http://ClinicalTrials.gov/show/NCT01390337
Study 530:
Phase I/II Study of DFP-10917 in Patients With Acute
Leukemia
http://ClinicalTrials.gov/show/NCT01702155
Study 531:
Study of Lenalidomide to Evaluate Safety and
Effectiveness in Patients With Diffuse Large B-Cell
Lymphoma (DLBCL)
http://ClinicalTrials.gov/show/NCT01197560
Study 532:
Phase I/II Study of Different Doses and Dose
Schedules of Milatuzumab (hLL1) in CLL
http://ClinicalTrials.gov/show/NCT00603668
Study 533:
Dasatinib Combo With SMO Inhibitor (BMS-833923)
http://ClinicalTrials.gov/show/NCT01218477
Study 538:
A Study to Evaluate the Efficacy and Safety of
Ibrutinib, in Patients With Mantle Cell Lymphoma Who
Progress After Bortezomib Therapy
http://ClinicalTrials.gov/show/NCT01599949
Study 539:
A Study Combining Ibrutinib With Rituximab,
Cyclophosphamide, Doxorubicin, Vincristine, and
Prednisone in Patients With CD20-Positive B-Cell Non
Hodgkin Lymphoma
http://ClinicalTrials.gov/show/NCT01569750
Study 540:
A Study of AC220 Given After Transplant in Subjects
With Acute Myeloid Leukemia (AML)
http://ClinicalTrials.gov/show/NCT01468467
Study 541:
An Open Label Study to Evaluate the Safety and
Efficacy of Two Doses of Quizartinib in Patients With
Relapsed or Refractory Acute Myeloid Leukemia
http://ClinicalTrials.gov/show/NCT01565668
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
51
Study 542:
A Study of Ibrutinib in Combination With
Bendamustine and Rituximab in Patients With
Relapsed or Refractory Chronic Lymphocytic
Leukemia or Small Lymphocytic Lymphoma
http://ClinicalTrials.gov/show/NCT01611090
Study 543:
Study 550:
Safety and Efficacy of BKM120 in Relapsed and
Refractory NHL
http://ClinicalTrials.gov/show/NCT01693614
Study 551:
Study of Hypoxia-Activated Prodrug TH-302 to Treat
Advanced Leukemias
A Phase 3 Trial of Brentuximab Vedotin(SGN-35)
Versus Physician’s Choice (Methotrexate or
Bexarotene) in Patients With CD30-Positive Cutaneous
T-Cell Lymphoma
http://ClinicalTrials.gov/show/NCT01149915
http://ClinicalTrials.gov/show/NCT01578499
Study to Evaluate the Safety and Tolerability of Weekly
Intravenous (IV) Doses of BMS-906024 in Subjects
With Acute T-cell Lymphoblastic Leukemia or T-cell
Lymphoblastic Lymphoma
Study 544:
A Study in Participants With Acute Leukemia
Study 552:
http://ClinicalTrials.gov/show/NCT01363817
http://ClinicalTrials.gov/show/NCT01214603
Study 545:
Study 553:
Phase 2 Safety and Efficacy Study of CAL-101 (GS1101) in Relapsed or Refractory Hodgkin Lymphoma
Safety and Tolerability of AZD1208 and the
Pharmacokinetics and Efficacy of AZD1208 in Acute
Myelogenous Leukemia (AML) Patients
http://ClinicalTrials.gov/show/NCT01393106
http://ClinicalTrials.gov/show/NCT01489722
Study 546:
Safety, Efficacy, & Pharmacokinetic Study of
Tamibarotene to Treat Patients With Relapsed or
Refractory APL
http://ClinicalTrials.gov/show/NCT00520208
Study 547:
Study Of The Effectiveness & Safety Of Lenalidomide
Versus Chlorambucil As First Line Therapy For Elderly
Patients With B-Cell CLL (The ORIGIN Trial)
http://ClinicalTrials.gov/show/NCT00910910
Study 548:
Study to Evaluate Pharmacokinetics, Food Effect,
Safety and Efficacy of Oral Azacitidine
http://ClinicalTrials.gov/show/NCT01519011
Study 549:
Study Combining SAR245409 With Bendamustine and/
or Rituximab in Subjects With Indolent Lymphoma,
Mantle Cell Lymphoma & Chronic Lymphocytic
Leukemia
Study 554:
A Study Being Conducted at Multiple Locations
to Compare the Safety and Effectiveness of Three
Different Treatment Regimens; 1) Lenalidomide, 2)
Lenalidomide + Azacitidine, or 3) Azacitidine Alone in
Newly Diagnosed Acute Myeloid Leukemia in Elderly
Subjects ≥ 65 Years of Age
http://ClinicalTrials.gov/show/NCT01358734
Study 555:
Study of MK-8242 Alone and in Combination With
Cytarabine in Participants With Acute Myelogenous
Leukemia (P07649 AM3)
http://ClinicalTrials.gov/show/NCT01451437
Study 556:
A Study To Evaluate PF-04449913 With Chemotherapy
In Patients With Acute Myeloid Leukemia or
Myelodysplastic Syndrome
http://ClinicalTrials.gov/show/NCT01546038
http://ClinicalTrials.gov/show/NCT01410513
52
PhRMA • Pharmaceutical Clinical Trials in texas
Study 557:
Efficacy and Safety of Decitabine as Epigenetic
Priming With Induction Chemotherapy in Pediatric
Acute Myelogenous Leukemia (AML) Subjects
http://ClinicalTrials.gov/show/NCT01177540
Study 558:
Study of AEB071 (a Protein Kinase C Inhibitor) in
Patients With CD79-mutant Diffuse Large B-Cell
Lymphoma
http://ClinicalTrials.gov/show/NCT01402440
Study 564:
Study to Investigate CAL-101 in Combination With
Chemotherapeutic Agents and CD20 mAb in Patients
With Relapsed or Refractory Indolent B-cell NonHodgkin’s Lymphoma, Mantle Cell Lymphoma or
Chronic Lymphocytic Leukemia
http://ClinicalTrials.gov/show/NCT01088048
Study 565:
Phase I Clinical Study of CWP232291 in Acute Myeloid
Leukemia Patients
http://ClinicalTrials.gov/show/NCT01398462
Study 559:
Pralatrexate and Bexarotene in Patients With Relapsed
or Refractory Cutaneous T-cell Lymphoma
http://ClinicalTrials.gov/show/NCT01134341
Study 560:
A Study to Evaluate the Efficacy and Safety of
Lenalidomide as Maintenance Therapy for Patients
With B-Cell CLL Following Second Line Therapy
(THE CONTINUUM TRIAL)
http://ClinicalTrials.gov/show/NCT00774345
Study 566:
Alisertib (MLN8237) or Investigator’s Choice in
Patients With Relapsed/Refractory Peripheral T-Cell
Lymphoma
http://ClinicalTrials.gov/show/NCT01482962
Study 567:
MLN4924 for the Treatment of Acute Myelogenous
Leukemia, Myelodysplastic Syndrome, and Acute
Lymphoblastic Leukemia
http://ClinicalTrials.gov/show/NCT00911066
Study 561:
A Phase Ib/IIb, Open-label, Multi-center, Study of
Oral Panobinostat Administered With 5-Azacitidine (in
Adult Patients With Myelodysplastic Syndromes (MDS),
Chronic Myelomonocytic Leukemia (CMML), or Acute
Myeloid Leukemia (AML)
http://ClinicalTrials.gov/show/NCT00946647
Study 562:
Study of Vidaza Versus Conventional Care Regimens
for the Treatment of Acute Myeloid Leukemia (AML)
http://ClinicalTrials.gov/show/NCT01074047
Study 563:
A Phase 3 Study to Evaluate Marqibo® in the
Treatment of Subjects ≥ 60 Years Old With Newly
Diagnosed ALL
http://ClinicalTrials.gov/show/NCT01439347
Study 568:
Phase II Study of Crenolanib in Subjects With Relapsed
AML With FLT3-D835 Activating Mutations
http://ClinicalTrials.gov/show/NCT01522469
Study 569:
A Study to Assess AFM13 in Patients With Hodgkin
Lymphoma
http://ClinicalTrials.gov/show/NCT01221571
Study 570:
Safety & Efficacy Study of Oral Panobinostat (LBH589)
With Chemotherapy in Patients < 65 Years Old With
Acute Myeloid Leukemia (AML)
http://ClinicalTrials.gov/show/NCT01242774
Study 571:
ALT-801-activated Natural Killer Cells After FLAG
Induction for Acute Myeloid Leukemia
http://ClinicalTrials.gov/show/NCT01478074
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
53
Study 572:
Nilotinib and LDE225 in the Treatment of Phase
Chronic Myeloid Leukemia Patients Who Developed
Resistance to Prior Therapy
Study 580:
Clinical Study of PM01183 in Patients With Acute
Leukemia
http://ClinicalTrials.gov/show/NCT01314599
http://ClinicalTrials.gov/show/NCT01456676
Study 573:
Study 581:
SAR3419 in Acute Lymphoblastic Leukemia
Bortezomib and Rituximab for Patients With
Waldenstrom’s Macroglobulinemia
http://ClinicalTrials.gov/show/NCT01440179
http://ClinicalTrials.gov/show/NCT00492050
Study 574:
Clinical Study With Blinatumomab in Patients With
Relapsed/Refractory B-precursor Acute Lymphoblastic
Leukemia (ALL)
http://ClinicalTrials.gov/show/NCT01466179
Study 575:
A Phase II Study of Crenolanib in Relapsed/Refractory
Acute Myeloid Leukemia Patients With FLT3 Activating
Mutations
Study 582:
Pomalidomide for Relapse/Refractory Waldenstrom’s
http://ClinicalTrials.gov/show/NCT01198067
Study 583:
A Trial of Temsirolimus With Etoposide and
Cyclophosphamide in Children With Relapsed
Acute Lymphoblastic Leukemia and Non-Hodgkins
Lymphoma
http://ClinicalTrials.gov/show/NCT01614197
http://ClinicalTrials.gov/show/NCT01657682
Study 576:
Efficacy Study of Oral Sapacitabine to Treat Acute
Myeloid Leukemia in Elderly Patients
Study 584:
Sorafenib and 5-Azacitidine in Acute Leukemia +
Myelodysplastic Syndrome
http://ClinicalTrials.gov/show/NCT01254890
http://ClinicalTrials.gov/show/NCT00590187
Study 577:
Single Agent Ofatumumab Vs. Single Agent Rituximab
in Follicular Lymphoma Relapsed After RituximabContaining Therapy
Study 585:
Combination Study of Cytarabine and Tosedostat
in Acute Myeloid Leukemia (AML) or High Risk
Myelodysplastic Syndromes (MDS)
http://ClinicalTrials.gov/show/NCT01636609
http://ClinicalTrials.gov/show/NCT01200589
Study 578:
A Study of RO5045337 in Combination With
Cytarabine in Patients With Acute Myelogenous
Leukemia
http://ClinicalTrials.gov/show/NCT01635296
Study 579:
A Study of DCDT2980S in Combination With
MabThera/Rituxan or DCDS4501A in Combination
With MabThera/Rituxan in Patients With NonHodgkin’s Lymphoma
Study 586:
SAHA + CHOP in Untreated T-cell Non-Hodgkin’s
Lymphoma
http://ClinicalTrials.gov/show/NCT00787527
Study 587:
Inotuzumab Ozogamycin in Elderly Acute
Lymphoblastic Leukemia (ALL)
http://ClinicalTrials.gov/show/NCT01371630
http://ClinicalTrials.gov/show/NCT01691898
54
PhRMA • Pharmaceutical Clinical Trials in texas
Study 588:
Study 597:
5-Azacytidine With Lenalidomide in Patients With
High Risk Myelodysplastic Syndrome (MDS) and
Acute Myelogenous Leukemia (AML)
Phase II Study of Idarubicin, Cytarabine, and Vorinostat
With High-Risk Myelodysplastic Syndrome (MDS) and
Acute Myeloid Leukemia (AML)
http://ClinicalTrials.gov/show/NCT01038635
http://ClinicalTrials.gov/show/NCT00656617
Study 589:
Panobinostat Plus Ifosfamide, Carboplatin, and
Etoposide (ICE) Compared With ICE For Relapsed
Hodgkin Lymphoma
http://ClinicalTrials.gov/show/NCT01169636
Study 598:
Clofarabine Plus Cytarabine Versus Conventional
Induction Therapy And A Study Of NK Cell
Transplantation In Newly Diagnosed Acute Myeloid
Leukemia
http://ClinicalTrials.gov/show/NCT00703820
Study 590:
Phase I/II-Dasatinib and Decitabine
http://ClinicalTrials.gov/show/NCT01498445
Study 591:
RAD001 Study in Treatment of Relapsed or Refractory
Acute Lymphocytic Leukemia
http://ClinicalTrials.gov/show/NCT00968253
Study 592:
Plerixafor and Clofarabine in Frontline Treatment of
Elderly Patients With Acute Myelogenous Leukemia
(AML)
http://ClinicalTrials.gov/show/NCT01160354
Study 599:
Phase II Eltrombopag in Chronic Lymphocytic
Leukemia (CLL)
http://ClinicalTrials.gov/show/NCT01168921
Study 600:
Study of Dasatinib in Patients With Chronic
Myelogenous Leukemia
http://ClinicalTrials.gov/show/NCT00254423
Study 601:
Hyper CVAD Plus Ofatumumab in CD-20 Positive
Acute Lymphoblastic Leukemia (ALL)
http://ClinicalTrials.gov/show/NCT01363128
Study 593:
PKC412 and 5-Azacytidine
http://ClinicalTrials.gov/show/NCT01202877
Study 594:
Granulocyte-colony Stimulating Factor (G-CSF) and
Plerixafor Plus Sorafenib for Acute Myelogenous
Leukemia (AML) With FLT3 Mutations
http://ClinicalTrials.gov/show/NCT00943943
Study 602:
Nonmyeloablative Stem Cell Transplantation for
Chronic Lymphocytic Leukemia (CLL)
http://ClinicalTrials.gov/show/NCT00899431
Study 603:
Phase II R-ABVD Versus ABVD for Advanced Stage
Classical Hodgkin Lymphoma
http://ClinicalTrials.gov/show/NCT00654732
Study 595:
Stem Cell Collection With Ofatumumab
http://ClinicalTrials.gov/show/NCT01329900
Study 596:
Bortezomib (Velcade) Plus Rituximab-HyperCVAD in
Patients With Mantle Cell Lymphoma
Study 604:
Phase I Study of Romidepsin Plus ICE for Patients
With Relapsed or Refractory Peripheral T-Cell
Lymphoma
http://ClinicalTrials.gov/show/NCT01590732
http://ClinicalTrials.gov/show/NCT00477412
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
55
Study 605:
Study 614:
Combination of Lenalidomide and Rituximab in
Chronic Lymphocytic Leukemia/Small Lymphocytic
Lymphoma (CLL-SLL)
A Phase I Study of AC220 for Children With Relapsed
or Refractory Acute Lymphoblastic Leukemia or Acute
Myelogenous Leukemia
http://ClinicalTrials.gov/show/NCT01446133
http://ClinicalTrials.gov/show/NCT01411267
Study 606:
Eltrombopag for Management of Thrombocytopenia
http://ClinicalTrials.gov/show/NCT01428635
Study 615:
Ponatinib-Frontline for Chronic Myeloid Leukemia
(CML) in Chronic Phase (CP)
http://ClinicalTrials.gov/show/NCT01570868
Study 607:
A Study of the HSP90 Inhibitor AUY922
http://ClinicalTrials.gov/show/NCT01485536
Study 608:
Phase II Nilotinib With Newly Diagnosed Chronic
Phase Chronic Myelogenous Leukemia (CML)
http://ClinicalTrials.gov/show/NCT00129740
Study 609:
Omacetaxine and Low Dose Cytarabine in Older
Patients With Acute Myelogenous Leukemia (AML) and
High-Risk Myelodysplastic Syndrome (MDS)
http://ClinicalTrials.gov/show/NCT01272245
Study 610:
Study of Bortezomib in Combination With
Cyclophosphamide and Rituximab
http://ClinicalTrials.gov/show/NCT00958256
Study 611:
Study 616:
Hyper-CVAD With Liposomal Vincristine in Acute
Lymphoblastic Leukemia
http://ClinicalTrials.gov/show/NCT01319981
Study 617:
Hyper-CVAD and Ponatinib in Ph-Positive and/or
BCR-ABL Positive Acute Lymphoblastic Leukemia
(ALL)
http://ClinicalTrials.gov/show/NCT01424982
Study 618:
Lenalidomide Plus Rituximab for Indolent NonHodgkin’s Lymphoma
http://ClinicalTrials.gov/show/NCT00695786
Study 619:
Ofatumumab for High-Risk Chronic Lymphocytic
Leukemia (CLL)
http://ClinicalTrials.gov/show/NCT01243190
Sapacitabine, Cyclophosphamide, Rituximab for Relapsed
Chronic Lymphocytic Leukemia, Small Lymphocytic
Lymphoma (CLL/SLL) With Deletion (11q22-23)
2CDA With Rituximab in Hairy Cell Leukemia
http://ClinicalTrials.gov/show/NCT01253460
http://ClinicalTrials.gov/show/NCT00412594
Study 612:
Study 620:
Study 621:
Acute Promyelocytic Leukemia (APL) Treated With
ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin
Pilot Phase II-Erlotinib for Acute Myeloid Leukemia
(AML)
http://ClinicalTrials.gov/show/NCT01409161
http://ClinicalTrials.gov/show/NCT01664897
Study 613:
Vorinostat in Combination With Azacitidine in Patients
With Newly-Diagnosed Acute Myelogenous Leukemia
(AML) or Myelodysplastic Syndrome (MDS)
Study 622:
E7070, Idarubicin and Cytarabine in Relapsed AML and
High-Risk Myelodysplastic Syndromes
http://ClinicalTrials.gov/show/NCT01692197
http://ClinicalTrials.gov/show/NCT00948064
56
PhRMA • Pharmaceutical Clinical Trials in texas
Study 623:
Study to Assess Safety, Tolerability and Preliminary
Efficacy of BKM120, PI3K Kinase Inhibitor, With
Advanced Leukemias
http://ClinicalTrials.gov/show/NCT01396499
Study 631:
Safety and Tolerability Study of Oral NS-018
in Patients With Primary Myelofibrosis (MF),
Post-polycythemia Vera MF or Post-essential
Thrombocythemia MF
http://ClinicalTrials.gov/show/NCT01423851
Study 624:
Myelodysplastic Syndromes (MDS) Event Free Survival
With Iron Chelation Therapy Study
http://ClinicalTrials.gov/show/NCT00940602
Study 625:
Study 632:
Open-label Study of the Safety and Efficacy of
Adalimumab in the Treatment of Hidradenitis
Suppurativa
http://ClinicalTrials.gov/show/NCT01635764
A Study of Lenalidomide Versus Placebo in Subjects
With Transfusion Dependent Anemia in Low Risk
Myelodysplastic Syndrome (MDS) Without Del 5Q
TKI 258 in Von Hippel-Lindau Syndrome (VHL)
http://ClinicalTrials.gov/show/NCT01029262
http://ClinicalTrials.gov/show/NCT01266070
Study 626:
A Study of ARRY-614 in Patients With Low or
Intermediate-1 Risk Myelodysplastic Syndromes
Study 633:
Diabetes
(92 clinical trials recruiting)
http://ClinicalTrials.gov/show/NCT01496495
Study 627:
Evaluation of SQ109 Plus PPI in Urea Breath TestPositive Volunteers
http://ClinicalTrials.gov/show/NCT01252108
Study 628:
Phase 2 Reduction of Dietary Mycotoxin Exposure by
ACCS100”
http://ClinicalTrials.gov/show/NCT01677195
Study 629:
Decitabine and Clofarabine in Higher Risk
Myelodysplastic Syndromes (MDS)
http://ClinicalTrials.gov/show/NCT00903760
Study 630:
An Open-label, Multi-center, Expanded Access Study
of Pasireotide s.c. in Patients With Cushing’s Disease
http://ClinicalTrials.gov/show/NCT01582061
Study 1:
The Effect of Liraglutide Versus Placebo When Added
to Basal Insulin Analogues With or Without Metformin
in Subjects With Type 2 Diabetes
http://ClinicalTrials.gov/show/NCT01617434
Study 2:
Efficacy and Safety of Liraglutide in Combination With
Metformin Compared to Metformin Alone, in Children
and Adolescents With Type 2 Diabetes
http://ClinicalTrials.gov/show/NCT01541215
Study 3:
Safety and Efficacy of Exenatide as Monotherapy and
Adjunctive Therapy to Oral Antidiabetic Agents in
Adolescents With Type 2 Diabetes
http://ClinicalTrials.gov/show/NCT00658021
Study 4:
The Effect of Insulin Degludec in Combination With
Liraglutide and Metformin in Subjects With Type 2
Diabetes Qualifying for Treatment Intensification
http://ClinicalTrials.gov/show/NCT01664247
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
57
Study 5:
The Efficacy of Insulin Degludec/Liraglutide in
Controlling Glycaemia in Adults With Type 2 Diabetes
Inadequately Controlled on GLP-1 Receptor Agonist
and Metformin Therapy
Study 13:
CAROLINA: Cardiovascular Outcome Study of
Linagliptin Versus Glimepiride in Patients With Type 2
Diabetes
http://ClinicalTrials.gov/show/NCT01243424
http://ClinicalTrials.gov/show/NCT01676116
Study 6:
A Trial Comparing the Efficacy, Patient-reported
Outcomes and Safety of Insulin Degludec 200 U/mL
vs Insulin Glargine in Subjects With Type 2 Diabetes
Mellitus Requiring High-dose Insulin
Study 14:
A Study of BMS-512148 (Dapagliflozin) in Patients
With Type 2 Diabetes With Inadequately Controlled
Hypertension on an ACEI or ARB and an Additional
Antihypertensive Medication
http://ClinicalTrials.gov/show/NCT01195662
http://ClinicalTrials.gov/show/NCT01570751
Study 7:
Study 15:
Comparison of the Efficacy and Safety of Two Different
Dose Adjustment Regimens for Insulin Degludec/
Insulin Aspart in Subjects With Type 2 Diabetes Mellitus
Previously Treated With Insulin Glargine
A Study of BMS-512148 (Dapagliflozin) in Patients
With Type 2 Diabetes With Inadequately Controlled
Hypertension on an Angiotensin-Converting Enzyme
Inhibitor (ACEI) or Angiotensin Receptor Blocker
(ARB)
http://ClinicalTrials.gov/show/NCT01680341
http://ClinicalTrials.gov/show/NCT01137474
Study 8:
Study 16:
A Study in Patients With Type 2 Diabetes Mellitus
A Study in Patients With Type I Diabetes Mellitus
http://ClinicalTrials.gov/show/NCT01435616
http://ClinicalTrials.gov/show/NCT01454284
Study 9:
Study to Assess Safety & Efficacy of Sitagliptin as
Initial Monotherapy for Treatment of Type 2 Diabetes
Mellitus in Pediatric Participants (MK-0431-083)
Study 17:
BI 10773 Cardiovascular Outcome Event Trial in Type 2
Diabetes Mellitus Patients.
http://ClinicalTrials.gov/show/NCT01131676
http://ClinicalTrials.gov/show/NCT01485614
Study 10:
Study 18:
A Study in Participants With Type 2 Diabetes Mellitus
The Efficacy of Insulin Degludec/Liraglutide as add-on
Therapy in Controlling Glycaemia in Adults With Type
2 Diabetes Inadequately Controlled on Sulphonylurea
With or Without Metformin Therapy
http://ClinicalTrials.gov/show/NCT01468987
http://ClinicalTrials.gov/show/NCT01618162
A Study of LY2605541 in Participants With Type 2
Diabetes Mellitus
Study 11:
Safety Study of Mesenchymal Precursor Cells in Type 2
Diabetes
Study 19:
http://ClinicalTrials.gov/show/NCT01582451
Study 20:
Researching Cardiovascular Events With a Weekly
Incretin in Diabetes (REWIND)
A Multicenter, Randomized, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety
of Saxagliptin (BMS-477118) in Combination With
Metformin IR or Metformin XR in Pediatric Patients
With Type 2 Diabetes Who Have Inadequate Glycemic
Control on Metformin Alone
http://ClinicalTrials.gov/show/NCT01394952
http://ClinicalTrials.gov/show/NCT01434186
http://ClinicalTrials.gov/show/NCT01576328
Study 12:
58
PhRMA • Pharmaceutical Clinical Trials in texas
Study 21:
Exenatide Study of Cardiovascular Event Lowering
Trial (EXSCEL): A Trial To Evaluate Cardiovascular
Outcomes After Treatment With Exenatide Once
Weekly In Patients With Type 2 Diabetes Mellitus
http://ClinicalTrials.gov/show/NCT01144338
Study 22:
Cardiovascular Outcomes Study of Alogliptin in
Subjects With Type 2 Diabetes and Acute Coronary
Syndrome
http://ClinicalTrials.gov/show/NCT00968708
Study 23:
Single Ascending Dose Trial in Patients With Type 2
Diabetes
http://ClinicalTrials.gov/show/NCT01492465
Study 24:
Efficacy and Safety of Azilsartan Medoxomil Used in
Combination With Metformin in Participants With
Hypertension and Diabetes
http://ClinicalTrials.gov/show/NCT01496430
Study 25:
A Study Comparing the Effect of Dulaglutide With
Liraglutide in Type 2 Diabetes
Study 29:
Efficacy and Safety Study of DiaPep277 in Newly
Diagnosed Type 1 Diabetes Adults
http://ClinicalTrials.gov/show/NCT01103284
Study 30:
A Pharmacodynamic Study of Measured Glomerular
Filtration Rate in Patients With Chronic Kidney
Disease and Type 2 Diabetes
http://ClinicalTrials.gov/show/NCT01500798
Study 31:
Comparison of TAK-875 With Placebo in Participants
With Type 2 Diabetes
http://ClinicalTrials.gov/show/NCT01456195
Study 32:
Efficacy and Safety of TAK-875 Compared to
Glimepiride When Used With Metformin in
Participants With Type 2 Diabetes
http://ClinicalTrials.gov/show/NCT01481116
Study 33:
Study of TAK-875 in Adults With Type 2 Diabetes
and Cardiovascular Disease or Risk Factors for
Cardiovascular Disease
http://ClinicalTrials.gov/show/NCT01609582
http://ClinicalTrials.gov/show/NCT01624259
Study 26:
Study 34:
Safety and Efficacy Study of JTT-851 in Patients With
Type 2 Diabetes Mellitus
Comparison of Technosphere Insulin Versus
Technosphere Powder (Placebo) in Insulin-Naive
Subjects With Type 2 Diabetes Mellitus
http://ClinicalTrials.gov/show/NCT01699737
http://ClinicalTrials.gov/show/NCT01451398
Study 27:
Ranolazine Monotherapy in Subjects With Type 2
Diabetes Mellitus
http://ClinicalTrials.gov/show/NCT01472185
Study 28:
Ranolazine When Added to Glimepiride in Subjects
With Type 2 Diabetes Mellitus
http://ClinicalTrials.gov/show/NCT01494987
Study 35:
A Study Comparing Dulaglutide With Insulin Glargine
on Glycemic Control in Participants With Type 2
Diabetes (T2D) and Moderate or Severe Chronic
Kidney Disease (CKD)
http://ClinicalTrials.gov/show/NCT01621178
Study 36:
A Study With Aleglitazar in Patients With a Recent
Acute Coronary Syndrome and Type 2 Diabetes
Mellitus
http://ClinicalTrials.gov/show/NCT01042769
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
59
Study 37:
Study 44:
Efficacy and Safety of Liraglutide Versus Placebo as
add-on to Existing Diabetes Medication in Subjects
With Type 2 Diabetes and Moderate Renal Impairment
A Study of the Co-administration of Sitagliptin
and Atorvastatin in Inadequately Controlled Type 2
Diabetes Mellitus (MK-0431E-211 AM1)
http://ClinicalTrials.gov/show/NCT01620489
http://ClinicalTrials.gov/show/NCT01477853
Study 38:
Study To Understand Efficacy And Safety Of
Investigational Agent (PF-04937319) Compared To
Approved Agent (Glimepiride) In Patients With
Diabetes On Metformin
Study 45:
Clinical Trial Evaluating Technosphere® Insulin Versus
Insulin Aspart in Subjects With Type 1 Diabetes
Mellitus Over a 24-week Treatment Period
http://ClinicalTrials.gov/show/NCT01445951
http://ClinicalTrials.gov/show/NCT01517373
Study 39:
A Study of the Safety and Efficacy of MK-0431A in
Pediatric Participants With Type 2 Diabetes Mellitus
(MK-0431A-170 AM1)
Study 46:
Comparison of a New Formulation of Insulin Glargine
With Lantus in Patients With Type 2 Diabetes on Basal
Insulin With Oral Antidiabetic Therapy
http://ClinicalTrials.gov/show/NCT01499095
http://ClinicalTrials.gov/show/NCT01472367
Study 40:
Evaluate Safety of Technosphere® Insulin Inhalation
Powder (TI Inhalation Powder) on Diabetic Subjects
With Mild Obstructive Pulmonary Disease
Study 47:
Study of Sitagliptin for the Treatment of Type 2
Diabetes Mellitus With Inadequate Glycemic Control
on Insulin (MK-0431-260 AM3)
http://ClinicalTrials.gov/show/NCT01462266
http://ClinicalTrials.gov/show/NCT00642616
Study 41:
A Study to Evaluate Safety and Efficacy of TTP054 for
12 Weeks in Subjects With Type 2 Diabetes
Study 48:
Diabetes Technology Study of Real-Time Glucose
Alerts in the Team Management of Diabetes
http://ClinicalTrials.gov/show/NCT00322478
http://ClinicalTrials.gov/show/NCT01665352
Study 42:
A 16 Weeks Study on Efficacy and Safety of Two Doses
of Empagliflozin (BI 10773) (Once Daily Versus Twice
Daily) in Patients With Type 2 Diabetes Mellitus and
Preexisting Metformin Therapy
http://ClinicalTrials.gov/show/NCT01649297
Study 43:
A Phase 3 Study of Ranolazine in Subjects With Type 2
Diabetes Who Are Not Well Controlled on Metformin
Alone
http://ClinicalTrials.gov/show/NCT01555164
Study 49:
Safety and Efficacy of BGP-15 in Patients With Type 2
Diabetes Mellitus
http://ClinicalTrials.gov/show/NCT01069965
Study 50:
AMG 151 Amgen Protocol Number 20100761
http://ClinicalTrials.gov/show/NCT01464437
Study 51:
Study to Evaluate the Efficacy, Safety, Tolerability, and
Pharmacokinetics of Saxagliptin as Monotherapy in
Pediatric Patients With Type 2 Diabetes
http://ClinicalTrials.gov/show/NCT01204775
60
PhRMA • Pharmaceutical Clinical Trials in texas
Study 52:
Study 60:
Safety and Efficacy of Combination Saxagliptin &
Dapagliflozin Added to Metformin to Treat Subjects
With Type 2 Diabetes
Pharmacokinetic and Pharmacodynamic Study of
Bardoxolone Methyl in Patients With Chronic Kidney
Disease and Type 2 Diabetes
http://ClinicalTrials.gov/show/NCT01606007
http://ClinicalTrials.gov/show/NCT01549769
Study 53:
Finding a Safe and Effective Dose of Linagliptin in
Peadiatric Patients With Type 2 Diabetes
http://ClinicalTrials.gov/show/NCT01342484
Study 61:
Safety, Tolerability, Pharmacokinetics,Pharmacodyn
amics Study of LAPS-Exendin in Subjects of Type 2
Diabetes Mellitus
http://ClinicalTrials.gov/show/NCT01452451
Study 54:
BMS-Safety, Pharmacokinetics (PK) and
Pharmacodynamics (PD) of Dapagliflozin in Type 1
Diabetes
http://ClinicalTrials.gov/show/NCT01498185
Study 62:
Study to Evaluate the Pharmacodynamic and
Pharmacokinetic Effects of LX4211 in Subjects With
Type 2 Diabetes and Renal Impairment
http://ClinicalTrials.gov/show/NCT01555008
Study 55:
Pharmacokinetics, Pharmacodynamics and Safety of
Alogliptin in Children, Adolescents and Adults With
Type 2 Diabetes Mellitus
http://ClinicalTrials.gov/show/NCT00957268
Study 63:
Comparison of a New Formulation of Insulin Glargine
With Lantus in Patients With Type 2 Diabetes on Noninsulin Antidiabetic Therapy
http://ClinicalTrials.gov/show/NCT01676220
Study 56:
Study 64:
A Phase III Study to Evaluate Safety, Tolerability and
Efficacy of CureXcell™ in Treating Lower Extremity
Chronic Ulcers in Adults With Diabetes Mellitus
A Study Evaluating Safety and Efficacy of BIOD-123
Compared to Insulin Lispro (Humalog®)
http://ClinicalTrials.gov/show/NCT01421966
http://ClinicalTrials.gov/show/NCT01686620
Study 57:
Phase 2 Study to Evaluate Safety & Efficacy of RM-131
Administered to Patients With Diabetic Gastroparesis
http://ClinicalTrials.gov/show/NCT01571297
Study 58:
A Phase 2 Study to Evaluate the Safety and Efficacy of
CTP-499 in Type 2 Diabetic Nephropathy Patients
http://ClinicalTrials.gov/show/NCT01487109
Study 59:
A Pharmacodynamic/Pharmacokinetic Study of
Aleglitazar in Patients With Type 2 Diabetes Mellitus on
Treatment With Lisinopril
Study 65:
Phase 2b Multicenter, Randomized, Double-Blind,
Placebo- and Active-Controlled, Parallel-Group Study
to Assess the PD Response and Safety of Three Dose
Levels of Glymera Injection Following 20 Weeks of
Weekly SC Dosing in Adults With T2DM
http://ClinicalTrials.gov/show/NCT01658501
Study 66:
A Study of Aleglitazar in Combination With Metformin
in Patients With Type 2 Diabetes Mellitus Who Are
Inadequately Controlled With Metformin Alone
http://ClinicalTrials.gov/show/NCT01691846
http://ClinicalTrials.gov/show/NCT01398267
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
61
Study 67:
A Study of Aleglitazar in Combination With Metformin
in Patients With Type 2 Diabetes Mellitus Who Are
Inadequately Controlled With Sulfonylurea Alone or
Sulfonylurea Plus Metformin Therapy
http://ClinicalTrials.gov/show/NCT01691989
Study 68:
A Phase 2, Placebo-Controlled Study To Evaluate The
Efficacy And Safety Of PF-00489791 In Patients With
Type 2 Diabetes And Overt Nephropathy
http://ClinicalTrials.gov/show/NCT01200394
Study 69:
Comparison of TAK-875 to Placebo and Sitagliptin
in Combination With Metformin in Participants With
Type 2 Diabetes
http://ClinicalTrials.gov/show/NCT01549964
Study 70:
Immunosafety Study of Recombinant Human Insulins
in Type 1 Diabetics
http://ClinicalTrials.gov/show/NCT01308437
Study 71:
Outpatient Study to Evaluate Safety and Effectiveness
of the Low Glucose Suspend Feature
http://ClinicalTrials.gov/show/NCT01497938
Study 72:
Effects of Metreleptin in Type 1 Diabetes Mellitus
http://ClinicalTrials.gov/show/NCT01268644
Study 76:
Treatment of Neuropathic Pain Associated With
Diabetic Peripheral Neuropathy
http://ClinicalTrials.gov/show/NCT01496365
Study 77:
Safety and Efficacy of HO/03/03 10μg in the Treatment
of Plantar Neuropathic Diabetic Foot Ulcers
http://ClinicalTrials.gov/show/NCT00926068
Study 78:
Evaluation of Cardiovascular Outcomes in Patients
With Type 2 Diabetes After Acute Coronary Syndrome
During Treatment With AVE0010 (Lixisenatide)
http://ClinicalTrials.gov/show/NCT01147250
Study 79:
Efficacy and Safety Trial of Intravitreal Injections
Combined With PRP for the Treatment of CSME
Secondary to Diabetes Mellitus (DAVE)
http://ClinicalTrials.gov/show/NCT01552408
Study 80:
A Study to Test Safety and Efficacy of Baricitinib in
Participants With Diabetic Kidney Disease
http://ClinicalTrials.gov/show/NCT01683409
Study 81:
A Study to Evaluate the Efficacy and Safety of a Single
Application of QUTENZA Compared to That of
Placebo in Reducing Pain Intensity in Subjects With
Painful Diabetic Peripheral Neuropathy (PDPN)
http://ClinicalTrials.gov/show/NCT01533428
Study 73:
Insulin Resistance Intervention After Stroke Trial
http://ClinicalTrials.gov/show/NCT00091949
Study 74:
A Study in Patients With Diabetic Kidney Disease
http://ClinicalTrials.gov/show/NCT01113801
Study 75:
Novel Therapies for Metabolic Complications of
Lipodystrophies
Study 82:
Acthar for Treatment of Proteinuria in Diabetic
Nephropathy Patients
http://ClinicalTrials.gov/show/NCT01601236
Study 83:
Study to Evaluate MK-6096 in the Treatment of Painful
Diabetic Neuropathy (PDN) in Adults (MK-6096-021
AM1)
http://ClinicalTrials.gov/show/NCT01564459
http://ClinicalTrials.gov/show/NCT00457938
62
PhRMA • Pharmaceutical Clinical Trials in texas
Study 84:
Study 92:
Effect Of Pregabalin Treatment In Patients With
Diabetic Nerve Pain Who Currently Use A Non-Steroid
Anti-Inflammatory Drug (NSAID) For Another Pain
Dose Response of 28 Days of Dosing of GSK962040 in
Type I and II Diabetic Male and Female Subjects With
Gastroparesis
http://ClinicalTrials.gov/show/NCT01455415
http://ClinicalTrials.gov/show/NCT01262898
Study 85:
Efficacy and Safety Study of Pregabalin in the
Treatment of Pain on Walking in Patients With Diabetic
Peripheral Neuropathy (DPN)
http://ClinicalTrials.gov/show/NCT01474772
Study 86:
PF-04523655 Dose Escalation Study, and Evaluation of
PF-04523655 With/Without Ranibizumab in Diabetic
Macular Edema (DME)
http://ClinicalTrials.gov/show/NCT01445899
Study 87:
A Clinical Study of the Safety and Efficacy of MEBO
Wound Ointment in Subjects With Diabetic Foot
Ulcers
http://ClinicalTrials.gov/show/NCT01070433
Study 88:
Transdermal Continuous Oxygen Therapy for Diabetic
Foot Ulcers
http://ClinicalTrials.gov/show/NCT01291160
Study 89:
Safety and Efficacy Study for the Treatment of Painful
Diabetic Neuropathy
http://ClinicalTrials.gov/show/NCT01475786
Study 90:
Prompt Panretinal Photocoagulation Versus
Ranibizumab+Deferred Panretinal Photocoagulation
for Proliferative Diabetic Retinopathy
http://ClinicalTrials.gov/show/NCT01489189
Study 91:
Cardiovascular Outcomes Study of Naltrexone SR/
Bupropion SR in Overweight and Obese Subjects With
Cardiovascular Risk Factors (The Light Study)
http://ClinicalTrials.gov/show/NCT01601704
Heart Disease
(49 clinical trials recruiting)
Study 1:
A Phase II Study of the Safety and Efficacy of
MPSK3169A in Patients With Coronary Heart Disease
or High Risk of Coronary Heart Disease
http://ClinicalTrials.gov/show/NCT01609140
Study 2:
A Study of Dalcetrapib in Patients With Stable Coronary
Heart Disease, With Coronary Heart Disease Risk
Equivalents or at Elevated Risk for Cardiovascular Disease
http://ClinicalTrials.gov/show/NCT01516541
Study 3:
Intracardiac CrYoablation for AtrioVentricular Nodal
Reentrant Tachycardia
http://ClinicalTrials.gov/show/NCT01426425
Study 4:
Efficacy and Safety Study of Azimilide on the
Incidence of Cardiovascular Hospitalizations/
Emergency Department Visits or Cardiovascular
Death in Patients With an Implantable Cardioverter
Defibrillators (ICD) (SHIELD-2)
http://ClinicalTrials.gov/show/NCT01464476
Study 5:
Efficacy and Safety of Targeted Intramyocardial
Delivery of Auto CD34+ Stem Cells for Improving
Exercise Capacity in Subjects With Refractory Angina
http://ClinicalTrials.gov/show/NCT01508910
Study 6:
A Study With Aleglitazar in Patients With a Recent
Acute Coronary Syndrome and Type 2 Diabetes
Mellitus
http://ClinicalTrials.gov/show/NCT01042769
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
63
Study 7:
Safety and Feasibility Trial of Adipose-Derived
Regenerative Cells in the Treatment of Chronic
Myocardial Ischemia
Study 15:
Evaluate the Safety and Efficacy of OAS in Treating
Severely Calcified Coronary Lesions
http://ClinicalTrials.gov/show/NCT01092416
http://ClinicalTrials.gov/show/NCT01556022
Study 8:
Study 16:
Echocardiography Guided Cardiac Resynchronization
Therapy (EchoCRT)
ST Monitoring to Detect Acute Coronary Syndrome
Events in Implantable Cardioverter Defibrillator
Patients
http://ClinicalTrials.gov/show/NCT00683696
http://ClinicalTrials.gov/show/NCT01424722
Study 9:
Prevention of Cardiovascular Events (eg, Death From
Heart or Vascular Disease, Heart Attack, or Stroke)
in Patients With Prior Heart Attack Using Ticagrelor
Compared to Placebo on a Background of Aspirin
http://ClinicalTrials.gov/show/NCT01225562
Study 10:
Safety and Efficacy Continued Access Study of the
Medtronic CoreValve® System in the Treatment of
Symptomatic Severe Aortic Stenosis in Very High Risk
Subjects and High Risk Subjects Who Need Aortic
Valve Replacement
http://ClinicalTrials.gov/show/NCT01531374
Study 11:
A Study of Genetically Targeted Enzyme Replacement
Therapy for Advanced Heart Failure
http://ClinicalTrials.gov/show/NCT01643330
Study 12:
RED-HF™ Trial-Reduction of Events With
Darbepoetin Alfa in Heart Failure Trial
http://ClinicalTrials.gov/show/NCT00358215
Study 13:
A Phase 3 Multi-center Study to Assess PET Imaging
of Flurpiridaz F 18 Injection in Patients With CAD.
Study 17:
Efficacy and Safety of Human Neuregulin-1 to Treat
Stable Chronic Heart Failure
http://ClinicalTrials.gov/show/NCT01251406
Study 18:
Cardiovascular Outcomes Study of Alogliptin in
Subjects With Type 2 Diabetes and Acute Coronary
Syndrome
http://ClinicalTrials.gov/show/NCT00968708
Study 19:
AngelMed for Early Recognition and Treatment of
STEMI
http://ClinicalTrials.gov/show/NCT00781118
Study 20:
Evaluation of Cardiovascular Outcomes in Patients
With Type 2 Diabetes After Acute Coronary Syndrome
During Treatment With AVE0010 (Lixisenatide)
http://ClinicalTrials.gov/show/NCT01147250
Study 21:
Effect of Otamixaban Versus Unfractionated Heparin
+ Eptifibatide in Patients With Unstable Angina/Non
ST Elevation Myocardial Infarction Undergoing Early
Invasive Strategy
http://ClinicalTrials.gov/show/NCT01076764
http://ClinicalTrials.gov/show/NCT01347710
Study 14:
Ranolazine for Incomplete Vessel Revascularization
Post-Percutaneous Coronary Intervention (PCI)
Study 22:
Cardiovascular Risk Reduction Study (Reduction in
Recurrent Major CV Disease Events)
http://ClinicalTrials.gov/show/NCT01327846
http://ClinicalTrials.gov/show/NCT01442038
64
PhRMA • Pharmaceutical Clinical Trials in texas
Study 23:
The PARTNER II Trial: Placement of AoRTic
TraNscathetER Valves
http://ClinicalTrials.gov/show/NCT01314313
Study 24:
AMR-001 Versus Placebo Post ST Segment Elevation
Myocardial Infarction
http://ClinicalTrials.gov/show/NCT01495364
Study 25:
Vest Prevention of Early Sudden Death Trial and VEST
Registry
http://ClinicalTrials.gov/show/NCT01446965
Study 26:
Pivotal Clinical Study of the CardioFocus Endoscopic
Ablation System-Adaptive Contact (EAS-AC)
(HeartLight) in Patients With Paroxysmal Atrial
Fibrillation (PAF)
http://ClinicalTrials.gov/show/NCT01456000
Study 27:
A Study to Evaluate the Effect of Ranolazine and
Dronedarone When Given Alone and in Combination
in Patients With Paroxysmal Atrial Fibrillation
(HARMONY)
Study 31:
Study to Evaluate the Safety and Efficacy of IV
Infusion Treatment With Omecamtiv Mecarbil in
Subjects With Left Ventricular Systolic Dysfunction
Hospitalized for Acute Heart Failure (ATOMIC-AHF)
http://ClinicalTrials.gov/show/NCT01300013
Study 32:
CANARY: Coronary Assessment by Near-infrared of
Atherosclerotic Rupture-prone Yellow
http://ClinicalTrials.gov/show/NCT01268319
Study 33:
Safety Study of Allogeneic Mesenchymal Precursor
Cells (MPCs) in Subjects With Recent Acute
Myocardial Infarction
http://ClinicalTrials.gov/show/NCT00555828
Study 34:
Clinical Outcomes Assessment of the MitraClip
Therapy Percutaneous Therapy for High Surgical Risk
Patients
http://ClinicalTrials.gov/show/NCT01626079
Study 35:
Premium Migraine Trial
http://ClinicalTrials.gov/show/NCT00355056
http://ClinicalTrials.gov/show/NCT01522651
Study 28:
Study 36:
Efficacy of LCQ908 on Cardiovascular Risk
Post-Myocardial Infarction Remodeling Prevention
Therapy
http://ClinicalTrials.gov/show/NCT01474434
http://ClinicalTrials.gov/show/NCT01213251
Study 29:
Study 37:
A Study to Assess Regadenoson Administration
Following an Inadequate Exercise Stress Test as
Compared to Regadenoson Alone for Myocardial
Perfusion Imaging (MPI) Using Single Photon
Emission Computed Tomography (SPECT)
INcrease Of VAgal TonE in CHF
http://ClinicalTrials.gov/show/NCT01618669
Feasibility Study of BMAC Enhanced CABG
An Efficacy, Safety and Tolerability Study of
Ixmyelocel-T Administered Via Transendocardial
Catheter-based Injections to Subjects With Heart
Failure Due to Ischemic Dilated Cardiomyopathy
(IDCM)
http://ClinicalTrials.gov/show/NCT01074099
http://ClinicalTrials.gov/show/NCT01670981
Study 30:
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
http://ClinicalTrials.gov/show/NCT01303718
Study 38:
65
Study 39:
Safety and Efficacy Study of the Sorin 3D Annuloplasty
Ring For Mitral Repair
http://ClinicalTrials.gov/show/NCT00567853
Study 47:
A Study to Evaluate the Safety and Efficacy of AC607
for the Treatment of Kidney Injury in Cardiac Surgery
Subjects
http://ClinicalTrials.gov/show/NCT01602328
Study 40:
Vdrive Evaluation of Remote Steering and Testing in
Lasso Electrophysiology Procedures Study
http://ClinicalTrials.gov/show/NCT01656772
Study 41:
Ascending Dose Study of OPC-108459 Intravenous
Infusions in Patients With Paroxysmal and Persistent
Atrial Fibrillation
http://ClinicalTrials.gov/show/NCT01483183
Study 48:
Study Evaluating The Effects Of Oprelvekin On
Cardiac Repolarization In Subjects With Chemotherapy
Induced Thrombocytopenia
http://ClinicalTrials.gov/show/NCT00886743
Study 49:
Cardiovascular Safety of Febuxostat and Allopurinol in
Patients With Gout and Cardiovascular Comorbidities
http://ClinicalTrials.gov/show/NCT01101035
Study 42:
THERMOCOOL® SMARTTOUCH™ Catheter for
the Treatment of Symptomatic Paroxysmal Atrial
Fibrillation CONTINUED ACCESS
Mental Illness
(96 clinical trials recruiting)
http://ClinicalTrials.gov/show/NCT01639495
Study 43:
Insulin Resistance Intervention After Stroke Trial
http://ClinicalTrials.gov/show/NCT00091949
Study 44:
Amiodarone, Lidocaine or Neither for Out-Of-Hospital
Cardiac Arrest Due to Ventricular Fibrillation or
Tachycardia
http://ClinicalTrials.gov/show/NCT01401647
Study 45:
Clarification of Optimal Anticoagulation Through
Genetics
http://ClinicalTrials.gov/show/NCT00839657
Study 46:
Cardiovascular Outcomes Study of Naltrexone SR/
Bupropion SR in Overweight and Obese Subjects With
Cardiovascular Risk Factors (The Light Study)
http://ClinicalTrials.gov/show/NCT01601704
66
Study 1:
Study of the Safety and Efficacy of Two Fixed Doses of
OPC-34712 as Adjunctive Therapy in the Treatment of
Adults With Major Depressive Disorder (the Polaris Trial)
http://ClinicalTrials.gov/show/NCT01360632
Study 2:
Progressive Goal Attainment Program for Veterans
http://ClinicalTrials.gov/show/NCT01565863
Study 3:
SPD503 in Subjects Aged 6-17 Years With Generalized
Anxiety Disorder (GAD), Separation Anxiety Disorder
(SAD), or Social Phobia (SoP)
http://ClinicalTrials.gov/show/NCT01470469
Study 4:
Relapse Prevention Study in Patients With
Schizophrenia
http://ClinicalTrials.gov/show/NCT01291511
PhRMA • Pharmaceutical Clinical Trials in texas
Study 5:
A Open-label Food Effect Study With SEN0014196 in
Subjects With Huntington Disease
http://ClinicalTrials.gov/show/NCT01485965
Study 13:
A Study of the Safety and Tolerability of Pimavanserin
(ACP-103) in Patients With Parkinson’s Disease
Psychosis
http://ClinicalTrials.gov/show/NCT00550238
Study 6:
Dose-optimization in Adolescents Aged 13-17
Diagnosed With Attention-deficit/Hyperactivity
Disorder (ADHD) Using Extended-release Guanfacine
HCl
Study 14:
Treatment of Sleep Problems in Children With Autism
Spectrum Disorder With Melatonin
http://ClinicalTrials.gov/show/NCT00691080
http://ClinicalTrials.gov/show/NCT01081132
Study 7:
An Open-Label Safety Study of Memantine in
Pediatric Patients With Autism, Asperger’s Disorder,
or Pervasive Developmental Disorder Not Otherwise
Specified (PDD-NOS)
http://ClinicalTrials.gov/show/NCT01592786
Study 8:
Open-label Extension Evaluating Methylphenidate
Hydrochloride Modified Release in Adults With
Attention Deficit/Hyperactivity Disorder
http://ClinicalTrials.gov/show/NCT01338818
Study 9:
Study of Rufinamide in Pediatric Subjects 1 to Less
Than 4 Years of Age With Lennox-Gastaut Syndrome
Inadequately Controlled With Other Anti-epileptic Drugs
http://ClinicalTrials.gov/show/NCT01405053
Study 15:
Safety, Tolerability, and Efficacy of Cariprazine for
Patients With Bipolar Depression
http://ClinicalTrials.gov/show/NCT01396447
Study 16:
Safety and Efficacy of Cariprazine as an Adjunctive to
Antidepressant Therapy in Major Depressive Disorder
http://ClinicalTrials.gov/show/NCT01469377
Study 17:
Cariprazine Relative to Placebo in the Prevention of
Relapse of Symptoms in Patients With Schizophrenia
http://ClinicalTrials.gov/show/NCT01412060
Study 18:
Extension Study of Asenapine {P06107 (NCT01244815)}
for Pediatric Bipolar Disorder (P05898 AM3)
http://ClinicalTrials.gov/show/NCT01349907
Study 10:
A Trial of CM-AT in Children With Autism- Open
Label Extension Study
http://ClinicalTrials.gov/show/NCT00912691
Study 11:
Safety and Tolerability of Aripiprazole in Adolescents
With Schizophrenia or Children and Adolescents With
Bipolar I Disorder, Manic or Mixed Episode With or
Without Psychotic Features
http://ClinicalTrials.gov/show/NCT01122927
Study 19:
Efficacy and Safety of Asenapine Treatment for
Pediatric Bipolar Disorder {P06107 Has an Extension
(P05898; NCT01349907}(P06107 AM3)
http://ClinicalTrials.gov/show/NCT01244815
Study 20:
Open-label Study to Compare Hospitalization
Rates of Schizophrenic Patients Treated With Oral
Antipsychotics Versus IM Depot Aripiprazole
http://ClinicalTrials.gov/show/NCT01432444
Study 12:
A Study of the Safety and Efficacy of Pimavanserin in
Patients With Parkinson’s Disease Psychosis
http://ClinicalTrials.gov/show/NCT01174004
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
67
Study 21:
Long-term Safety and Tolerability of BMS-820836 in
the Treatment of Patients With Treatment Resistant
Major Depression
Study 29:
A Study to Evaluate ALKS 5461 in Subjects With Major
Depressive Disorder (MDD)
http://ClinicalTrials.gov/show/NCT01500200
http://ClinicalTrials.gov/show/NCT01361555
Study 22:
Efficacy and Safety of Fixed Doses of BMS 820836 in
the Treatment of Patients With Treatment Resistant
Major Depression
Study 30:
A Fixed Dose Study of Adjunctive Treatment to
Antidepressant Therapy for Adults With Major
Depressive Disorder
http://ClinicalTrials.gov/show/NCT01173601
http://ClinicalTrials.gov/show/NCT01369095
Study 23:
A 6-Month Extension Study To The B2061032 Study
To Evaluate The Safety, Tolerability, And Efficacy Of
DVS SR In The Treatment Of Child And Adolescent
Outpatients With MDD
http://ClinicalTrials.gov/show/NCT01371708
Study 31:
Efficacy and Safety of Ramelteon Sublingual as
Adjunctive Therapy for Maintenance Treatment of
Bipolar I Disorder in Adult Patients
http://ClinicalTrials.gov/show/NCT01467713
Study 32:
PEARL Schizophrenia Maintenance
A Study of Paliperidone Palmitate 3 Month
Formulation for the Treatment of Patients With
Schizophrenia
http://ClinicalTrials.gov/show/NCT01435928
http://ClinicalTrials.gov/show/NCT01529515
Study 24:
Study 25:
Study 33:
A Study Of DVS SR In Treatment Of Children And
Adolescent Outpatients With MDD
A Study of RO4917838 in Patients With Sub-optimally
Controlled Symptoms of Schizophrenia (NN25307)
http://ClinicalTrials.gov/show/NCT01371734
http://ClinicalTrials.gov/show/NCT01235520
Study 26:
Study 34:
Extension Study of the Safety and Efficacy of
Armodafinil Treatment as Adjunctive Therapy in Adults
With Major Depression Associated With Bipolar I
Disorder
Study to Evaluate the Efficacy and Safety of
Armodafinil Treatment as Adjunctive Therapy in Adults
With Major Depression Associated With Bipolar I
Disorder
http://ClinicalTrials.gov/show/NCT01121536
http://ClinicalTrials.gov/show/NCT01072630
Study 27:
Study 35:
SPD489 in Combination With an Antidepressant in the
Treatment of Adults With Major Depressive Disorder
Major Depressive Disorder (MDD) With Mixed
Features-Flexible Dose
http://ClinicalTrials.gov/show/NCT01435759
http://ClinicalTrials.gov/show/NCT01421134
Study 28:
Study 36:
Efficacy and Safety of Ramelteon Sublingual in Adult
Patients With Acute Depressive Episodes Associated
With Bipolar I Disorder
Efficacy and Safety of Flexibly Dosed BMS-820836 in
the Treatment of Patients With Treatment Resistant
Major Depression
http://ClinicalTrials.gov/show/NCT01467700
http://ClinicalTrials.gov/show/NCT01309945
68
PhRMA • Pharmaceutical Clinical Trials in texas
Study 37:
Study 46:
Major Depressive Disorder With Mixed FeaturesExtension
Efficacy Study of OPC-34712 in Adults With Acute
Schizophrenia
http://ClinicalTrials.gov/show/NCT01423253
http://ClinicalTrials.gov/show/NCT01393613
Study 38:
A Twelve Week, Open Label Extension Study in Patients
With Schizophrenia
http://ClinicalTrials.gov/show/NCT01566162
Study 47:
Efficacy, Safety, and Tolerability of TC-5619 as
Augmentation Therapy to Improve Negative Symptoms
and Cognition in Outpatients With Schizophrenia
http://ClinicalTrials.gov/show/NCT01488929
Study 39:
Efficacy of LuAA21004 on Cognitive Dysfunction in
Major Depressive Disorder
http://ClinicalTrials.gov/show/NCT01564862
Study 40:
Safety and Efficacy Study of IPX159 in Restless Legs
Syndrome (RLS)
http://ClinicalTrials.gov/show/NCT01521663
Study 41:
Study 48:
A Phase 3b Multicenter Study of Pregabalin in
Fibromyalgia Subjects Who Have Comorbid
Depression
http://ClinicalTrials.gov/show/NCT01432236
Study 49:
A Study to Evaluate the Efficacy and Safety of ALKS
9072 in Subjects With Schizophrenia
http://ClinicalTrials.gov/show/NCT01469039
A Study of RO4917838 in Patients With Persistent,
Predominant Negative Symptoms of Schizophrenia
(NN25310)
Major Depressive Disorder With Mixed Features
http://ClinicalTrials.gov/show/NCT01192867
http://ClinicalTrials.gov/show/NCT01423240
Study 42:
A Study to Evaluate ABT-126 for the Treatment of
Cognitive Deficits in Schizophrenia
http://ClinicalTrials.gov/show/NCT01655680
Study 50:
Study 51:
Efficacy and Safety Study of SPD489 in Combination
With an Antidepressant in the Treatment of Adults With
Major Depressive Disorder
http://ClinicalTrials.gov/show/NCT01436162
Study 43:
Safety and Tolerability Study of Oral OPC-34712 as
Maintenance Treatment in Adults With Schizophrenia
http://ClinicalTrials.gov/show/NCT01397786
Study 44:
Phase 3 IGIV, 10% in Alzheimer´s Disease
http://ClinicalTrials.gov/show/NCT01524887
Study 45:
Study to Evaluate the Efficacy and Safety of
Armodafinil Treatment (150 mg/Day) as Adjunctive
Therapy in Adults With Major Depression Associated
With Bipolar I Disorder
Study 52:
A Study of RO4917838 (Bitopertin) in Patients With
Persistent, Predominant Negative Symptoms of
Schizophrenia (WN25308)
http://ClinicalTrials.gov/show/NCT01192880
Study 53:
A Study of Gantenerumab in Patients With Prodromal
Alzheimer’s Disease
http://ClinicalTrials.gov/show/NCT01224106
http://ClinicalTrials.gov/show/NCT01305408
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
69
Study 54:
Study 62:
Prospective Multicenter Trial to Explore the Tolerability
and Safety of the H-Coil Deep TMS in Combination
With Serotonin Selective Reuptake Inhibitor(SSRI)
Rotigotine Effect on All-day Functioning and Quality
of Life in Subjects With Moderate to Severe Restless
Legs Syndrome (RLS)
http://ClinicalTrials.gov/show/NCT01361815
http://ClinicalTrials.gov/show/NCT01569464
Study 55:
A Study to Assess the Effect and Safety of AZD6765 in
Patients With Major Depressive Disorder
Study 63:
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
http://ClinicalTrials.gov/show/NCT01518374
http://ClinicalTrials.gov/show/NCT01482221
Study 56:
Study 64:
A Study of the Safety and Effectiveness of ADX-N05
for Excessive Daytime Sleepiness in Subjects With
Narcolepsy
Safety and Efficacy of MK-6096 as Adjunctive Therapy
in Participants With Major Depressive Disorder And
Partial Response to Antidepressant Monotherapy (MK6096-022 AM2)
http://ClinicalTrials.gov/show/NCT01681121
http://ClinicalTrials.gov/show/NCT01554176
Study 57:
Study 65:
Efficacy and Safety of Tasimelteon Compared With
Placebo in Totally Blind Subjects With Non-24-Hour
Sleep-Wake Disorder
ARTDeCo Study: A Study of RO4995819 in Patients
With Major Depressive Disorder And Inadequate
Response to Ongoing Antidepressant Treatment
http://ClinicalTrials.gov/show/NCT01163032
http://ClinicalTrials.gov/show/NCT01457677
Study 58:
Effect of Lu AA21004 Versus Escitalopram on Sexual
Functioning in Adults With Well-Treated Major
Depressive Disorder
Study 66:
A Study of RO4917838 (Bitopertin) in Patients With
Acute Exacerbation of Schizophrenia
http://ClinicalTrials.gov/show/NCT01234779
http://ClinicalTrials.gov/show/NCT01364649
Study 59:
Withdrawal Study to Demonstrate the Maintenance
Effect in the Treatment of Non-24-Hour Sleep-Wake
Disorder
http://ClinicalTrials.gov/show/NCT01430754
Study 60:
A Long-term Safety Study of ALKS 9072 (Also Known
as ALKS 9070)
http://ClinicalTrials.gov/show/NCT01626456
Study 61:
Study 67:
Safety and Efficacy Study of Deep Transcranial
Magnetic Stimulation in Bipolar Depression
http://ClinicalTrials.gov/show/NCT01566591
Study 68:
A Paroxetine- and Placebo-Controlled Study of 50 mg/
Day and 100 mg/Day of EB-1010 Among Outpatients
With Major Depressive Disorder Who Have Responded
Inadequately to Prior Selective Serotonin Reuptake
Inhibitors (SSRIs) and Serotonin Norepinephrine
Reuptake Inhibitors (SNRIs)
http://ClinicalTrials.gov/show/NCT01318434
A Study of RO4917838 (Bitopertin) in Patients With
Sub-optimally Controlled Symptoms of Schizophrenia
(WN25305)
VI-1121 for the Treatment Alzheimer’s Disease
http://ClinicalTrials.gov/show/NCT01235559
http://ClinicalTrials.gov/show/NCT01428362
70
Study 69:
PhRMA • Pharmaceutical Clinical Trials in texas
Study 70:
Study 77:
A Study of RO4917838 (Bitopertin) in Patients With
Persistent, Predominant Negative Symptoms of
Schizophrenia (WN25309)
Study of the Effectiveness of Three Different Doses
of OPC-34712 in the Treatment of Adults With Acute
Schizophrenia
http://ClinicalTrials.gov/show/NCT01192906
http://ClinicalTrials.gov/show/NCT01396421
Study 71:
A Study of Flexible or Fixed Dose LLY2216684 as
Adjunctive Treatment for Participants With Major
Depressive Disorder Who Have Had a Partial Response
to Selective Serotonin Reuptake Inhibitor (SSRI)
Treatment
http://ClinicalTrials.gov/show/NCT01187407
Study 72:
Study of the Pharmacokinetics and Pharmacodynamics
of POSIPHEN® in Subjects With Amnestic Mild
Cognitive Impairment
http://ClinicalTrials.gov/show/NCT01072812
Study 73:
Tasimelteon for the Treatment of Non-24-hour SleepWake Disorder (N24HSWD) in Blind Individuals With
no Light Perception
http://ClinicalTrials.gov/show/NCT01429116
Study 74:
20101299: Study to Evaluate the Effect of AMG 747 on
Schizophrenia Negative Symptoms
http://ClinicalTrials.gov/show/NCT01568216
Study 75:
Long-Term Follow-Up Study for Safety, Efficacy and
Tolerability of Rotigotine in Adolescents With Restless
Legs Syndrome
http://ClinicalTrials.gov/show/NCT01498120
Study 76:
A 6-Month Open-Label Extension Study to the
B2061014 Study to Evaluate the Safety, Tolerability and
Efficacy of DVS SR in the Treatment of Children and
Adolescents With MDD
http://ClinicalTrials.gov/show/NCT01371721
Study 78:
A Study of ALKS 9072 in Subjects With Chronic Stable
Schizophrenia
http://ClinicalTrials.gov/show/NCT01493726
Study 79:
20110165: Study to Evaluate the Effect of AMG 747 on
Schizophrenia Negative Symptoms
http://ClinicalTrials.gov/show/NCT01568229
Study 80:
Synchronized Transcranial Magnetic Stimulation
(sTMS) in Major Depressive Disorder
http://ClinicalTrials.gov/show/NCT01370733
Study 81:
NBI-98854 for the Treatment of Tardive Dyskinesia
in Subjects With Schizophrenia or Schizoaffective
Disorder (KINECT Study)
http://ClinicalTrials.gov/show/NCT01688037
Study 82:
The Safety and Efficacy of AF-219 in Female Subjects
With Interstitial Cystitis /Bladder Pain Syndrome
http://ClinicalTrials.gov/show/NCT01569438
Study 83:
A Sleep Laboratory Study to Investigate the Safety and
Efficacy of the Rotigotine Skin Patch in Subjects With
Restless Legs Syndrome and End-Stage Renal Disease
Requiring Hemodialysis
http://ClinicalTrials.gov/show/NCT01537042
Study 84:
Efficacy and Safety Study of SPD489 in Combination
With an Antidepressant in the Treatment of Adults With
Major Depressive Disorder
http://ClinicalTrials.gov/show/NCT01436149
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
71
Study 85:
Study 93:
A Study Of DVS SR In Treatment Of Children And
Adolescent Outpatients With MDD
Dose Escalating Study of Rotigotine in Pediatric
Subjects With Restless Legs Syndrome
http://ClinicalTrials.gov/show/NCT01372150
http://ClinicalTrials.gov/show/NCT01495793
Study 86:
Efficacy & Safety Study of Oral Aripiprazole in
Adolescents With Schizophrenia
Study 94:
Cocaine Use Reduction With Buprenorphine
http://ClinicalTrials.gov/show/NCT01402492
http://ClinicalTrials.gov/show/NCT01149655
Study 87:
A Study to Evaluate the Efficacy and Safety of
MABT5102A in Patients With Mild to Moderate
Alzheimer’s Disease (ABBY)
http://ClinicalTrials.gov/show/NCT01343966
Study 88:
Safety, Efficacy and Tolerability of Vilazodone in
Generalized Anxiety Disorder
http://ClinicalTrials.gov/show/NCT01629966
Study 89:
A Study in Prevention of Re-emergence of Depression
Symptoms
http://ClinicalTrials.gov/show/NCT01299272
Study 90:
Study 95:
Preventing Sexual Dysfunction With Aromatase
Inhibitors
http://ClinicalTrials.gov/show/NCT01603303
Study 96:
Multisite Controlled Trial of Cocaine Vaccine
http://ClinicalTrials.gov/show/NCT00969878
Stroke
(15 clinical trials recruiting)
Study 1:
Study of ALD-401 Via Intracarotid Infusion in Ischemic
Stroke Subjects
http://ClinicalTrials.gov/show/NCT01273337
Study to Evaluate the Pharmacokinetics,
Pharmacodynamics, and Safety of Armodafinil in
Children and Adolescents With Excessive Sleepiness
Associated With Narcolepsy
Efficacy and Safety Study of Desmoteplase to Treat
Acute Ischemic Stroke (DIAS-4)
http://ClinicalTrials.gov/show/NCT01624480
http://ClinicalTrials.gov/show/NCT00856661
Study 91:
A Study to Evaluate the Effect of Genotype on
LY2216684
http://ClinicalTrials.gov/show/NCT01460381
Study 92:
Study 2:
Study 3:
Carotid Stenting vs. Surgery of Severe Carotid Artery
Disease and Stroke Prevention in Asymptomatic
Patients (ACT I)
http://ClinicalTrials.gov/show/NCT00106938
Study 4:
A Study of RO4917838 (Bitopertin) in Patients With
Sub-optimally Controlled Symptoms of Schizophrenia
(WN25306)
Efficacy and Safety Trial of Transcranial Laser Therapy
Within 24 Hours From Stroke Onset (NEST-3)
http://ClinicalTrials.gov/show/NCT01235585
http://ClinicalTrials.gov/show/NCT01120301
72
PhRMA • Pharmaceutical Clinical Trials in texas
Study 5:
Prevention of Cardiovascular Events (eg, Death From
Heart or Vascular Disease, Heart Attack, or Stroke)
in Patients With Prior Heart Attack Using Ticagrelor
Compared to Placebo on a Background of Aspirin
http://ClinicalTrials.gov/show/NCT01225562
Study 6:
Efficacy and Safety Study of Botulinum Toxin Type A
Against Placebo to Treat Spasticity in the Arm After a
Stroke
http://ClinicalTrials.gov/show/NCT01392300
Study 7:
Efficacy and Safety Study of Botulinum Toxin Type A
Against Placebo to Treat Spasticity in the Leg After a
Stroke
http://ClinicalTrials.gov/show/NCT01464307
Study 11:
Dysport® Adult Lower Limb Spasticity Study
http://ClinicalTrials.gov/show/NCT01249404
Study 12:
Dysport® Adult Upper Limb Spasticity
http://ClinicalTrials.gov/show/NCT01313299
Study 13:
Cardiovascular Outcomes Study of Alogliptin in
Subjects With Type 2 Diabetes and Acute Coronary
Syndrome
http://ClinicalTrials.gov/show/NCT00968708
Study 14:
Cardiovascular Safety of Febuxostat and Allopurinol in
Patients With Gout and Cardiovascular Comorbidities
http://ClinicalTrials.gov/show/NCT01101035
Study 8:
Insulin Resistance Intervention After Stroke Trial
http://ClinicalTrials.gov/show/NCT00091949
Study 9:
Study 15:
Cardiovascular Risk Reduction Study (Reduction in
Recurrent Major CV Disease Events)
http://ClinicalTrials.gov/show/NCT01327846
Safety of Intravenous Thrombolysis for Wake-up Stroke
http://ClinicalTrials.gov/show/NCT01183533
Study 10:
Clarification of Optimal Anticoagulation Through
Genetics
http://ClinicalTrials.gov/show/NCT00839657
RESEARCH IN YOUR BACKYARD: Developing Cures, Creating Jobs
73
Pharmaceutical Research and Manufacturers of America
950 F Street, NW, Washington, DC 20004
www.phrma.org